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ABSTRACT 
Variability between individuals in pain and analgesia phenotypes is often 
observed in both clinical and experimental settings. The source ofthis variability has 
long been attributed to the interplay of environmental and genetic factors, but we have 
only recently begun identifying these determinants. Experiments comparing isogenic 
strains of mice have suggested that different pain tests may share a genetic basis; 
likewise, analgesic magnitude induced by disparate drug classes may be influenced by a 
common set of genes. 
We have presently used a quantitative trait locus mapping strategy to search for 
genes responsible for variability in analgesic response to five analgesic drugs (the opioids 
morphine and U50,488, and the non-opioid drugs c1onidine, epibatidine, and WIN55,212-
2). We first used a B6129PF2 intercross population to map sensitivity to clonidine, 
morphine, and WIN55,212-2 to a 30 cM region on distal Chromosome 1. In si/ica and 
congenic strain mapping techniques allowed us to refine this linkage, as well as 
generalize it to four of the five drugs and seven mouse strains. Kcnj9 (GIRK3) was 
identified as a likely candidate gene underlying response to multiple analgesic modalities. 
We showed that this gene is differentially expressed between C57BL/6 and 129P3 strains 
in the periaqueductal gray. We also determined that Kcnj9 null mutant mice exhibit 
attenuated analgesic responses. 
IV 
We previously mapped nociceptive response to the formalin test to two loci on 
Chr. 9 and 10 using an AB6F2 cross. Using in silico mapping, we identified several 
haplotypes near the Afpi b3 gene on Chr. 9 (a subunit of the sodium-potassium pump) that 
correlated highly with early phase formalin response. We then showed that 
pharmacological antagonism of the sodium-potassium channel eliminates the strain 
difference observed between A and C57BL/6 mice, supporting a role for this gene in 
determining response to formalin. Positional cloning of the Chr. 10 locus, employing 
recombinant and congenic strains, allowed us to refine the location ofthe locus to a <3 
cM interval. A small number of genes in this region were identified as differentially 
expressed by microarray analysis, providing a short list of candidate genes for follow-up 
investigation. 
v 
ABSTRAIT 
Des variabilités en terme de douleur et d'analgésie ont souvent été observées entre 
individus dans les cadres cliniques et expérimentaux. Ces variabilité phénotypiques ont 
longtemps été expliquées par le jeu résultant des facteurs environnementaux et 
génétiques, mais ce n'est que récemment que ces derniers ont attiré l'attention des 
chercheurs. Des études comparant des lignées isogéniques de souris ont suggéré une base 
génétique commune pour les différents tests d'évaluation de la douleur; de même, il se 
pourrait que l'ampleur de l'effet analgésique causée par différentes classes de drogues 
dépende d'un même ensemble de gènes. 
Nous avons présentement utilisé une stratégie de cartographie des loci à effets 
quantitatifs (ou« QTL ») afin d'identifier les gènes responsables de la variabilité aux 
effets analgésiques de cinq substances analgésiques (les opiacés morphine et U50,488 et 
les non-opiacés clonidine, épibatidine et WIN55,212-2). D'abord, une cartographie 
génétique à partir de souris issues du croisement B6129PF2 nous a permis d'établir que 
les gènes associés à la sensibilité à la clonidine, à la morphine et au WIN55,212-2 se 
trouvaient sur la partie distale du chromosome 1, et ce, sur une longueur de 30 
centimorgans. Une cartographie selon une approche in silico à partir de souris 
congéniques nous a permis de mieux comprendre ce groupe de liaison de plusieurs gènes 
et de l'étendre à quatre des cinq drogues et à sept lignée murines. Le gène Kcnj9 (codant 
pour GIRK3) a été identifié comme étant le gène candidat sous-tendant le plus 
probablement la réponse aux multiples modalités analgésiques. Nous avons découvert que 
ce gène s'exprimait à des niveaux différents chez C57BL/6 et 129P3 dans la matière grise 
périaqueducale. De plus, des souris mutantes chez lesquelles le gène Kcnj9 fut rendu non 
fonctionnel montrait des réponses analgésiques moindres. 
,~ 
vi 
Précédemment, à partir de souris issues du croisement AB6F2, nous avons 
cartographié les gènes associés à la réponse nociceptive auformalin test et constaté qu'ils 
occupaient deux loci, l'un sur le chromosome 9 et l'autre sur le chromosome 10. Une 
cartographie in silico a indiqué la présence sur le chromosome 9 de plusieurs haplotypes 
fortement impliqués dans la phase du début de réponse au test et situés près du gène 
Atp1 b3 (codant pour une des sous-unités de la pompe sodium/potassium). Nous avons 
ensuite montré que le blocage du canal sodium/potassium par un antagoniste 
pharmacologique chez A et C57BL/6 éliminait la différence de réaction observée 
normalement entre ces deux lignées de souris lors du formalin test, démontrant du même 
coup le rôle joué par Atp 1 b3 dans la réponse à ce test. L'étude de souris recombinantes et 
congéniques nous a permis, au moyen du clonage positionnel, d'affiner la localisation du 
locus sur le chromosome 10 jusqu'à une distance d'au moins trois centimorgans. 
L'analyse de l'expression génique par micropuces à ADN nous a révélé que dans cette 
région existait un nombre restreint de gènes exprimés à des niveaux différents ce qui nous 
donne une courte liste de gènes candidats qui pourraient être étudiés dans le cadre de 
futures recherches. 
vu 
This work is dedicated to my parents: my father, who passed on to me his enthusiasm for 
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supported my efforts. 
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CHAPTER 1: A REVIEW OF THE GENETICS OF PAIN AND ANALGESIA 
A. Variability in pain and analgesia 
A.I. Pain-modulating circuitry 
1 
Nociception is a vital sensory mechanism necessary for waming an organism of 
danger, tissue damage, or illness, and at least in humans, the experience of pain is usually 
accompanied by an unpleasant emotional component and strong motivational impulses 
(IASP Subcommittee on Taxonomy, 1979). Until the mid-20th century, medical science 
did not stray far from the model of pain presented by René Descartes (1664), thatthe 
nociceptive signal was carried directly from the cutaneous site of injury to the brain via a 
single afferent neuron, without any modification of the transmission. The publication of 
the gate-control theory in 1965 by Melzack and Wall (1965) introduced the idea that pain-
transmitting neurons interact with other neurons in the spinal cord, such that the signal 
can be reduced or even blocked. The past decades have seen many refinements to this 
concept, and we now know that the multifaceted components of pain are supported by a 
complex system of neurochemical mediation, which inc1udes both feedback and 
feedforward regulation as weIl as signal modulation and dampening mechanisms 
(Basbaum and Fields, 1984). 
Nociception may be initiated by mechanical tissue damage, noxious heat or cold, 
or inflammatory chemical activation of specialized neurons known as nociceptors 
(reviewed in Julius and Basbaum, 2001). These nociceptors, small-diameter afferents that 
may be thinly myelinated (AD fibers) or unmyelinated (C fibers), terminate primarily in 
laminae l and II of the spinal cord dorsal homo From there, the ascending spinothalamic 
tract carries the nociceptive signal to the thalamus and then to somatosensory areas of the 
2 
cortex, where the sensory-discriminative aspects of sensation are processed (Willis and 
Westlund, 1997), and to the anterior cingulate and insular cortical areas, which have been 
implicated in the affective aspects of pain (Rainville et al., 1997). Information is also 
transmitted through the spinomesencephalic tract to midbrain areas such as the 
periaqueductal gray (P AG) (Wilberg and Blomqvist, 1987), a vital center for pain 
inhibition. 
It is believed that the PAG is involved in mediating the stress response, allowing 
an injured animal to make a "fight pr flight" response without regard to incapacitating 
pain (Bandler and Depaulis, 1991). Electrical stimulation of the P AG has been shown to 
produce substantial attenuation of nociceptive sensation, or analgesia, even sufficient to 
allow surgery in awake animaIs (Reynolds, 1969). Microinjection of opioids into the 
P AG produces profound analgesia, suggesting that the role of the endogenous 
neurotransmitters is to initiate descending pain inhibitory pathways (Murfin et al., 1976). 
Activation of neurons in the PAG, whether by electrode or by cortical signaling, results in 
the release of a number of neurotransmitter molecules, including catecholamines and 
endogenous opioids, into the midbrain (for a review, see Basbaum and Fields, 1984). 
Sorne ofthese projections release norepinephrine into the dorsolateral pontine tegmentum 
(DLPT) (Bajic and Proudfit, 1999); however, the bulk of the projections from the PAG 
terminate in the rostral ventromedial medulla (RVM) (Beitz, 1982). Both ofthese 
pathways contribute substantially to pain modulation via further projections to the dorsal 
horn of the spinal cord, where they inhibit ascending pain signaIs (Liebeskind et al., 
1973). Modulation ofnociceptive information may occur at any of the aforementioned 
levels of the nervous system. Pain, we now recognize, does not represent an 
unadulterated transduction of the precise qualities of the noxious stimulus; pain is rather a 
highly mutable, distinctly subjective experience that (almost) aIl humans have in 
common, but which is unique to every individual. 
A.2. Variability in pain and analgesia in humans 
3 
Humans exhibit an astounding array of responses to aversive stimuli, as noted by 
the surgeon Henry Beecher (1946), who reported that soldiers wounded in battle would 
often de cline pain-killers for even the most serious of wounds. Libman, a clinician, was 
among the first to experimentally categorize subjects, designating his patients as 
"responders" and "non-responders" based on their reaction to moderate pressure placed 
against their mastoid bone (Libman, 1934). Subsequent studies have shown that 
individuals vary widely in their pain threshold and tolerance. For example, hyposensitive 
subjects detect pressure pain at upto double the threshold ofhypersensitive individuals 
(Sherman, 1943; Chapman and Jones, 1944; Brennum et al., 1989); more recent studies 
show that differences in thermal pain response are equally considerable (Chen et al., 
1989b; Sheps et al., 1999; Coghill et al., 2003; Hutchinson et al., 2004). Wide variation 
in pain experience is not 1imited to experimental manipulations. lndividuals differ in their 
susceptibility to a number of painful clinical conditions, such as complex regional pain 
syndrome (CRPS) (Griepp and Thomas, 1991), fibromyalgia (Pellegrino et al., 1989; 
Stormorken and Brosstad, 1992), migraine (Honkasalo et al., 1995; Mulder et al., 2003), 
and painful neuropathy following nerve trauma (Devor, 2004), diabetes, or zoster 
infection (Schmader, 2002). 
The variability exhibited between individuals is also evident in response to 
analgesic compounds. Although this has been anecdotal knowledge to physicians for 
many years, Lasagna and Beecher (1954) first published findings of a lack of efficacy of 
4 
standard doses of morphine in a substantial minority of patients. Individual differences in 
opiate efficacy have since been documented repeatedly, both in experimental (Chapman 
et al., 1990) and clinical settings (Portenoy et al., 1990; Galer et al., 1992). Non-steroidal 
anti-inflammatory drugs, another important group of analgesic compounds including 
aspirin and ibuprofen, similarly show variation in patient response (Day et al., 1988). 
Acupuncture, which presumably relies on endogenous analgesic mechanisms, has also 
been shown to vary in effectiveness between subjects in experimental (Takeshige et al., 
1983) as well as clinical (Wong et al., 2003; Brinkhaus et al., 2006) contexts. 
A.3. Variability in nociception and antinociception in rodents 
AnimaIs have proven useful for basic studies of nociception and its inhibition, and 
a number of rat and mouse models of painful clinical states have been developed. Pain 
researchers have compared separate rat and mouse lines for differences between strains 
on a number of measures of nociception, including response threshold, hypersensitivity, 
analgesic magnitude, and analgesic tolerance (see Mogil, 1999 for an extensive review of 
this literature). In general, wide divergence between mouse strains has been observed for 
aH common tests ofnociception, ranging from 1.2- to 17.2-fold differences (in the tail-
withdrawal and magnesium sulfate abdominal constriction tests, respectively) in strain 
means (Mogil et al., 1999a; Lariviere et al., 2002). Mice also differ in their susceptibility 
to neuropathic pain; strains subjected to the same injury (autotomy, or complete 
denervation of a hindlimb) may respond with minimal (AKR and C58 strains) or extreme 
(C57BL/6 and C3HIHe strains) self-injurious behavior toward the offending paw (Mogil 
et al., 1999a). Both quantitative and qualitative differences have been noted in analgesic 
response in mice. We recently compared twelve mouse strains for analgesic magnitude 
5 
on five different drug classes against acute thermal pain, and found that the effective dose 
(AD50) ranged from 2.5- (for the K-opioid drug U50,488) to 36.8-fold (for the 
cannabinoid WIN55,212-2) differences between the least- and most-responsive strains 
(Wilson et al., 2003). Other researchers have shown that analgesia produced by stress or 
opioid injection arises via different neurochemical mechanisms in different mouse strains 
(Relmstetter and Fanselow, 1987), or is operational in only a particular subset of strains 
(Vaccarino et al., 1988). An extreme example was provided by Rady et al. (1998), who 
proved that heroin analgesia may be mediated by delta-, mu-, or kappa-opioid receptors, 
depending on the strain tested. 
A.4. Sources ofvariability in pain and analgesia 
The major foeus of our laboratory is to determine the sources ofvariability 
between individuals on measures of nociception and its inhibition. Researchers have 
found it useful to consider three major components of observed variance (although 
quantifying the contribution of each component remains a thorny problem): 
environmental variance, genetic variance, and measurement error. Rumans being the 
heterogeneous, dynamic creatures that we are, a large number of pain-relevant modifiers 
have been identified within each component of nociceptive variance. Differences in pain 
and analgesic sensitivity on the basis of race (Edwards et al., 2001; Mechlin et al., 2005) 
and especially sex (Berkley, 1997) have been observed; however, it is difficult in humans 
to determine whether such differences are accounted for better by genetic factors (such as 
gene polymorphisms, androgen effects, etc.) or by environmental influences (like cultural 
values, gender roles). What may seem to be obviously environmental causes of 
variability (e.g., stressfullife events, motorcycle accidents, exposure to workplace 
.~. 
6 
hazards) frequently interact with heritable susceptibility factors in producing clinical pain 
states. Psychological factors such as affective state, coping style, pain behavior 
modeling, hypervigilance, and catastrophizing aIl contribute to an individual's experience 
of pain, also in ways affected by both inherent genetic liabilities and the context of the 
particular painful event (McGrath, 1994). Pain, even at the most basic level of 
nociceptive sensation, is a remarkably complex trait; partitioning the sources of variance 
is a daunting challenge in humans, leading many investigators to devise animal mode1s in 
which either genetic or environmental uniformity may be maximized. 
We have recently published a data-mining exercise on variability on the tail-
withdrawal test, drawing on an archivaI data set of over 8000 separate mice tested in our 
laboratory over an eight year period (Chesler et al., 2002). Both environmental and 
genetic factors, and their corresponding interaction effects, were observed to influence 
tail-withdrawallatencies; in fact, the most important factor was tester, meaning that the 
pers on taking the reading was at least as important as the mouse being tested in 
determining the mouse's measured sensitivity. The next highest-ranked cluster of factors 
was related to the genotype of the mouse, however, confirming that heritable strain 
characteristics are an important determinant of nociceptive phenotypes (Takagi et al., 
1966; Frischknecht et al., 1988; Be1knap and O'Toole, 1991). Aiso noted as variables 
relevant to thermal pain tolerance were season and time of day when tested, housing 
conditions, sex, ambient humidity, and within-cage order oftesting. Independent 
observers have likewise implicated diet (Shir et al., 1998), ambient temperature (Tjolsen 
and Hole, 1993), barometric pressure (Sato et al., 1999), and pre- and postnatal maternaI 
behavior (Sudakov et al., 1996; Stephan et al., 2002) as factors contributing to 
nociceptive behavior in rodents. Although the environment clearly plays a major role in 
nociception, the study of genetic differences in mice is a worthwhile endeavor that has 
already proven to be of value in identifying genes of re1evance to pain in humans. 
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B. Exploiting inbred mouse strain differences to study nociception 
B.1. Characterization of inbred strains 
The modern laboratory mouse is an exquisitely, but finitely, complex model of 
mammalian behavior, thanks to the complimentary efforts of 1 9th century pet breeders 
and 21 st century geneticists. Many of the strains of mice in common use originated from 
the stocks of "fancy mice" bred by Abbie Lathrop for their interesting color varieties 
(Beck et al., 2000). Clarence Little, a biologist at nearby Harvard University, recognized 
the utility of multiple standardized genetic backgrounds in controlling for genetic and 
environmental variability in his experiments, and began inbreeding Lathrop's mice to 
create such lines (Silver, 1995). lnbred mice are the product of repeated brother-sister 
mating, in which each subsequent generation loses roughly half of the genetic 
heterogeneity of the previous generation. F oUowing 20 generations of inbreeding, aU 
mice of a particular strain are virtual clones of each other, sharing over 99% oftheir 
genetic code. Furthermore, inbred mice are homozygous at every locus, eliminating 
complications re1ated to dominance. GeneticaUy uniform mouse mode1s allow for 
research performed at one point in space and time to be compared with aU other 
experiments conducted on the same strains; just as importantly, they justify the massive 
efforts spent to sequence the entire mouse genome (Waterston and al., 2002), and to map 
markers (Schalkwyk et al., 1999) and haplotype blocks (Wade et al., 2002) that 
differentiate strains. Researchers will shortly have at their disposaI a viable number of 
commercially available inbred strains in which practically aIl sources of genetic 
variability have been meticu1ous1y cata1ogued. Determining the ways in which such 
genetic variation is expressed behaviorally remains a daunting, but surmountab1e, 
challenge. 
B.2. Strain differences in nociception and antinociception 
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Assuming they are bred and housed in equiva1ent environments, differences in the 
phenotypic me ans of isogenic strains may be attributed entire1y to genetic differences. A 
rich 1iterature of strain differences across many neurobio1ogica1 parameters has been 
compiled over severa1 decades, especially between the common strains C57BL/6 and 
DBA/2 (reviewed in Ingram and Corfman, 1980). More recent1y, a growing number of 
studies characterize behaviora1 differences between strains on measures of nociception 
and ana1gesia (Be1knap and O'Too1e, 1991; Mogil et al., 1999a; Lariviere et al., 2002; 
Wilson et al., 2003). It is tempting to causally attribute behaviora1 patterns to underlying 
physio1ogica1 divergence between the strains; however, the sheer number ofbio1ogica1 
differences cata10gued between common strains defeats any such attempts. We and 
others have taken a more systematic approach to documenting strain differences, the 
strain survey, in which a panel of strains (including 10 or more strains selected at 
random) is tested for sensitivity or resistance to a pain test or ana1gesic drug. Strain 
surveys have proven to be usefu1 too1s in the dissection of the genetic components of 
nociceptive behavior; thé remainder ofthis section will describe our use of 12 inbred 
strains to investigate numerous tests ofnociceptive sensitivity, hypera1gesia, and 
ana1gesic response (Mogil et al., 1999a; 1999b; Lariviere et al., 2002; Wilson et al., 
2003). These data have been submitted to the Mouse Phenome Project (Paigen and 
Eppig, 2000), a public database to which researchers from all over the world may 
contribute phenotypic results for a core group of inbred strains for comparison. 
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As each member of an inbred strain is genetically identical to all others, the true 
performance of a strain on a measure of nociception may be precisely assessed by 
averaging the performance of many individuals. Whereas between-strain variability 
represents genetic variance, within-strain variability characterizes the influence of 
environmental factors on the trait. It is possible to estimate the contribution of additive 
genetic factors to a given phenotype, referred to as "narrow-sense heritability" (or h2), by 
comparing the allelic variance (VA) with the total variance from both genetic and 
environmental sources (phenotypic variance, or Vp), using a simple formula (Falconer, 
1989): 
We have experimentally determined estimates ofheritability for all major pain tests 
commonly used in the mouse (Mogil et al., 1999a; Lariviere et al., 2002). These 
estimates range from h2=0.30 (for thermal hypersensitivity produced by intraplantar 
injection of carrageenan) to 0.76 (for the acetic acid writhing test). Our work has shown 
that genetics and environmental factors share almost equally the mediation of the majority 
of pain tests in mice. The contribution of genetic factors to pharmacological 
antinociception is smaller (ranging from h2=0.12 for the K-opioid agoni st U50,488, to 
0.40 for the nicotinic agonist epibatidine and the u2-adrenergic agonist c1onidine), but still 
substantial (Wilson et al., 2003). 
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BJ. Genetic correlation 
By employing the same strains in multiple surveys, enough statistical power is 
achieved to investigate genetic correlations between phenotypes (Hegmann and 
Possidente, 1981; Crabbe et al., 1990). Traits that are genetically correlated (i.e., in 
which the same strains score high or low) are presumed to be so because oftheir 
mediation by overlapping sets of genes, due to the ability of individual genes to influence 
various traits (also known as pleiotropy). Observing which phenotypes share genetic 
mediation offers clues as to the nature ofthebiological systems underlying the traits. 
Pain assays may be characterized on a number of parameters (e.g., nociceptive vs. 
neuropathic, stimulus modality, site of injury, intensity, duration, etc.), any ofwhich may 
influence the genetic mediation of the phenotype. A multivariate analysis of our strain 
surveys revealed that genetically correlated assays may be grouped into five "clusters:" 
nociception produced by thermal or chemical/inflammatory stimuli, thermally or 
mechanically evoked hypersensitivity, and hypersensitivity driven by afferent activity 
(Lariviere et al., 2002). Similar sets of strains were sensitive to all tests of thermal 
sensitivity, but an entirely different set of strains scored high on tests of chemical pain. 
This principal held true even for neuropathic injury models-the relevant dimension was 
not the nature of the injury producing hypersensitivity, but rather the stimulus used to 
evoke pain. Additionally, negative correlations indicate that genes responsible for 
hypersensitivity (whether to thermal or mechanical stimuli) are the same as those 
mediating nociception in uninjured animaIs, but in the opposite direction (i.e., thermal 
sensitivity genes are protective of thermal hyperalgesia). 
We have also used genetic correlation to examine the relationship between 
nociceptive sensitivity and analgesic response. Genetic correlations between analgesics 
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of different classes (acting at different receptor types, opioid and non-opioid) range from 
r s=0.39-0.77, suggesting that genes downstream from the receptor in the analgesic 
pathway are responsible for variability in analgesic sensitivity (Wilson et al., 2003). 
Furthermore, the patterns of analgesic variability evinced in this study correlated 
significantly with strain means oftail-withdrawallatency (rs=0.33-0.68) and with 
formalin-induced licking behavior (rs=0.79-0.86). Although there is sorne evidence that 
analgesic magnitude is specific to the type of pain being inhibited (Mogil et al., 1996; 
Elmer et al., 1998), our results suggest the striking possibility that variability in analgesic 
response is an indirect consequence of genes modulating nociceptive sensitivity. 
C. Mapping pain and analgesia genes 
As noted previously, the genetic determinants ofindividual differences in a 
complex trait such as pain are numerous, each contributing a small amount to the overall 
trait variance. Phenotypes regulated by multiple genes usually have a normal (bell-
shaped) distribution in a population, and are referred to as quantitative traits; these differ 
from Mendelian traits, which are controlled by a single gene and are bimodally 
distributed. Localizing the gene underlying a Mendelian trait is a straightforward 
(although quite demanding) process offollowing the trait across multiple generations by 
tracing its coinheritance with genetic markers (a technique referred to as linkage 
mapping). Finding loci responsible for variability in a quantitative trait (quantitative trait 
locus mapping, or QTL mapping) is much more difficult, as there are many more sources 
of variation to capture. lnbred mouse strains are the optimum starting point for QTL 
mapping, as they have quantifiable inherited differences, but can be crossed to produce 
mice with only three possible genotypes at any particular locus (two in the case of 
backcrossed progeny or recombinant inbred strains). 
C.l. QTL mapping methods 
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Properly detined, a quantitative trait locus, or QIL, is simply a region of the 
genome responsible for variation in the trait of interest (Doerge, 2002). Plant geneticists 
have followed the coinheritance of morphological characteristics to map QTL since the 
1920s (Sax, 1923; see also Rasmusson, 1933; Thoday, 1961), but the application of the 
technique to mammalian behavior was impractical before the advent of modem genomics. 
The past two decades have seen tremendous advances in the tools available to geneticists, 
and it is now feasible to undertake QIL mapping projects as the tirst step in identifying 
the precise DNA sequence differences underlying behavioral variation. Optimization of 
this process is essential for proper evaluation of a QTL's size and location, and requires 
attention to such features of study design as population construction, genetic marker 
selection, and statistical modeling (Belknap et al., 1996). 
Strain surveys provide valuable information for the selection of starting strains to 
use in QTL mapping, as strains with polar phenotypes will most likely be those in which 
allelic variation most directly influences performance. Iwo parental strains (generation 
"Pl") are chosen such that phenotypic and genetic divergence are maximized; these 
strains are crossed to produce an FI ("first filial") generation heterozygous at aIl loci. AIl 
FI animaIs are identical, but due to homologous recombination, FI animaIs produce 
offspring (the F2 generation) that are each unique combinations of the Pl strains' alleles 
(homozygous paternal, homozygous maternaI, or heterozygous) when crossed with each 
other. Another common method is to backcross FI animaIs to one of the Pl strains, 
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thereby producing offspring with random assortments of genes with either one or two 
alleles from the backcrossed strain. Although backcrosses have been frequently used to 
map variability loci due to their simplicity (i.e., only one degree of freedom), intercrosses 
have many advantages; as twice as many meioses are evident in an intercross, only about 
halfthe number ofprogeny need be phenotyped (Lander and Botstein, 1986). 
Backcrosses are also ill-suited for determining dominance and epistatic effects. However, 
as mapping precision is directly related to the number of recombination events between 
markers, two other population types offer potentially greater resolution. Advanced 
intercross lines (Darvasi and Soller, 1995) and recombinant inbred lines (Plomin et al., 
1991) both rely on successive crosses in F2lines to increase the recombination density in 
phenotyped animaIs. 
As all F2lbackcross individuals are genetically unique, phenotypic variance 
between them implicates allelic variation at genes involved in its mediation. Although it 
is impractical (using present technology, at least; Carlson et al., 2004) to assay every gene 
for association with the phenotype, a smaller number of markers spread across the 
genome is sufficient to detect linkage. Useful genetic markers are sections ofDNA that 
can be amplified and visualized efficiently, and that differentiate between the parental 
strains, either by length or by nucleotide sequence. Early QTL mapping projects relied on 
restriction fragment length polymorphisms (RFLPs) (Lander and Botstein, 1986), but the 
more common repeat polymorphisms called microsatellites have supplanted them 
(Dietrich et al., 1996), and future mapping studies will increasingly take advantage of the 
ubiquitous single nucleotide polymorphisms (SNPs) (Lindblad-Toh et al., 2000). To 
achieve complete coverage at ~20 cM resolution ofall19 autosomes and the X 
chromosome in the mouse genome, at least 100 markers are required (Flint et al., 2005). 
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Because complex, multigenic traits are influenced by numerous factors, linkage to 
a QTL region is a matter of probability, and numerous statistical techniques have been 
developed to model phenotype-genotype relationships in the various mapping crosses. 
The traditional model of marker regression is the simplest (Doerge, 2002); an analysis of 
variance is performed for each marker, contrasting the hypothesis that the allelic status of 
the marker and the trait cosegregate with the null hypothesis of no linkage. Such single 
marker tests are inefficient, as the markers themselves are not responsible for QTL 
effects, nor do they offer much information as to where a quantitative trait gene might be 
located. 
Interval mapping (Lander and Botstein, 1989) is an alternative strategy whereby 
the genetic map is estimated for entire chromosomes, not just at marker locations, 
enabling a probabilistic full-genome scan. This method employs an iterative algorithm, 
such as the EM algorithm (Dempster et al., 1977), to compute maximum likelihood 
estimates (MLEs) of linkage for missing data points (i.e., aIl intervals between actual 
marker locations). At any given location, the MLE is compared to the likelihood 
estimation under the assumption of no linkage. The strength of linkage at a location is 
expressed as a LOD (logarithm of the odds) score, calculated as the odds of the phenotype 
distribution given linkage to the genotype, over the odds if the phenotype is unlinked to 
the genotype: 
LOD = 10glO(probability of linkage/probability of no linkage). 
Several statistical packages have been developed to perform the mapping calculations 
(e.g., Manly and OIson, 1999; Broman et al., 2003). 
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C.2. Considerations and limitations for QTL mapping 
Even in assiduously characterized experimental populations, quantitative trait 
genes are needles in immense haystacks, and mapping them in practice requires 
surmounting a number of technical and statisticai hurdies. The very nature of a 
quantitative trait implies that genes modifying such a trait willIikely exert a small effect 
on the overall variance, typically on the order of 1-10%, and the number of progeny 
needed to detect differences between genotypes is often over 300. The actual effect 
size(s) is unknown before the experiment is actually performed; therefore, studies can 
only be designed to detect loci above a certain threshold (Lander and Schork, 1994). 
Furthermore, the size of the genome (> 1600 cM) necessitates a large number of markers 
(> I 00 for ~20 cM resolution) be genotyped in each mouse. The number of potentiai faise 
positives is great when such a large number ofinterdependent tests are performed (as in 
marker regression), with a standard Type 1 error rate of 0.05%. The method of maximal 
likelihood used in interval mapping was devised to avoid problems with overcorrecting 
for multiple tests, but the appropriate LOD threshold for significant linkage has been a 
controversial topic. Lander and Kruglyak (1995) proposed standardized threshold values 
of2.8 (suggestive) and 4.3 (significant) as benchmarks for intercross mapping in the 
mouse. However, others have proposed permutation testing, based on resampling from 
the original data, as an empirical means of obtaining thresholds (Churchill and Doerge, 
1994), especially for study designs that violate the assumptions of the Lander and 
Kruglyak model. The criteria for inclusion in the confidence interval (C.I.) are similarly 
controversial. Lander and Botstein (1986) suggested a 1 LOD drop-off, indicating a 
reduction in confidence by a factor of 10, although others have advocated for more 
conservative estimates (1.5 or 2.0 LOD score drop-offs) (Moore and Nagle, 2000). 
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Although beyond the scope ofthis review, model selection for QTL analysis 
remains an area of great research interest. As every data set is unique, care must be taken 
to ensure the appropriate statistical methods are used to account for phenotype 
distribution, covariates, missing genotype data, multiple linked QTL (including 
interaction effects), and any other deviations from linear modeling assumptions. 
(Discussion ofvarious methods can be found in Jansen, 1993; Kao et al., 1999; Sen and 
Churchill, 2001; Broman, 2003). 
Statistical issues aside, there is considerable argument as to the relative usefulness 
of QTL mapping in mi ce as a method to explore the genetic architecture of behavioral 
traits (e.g., Nadeau and Frankel, 2000). Mapping techniques in common use frequently 
require hundreds of mice, thousands of individual genotyping reactions, and tens of 
thousands of dollars. Considering that QTL effects are usually a small proportion of the 
overall trait variance, and that the resolution ofloci is rarely limited to less than 20-30 
cM, what exclusive information do these studies provide? In contrast to studies of mutant 
animaIs (with either transgenic or spontaneous mutations), QTL mapping detects only 
those genes that actually cause variation in their naturally appearing forms; genes are 
never artificially altered. Similarly, genes identified in linkage studies are necessarily the 
first cause of phenotypic variance between two strains; unlike expression techniques such 
as whole-genome microarrays, the primary DNA sequence differences are implicated, 
rather than RNA changes that may be several steps removed from the initial difference. 
Mapping a gene by positionallinkage is not hypothesis-driven, meaning it is capable of 
finding genes for which no functional knowledge exists. Novel trait-relevant pathways 
may even be discovered, if the implicated gene interacts with the phenotype by a 
previously unknown mechanism. For example, oUr investigation of the sex -specific 
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efficacy ofkappa-opioid analgesia led to the gene for the melanocortin-I receptor (MeIr), 
a pivotaI protein modulating analgesia in females (Mogil et al., 2003). Most importantly, 
the potential for translation to human pain conditions is high for QTL mapping, as 
synteny between mice and humans is about 80% (Waterston and aL, 2002), and 
polymorphisms causing minor effects in one species willlikely be tolerated (if not 
common) in another. 
D. Identification of quantitative trait genes 
D.I. Fine mapping methods 
The result of a QTL mapping project is usually a number of20-30 cM regions 
where a quantitative trait gene (QTG) is likely to be located. A 30 cM region of the 
mouse genome may contain, on average, from 400-500 genes, many ofwhich could 
influence the trait in question based on their known biological functions. The process of 
narrowing the number of possible QTGs down to one is known as positional c1oning, 
although many steps are usually required to complete the task. From the initial 
confidence intervals obtained in the initial mapping project, the next step is to fine map 
the implicated region. Like QTL mapping, this process relies on informative 
recombinations in progeny of phenotypically-divergent inbred strains. Genotyping more 
markers around the peak of the QTL in the original F2 population may increase the 
mapping precision somewhat (5-20 cM), but rarely to the degree necessary for molecular 
dissection of the QTL (Moisan, 2000). 
Mapping variability loci can be accompli shed in populations other than 
backcrosses and intercrosses, and such methods can also be used to accelerate fine 
mapping efforts. Recombinant inbred (RI) strains have been used for decades (Bailey, 
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1971) to detect and locate major-effect genes, and have been used to find QTLs as weIl. 
An RI strain panel is constructed from the progeny of an F2 intercross; repeated brother-
sister mating of the F2 animaIs for multiple generations produces a number of reinbred 
lines, each ofwhich is a unique (and fixed) mosaic of the parental strains' genotypes. A 
number of such RI panels have been created, many consisting of over 20 strains each, and 
these have been extensively genotyped such that the strain of origin is known at virtually 
every locus in every strain. Because each member of an RI strain is essentially a clone of 
every other member, variability in a phenotype can be partitioned between genetic 
(between-strain variance) and non-genetic (within-strain variance) sources, when the 
means of multiple mi ce of each strain are considered (Blizard and Bailey, 1979). 
Between-strain variability can be correlated with the known genetic map in order to 
locate regions ofthe genome that predict phenotypic performance across strains (Gora-
Maslak et al., 1991). This method ofQTL detection is usually underpowered compared 
with traditional cross methods, due to the limited number of extant RI strains in any given 
panel; mapping results acquired using RI strains are frequently confirmed using other 
methods. However, once a QTL has been assigned to a broad confidence intervaI, RI 
strains containing recombinations within this interval may be compared in order to 
pinpoint a tightly linked segment. 
A similar strategy may be employed using another genetic model, the recombinant 
congenic strain. Whereas repeated brother-sister mating produces lines of recombinant 
inbred mice in which half of the alleles derive from each parental strain, a congenic line is 
produced by backcrossing an FI animal back to one of the parental strains for a number 
of generations before inbreeding (Demant and Hart, 1986). This produces a recombinant 
strain in which from 6.25-12.5% of the genome (depending on the number of generations 
of backcrossing) is "donor" -derived, the rest arising from the backcrossed, "recipient" 
strain. As with recombinant inbred strains, comparing congenic strains with differing 
alleles in a putative QTL region can associate a marker with variability in a trait. 
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Recently, techniques to create marker-assisted (or "speed") congenic strains have 
been developed that drastically reduce the time and expense of creating a panel of 
conventional congenic strains. Speed congenic mice are also created by backcrossing FI 
intercross progeny with one of the parental strains over 6-8 generations; however, each 
generation is genotyped at the QTL to select for animaIs retaining donor strain mark ers 
(Bailey, 1981; Markel et al., 1997). This process creates mice that are theoretically 
equivalent to the recipient strain throughout the genome, except for the interval between 
the markers used for selection. These animaIs should exhibit the phenotypic effect of the 
QTL when compared with the recipient strain, thereby confirming the presence of a QTG 
in the congenic region. Further congenic substrains may be created by continuing the 
backcrossing, although in practice this technique is limited by the decreasing frequency of 
recombination events in ever-narrowing regions (Darvasi, 1997). 
Congenic strain construction is a tedious and time-consuming (usually 2 years in 
rodents) endeavor, but an alternative strategy has recently been proposed by Bolivar et al. 
(2001). Their method involves exploiting the wealth ofknockout strains currently 
available from commercial suppliers. The construction of a knockout generally involves 
manipulating the desired gene in 129 strain embryonic stem cells before implantation, 
then backcrossing the resulting mice onto a C57BL/6 background. This process 
essentially creates a 129 (donor)1B6 (recipient) congenic region around the deleted gene. 
Assuming the mutation itself doesn't influence the relevant trait, the "knockoutlcongenic" 
can be assessed to determine whether polymorphisms in this region contribute to 
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observed strain differences. A simple breeding protocol can be employed to verify 
whether the mutation or neighboring donor DNA is responsible for phenotype differences 
(Bolivar et al., 2001). 
D.2. Positional/molecular cloning techniques 
Additional meioses to pro duce recombination events are impractical after the 
confidence interval is less than 1-2 cM. Further isolation of the QTL requires direct 
molecular cloning of tiny sequences, usually maintained as part of a library of large-insert 
vectors. These libraries are created by inserting small segments of mouse DNA into 
artificial chromosomes of prokaryotic or simple eukaryotic cells, such as bacteria (BAC 
clones) or yeast (YAC clones.) Transgenic mice can be produced expressing a few 
hundred kb of donor strain DNA. This technique has been successfully used to isolate a 
QTL for asthma (Symula et al., 1999). 
Empirical proof of the identity of a quantitative trait polymorphism requires a 
special type of congenic animal-one in which the precise allelic difference responsible 
for the QTL has been substituted from one strain onto the other (for example, a C~G 
nucleotide exchange) without any other modification. Although this is now technically 
feasible via transgenesis, carrying out the process of cloning a quantitative trait nucleotide 
by its position alone can take up to a decade, and epistasis can radically alter the 
expression of a trait when a single nucleotide change is isolated from the context of the 
full genome (Belknap et al., 1996). Clearly allele transfer is an untenable burden of 
proof, when other, more practical means are available to implicate single genes beyond a 
reasonable doubt. 
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D.3. Candidate gene approach 
The assemblage of all identified genes and expressed sequences in publicly 
accessible databases (e.g., MGI and Ensembl) has made it possible to inventory candidate 
genes at any point in the process of narrowing QTL intervals. A gene-dense 1 cM region 
can contain 20 or more genes, but individual genes on this list can be evaluated for 
evidence supporting a biological mechanism underlying the QTL effect. The standard of 
proof for accepting a candidate gene as responsible for a QTL is based on three factors: 
physiologie function, sequence variation, and/or expression differences. 
A list of positional candidates from a pain QTL study can be winnowed by 
searching the literature for evidence implicating each gene in the region in 
neurotransmission, inflammation, or other relevant biological function. In this regard, 
gene knockout studies play an invaluable role, as the most direct means of associating 
genetic variation with a change in phenotype. To date, over 125 genes have shown a pain 
phenotype in null mutant mice, providing an ever-growing inventory ofhigh-priority 
candidates (see also Belfer et al., 2004 for a discussion on prioritizing "pain genes" for 
human association studies). Of the many pain-relevant genes, only those containing 
actual sequence differences between the original inbred strains are potential candidates. 
Until very recently, researchers concentrated on exonic polymorphisms affecting the 
translated protein sequence, predicting that large differences in protein function were 
behind quantitative trait variability. However, most genetic factors underlying complex 
traits are subtle, and are more likely to be due to polymorphisms that affect the rate of 
transcription or translation (e.g., in introns or upstream regulatory regions, or silent point 
mutations in exons). Consequently, the search for relevant quantitative trait nucleotides 
cannot be limited to the gene itself, but may also include regulatory regions many 
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thousands ofnucleotides from the start of the gene. RNA expression differences (as 
quantified by qRT-PCR or microarray) in candidate genes are considered proxies for 
regulatory modulation in instances where comparing the sequence of the entire 
neighborhood of the gene in both strains is impractical. Ideally, only one gene within the 
QTL region will prove to be functionally important to pain processing, contain effectuaI 
nucleotide sequence variation, and/or be differentially expressed in the parental strains. 
E. In silico mapping in the mouse 
The technique of in silico mapping is a recently proposed alternative to QTL 
mapping in genetically segregating populations. This method relies on archivaI datasets 
of polymorphisms in common inbred strain Hnes; because aIl members of a strain are 
identical, each strain need be genotyped only once. Linkage with a trait is assessed by 
correlating strain means with known polymorphie regions (called haplotypes), rather than 
by associating genetic markers with phenotypes in individual mice. As more strains are 
sequenced, in silico mapping will become an inexpensive but powerful mapping tool, 
especially in the localization of QTL. 
E.1. Haplotype architecture in inbred strains 
The most frequent genetic differences are single nucleotide polymorphisms, or 
SNPs. The SNPview database (http://snp.gnf.org) has genotyped almost Il,000 SNPs in 
48 strains, and Roche (http://mousesnp.roche.com) currently catalogues over 184,000 
SNPs in 20 strains, but the true number is much higher. It is estimated that a SNP 
between mouse strains occurs, on average, every 1000 bases (Lindblad-Toh et al., 2000); 
however, the density of polymorphism is not consistent throughout the genome, as there 
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are regions ofboth high (~40 SNPs per 10 kb) and low (>0.5 SNPs per 10 kb) SNP 
density (Wade et al., 2002). The vast number of informative SNPs bears great promise 
for full-genome association studies in humans, which would allow variability genes to be 
mapped at very high resolution (Risch, 2000). Unfortunately, genotyping millions of 
SNPs in each subject would require immense resources by today's technology. 
In the mouse, it may not be necessary to determine the allelic status of every 
known SNP in order to perform genome-wide surveys. It has been suggested that the 
genomes of extant inbred strains are mosaics of European and Asian ancestral stocks, and 
their relatively recent divergence from a common ancestor is indicated by large regions of 
conserved sequences among strains (Wade et al., 2002). Genotypes are transmitted 
together in segments of high linkage disequilibrium called haplotype blocks; haplotype 
structure allows one to treat the entire block as a unit of inheritance. By sorne estimates, 
only 50,000 tag-SNPs (each representing a single haplotype) may be sufficient to 
characterize the entire genome (Cuppen, 2005), although others argue that a tag-SNP 
every 10 kb (i.e., 300,000 for complete genome coverage) is needed to preserve power 
(de Bakker et al., 2005). 
E.2. Mapping phenotypes with haplotypes 
Grupe et al. (2001) first described a practical strategy to map phenotypes using a . 
SNP database (publicly available at http://mousesnp.roche.com/). As a proof of concept 
experiment, they attempted to verify 26 published QTL for 10 different behavioral and 
physical traits. For each pair of strains, they computed distances between genetic loci 
based on allelic status; they then compared these values with archived phenotypic values, 
and computed a correlation value between the genetic and phenotypic distances for each 
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strain-pair comparison. They were able to confirm 15 of the 26 known QTL while 
excluding 90% of the genome from consideration. Their algorithm employed arbitrary 10 
cM haplotype blocks, rather than inherited, empirically-verified haplotypes, thereby 
compromising the resolution. The appropriate level of significance is also unclear, as the 
number of strains with both phenotypic and genotypic data was only 4-10 per phenotype 
(Chesler et al., 2001). However, refinements to this technique promise to vastly improve 
the detection and localization of QTL as more strains are included in the database, and it 
was recently reported that this method was able to pinpoint the aromatic hydrocarbon 
receptor based on its metabolic activity in 13 inbred strains (Liao et al., 2004). 
An alternative use for in silico mapping has been described by Marshall et al. 
(2002); they used allelic variation to prioritize coding-region SNPs within QTL attendant 
to traditionallinkage mapping. It is also advantageous to combine haplotype analysis 
with QTL mapping to disregard areas within a confidence interval that are identical-by-
descent between the parental strains, and therefore unlikely to produce phenotypic 
variability. 
F. CUITent knowledge of genes relevant to nociception and analgesia 
) 
We have consistently observed moderate-to-high heritability estimates for a range 
of nociceptive and analgesic phenotypes in mouse strain surveys (Mogil et al., 1999a; 
Lariviere et al., 2002; Wilson et al., 2003), indicating that they would be amenable to 
genetic dissection using the mapping techniques described above. Rather than attempt to 
separately map each ofthe dozens of pain tests, we have employed a strategy suggested 
by genetic correlation analysis. As most pain assays cluster with other tests activating the 
same stimulus modality (Mogil et al., 1999b), it is likely that QTL mapping of a 
representative test from each group will uncover major effect genes common between 
tests. Thermal, chemical/inflammatory, and neuropathic pain QTL have aIl been 
successfully mapped, and in several cases candidate genes have been identified. The 
genetic mediation of analgesia produced by opio id drugs and stress has also been 
explored. 
F .1. QTL mapping of nociception 
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Thermal pain was first mapped using the hot plate test in a recombinant inbred 
population derived from the C57BL/6 and DBA/2 strains (Mogil et al., 1997a). Six 
regions were implicated in a preliminary scan, and a subsequent repli cation experiment 
using an F2 intercross confirmed that distal chromosome 4 harbored a QTL for thermal 
sensitivity, dubbed Tnpr 1. Interestingly, the QTL effect was not significant in females, 
suggesting the gene contributes to thermal pain variability in males only. The o-opioid 
receptor gene Oprd1, located on Chr. 4 at 65 cM, appeared to be a strong candidate 
underlying this QTL, and pharmacological studies verified that blockade of this receptor 
affects sensitivity on the hot plate test in a sex- and strain-dependent manner. 
A differènt thermal pain assay, the radiant heat paw-withdrawal test of Hargreaves 
et al. (Hargreaves et al., 1988), was used to uncover a second thermal pain gene. Linkage 
mapping in two different F2 intercrosses (B6xAKR and B6xC) established that a QTL 
was located on Chr. 7 between 34 and 67 cM (Mogil et al., 2005). This region was 
further narrowed to a 12 cM interval using the A.B6-Tyr+/J congenic strain. The most 
likely candidate gene in this region was Ca/ca (54 cM), which encodes the 
neurotransmitter calcitonin gene-related peptide, alpha (CGRPa), known to be released 
by nociceptors following noxious activation. Injection of CGRPa into the tested paw 
. ~ .. 
completely eliminates the wide divergence between strains on the Hargreaves test, and 
other lines of electrophysiological and gene expression evidence support the role of this 
gene in variability in thermal sensitivity. 
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The Chr. 7 QTL region was observed in another test of "buming" pain, one which 
used the chemical capsaicin rather than a thermal stimulus. Capsaicin is the pungent 
component of chili peppers responsible for the sensation of heat, as it activates the same 
transduction molecule (the Trpvl receptor) that also responds to noxious heat. Furuse et 
al. (2003) mapped 4 QTL determining capsaicin intake, a measure of oral "bum," in a 
cross between sensitive C57BL/6 and insensitive KJR mice. None ofthese QTLs 
(Capsql-Capsq4, located on Chr. 2, proximal 7, medial 7, and 8 respectively) contained 
the Trpv 1 gene, serving as a reminder that variability does not have to occur at the 
activation of a pathway, but can occur at any level downstream as weIl . 
Neuropathic pain has been mapped using the autotomy model, in which 
transection of the hindlimb nerves produces self-mutilation behaviors (Wall et al., 1979). 
Seltzer et al. (2001) used a recombinant inbred set derived from the sensitive A and 
insensitive C57BL/6 strains to map a QTL on Chr. 15 to a 3 cM interval; unfortunately, 
the large number of potential candidates in this region has prec1uded positive 
identification ofthe QTG. These researchers have subsequently verified this painl locus 
in a backcross of C3HIHeN and C58/J mice (Devor et al., 2005). 
Ongoing work in our lab has focused on two QTL we observed using the biphasic 
formalin model of chemical/inflammatory pain. Previous strain surveys had identified A 
and C57BL/6 as strains with low and high incidences, respectively, oflicking following 
intraplantar injection with a dilute solution offormaldehyde (Mogil et al., 1998; Mogil et 
al., 1999a). Interval mapping with an F2 intercross ofthese strains revealed a QTL on 
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Chr. 9 (Nociq l, peak~60 cM) that predicted formalin response in the early phase only; a 
second region on Chr. 10 (Nociq2, peak~55 cM) associated with both early and late 
phases of the formalin test (Wilson et al., 2002). The Chr. 10 region has been linked to 
collagen-induced arthritis (Dracheva et al., 1999; Yang et al., 1999) and the acetic acid 
writhing test (H. Hain and J.K. Be1knap, unpublished results), suggesting the gene 
responsible for this QTL is also relevant to other inflammation models. We have 
employed a number of techniques to identify these two inflammation genes; this work 
will be fully detailed in this manuscript. 
F.2. QTL mapping of analgesia 
The genetic mediation of morphine analgesia has been thoroughly dissected using 
a number of approaches capitalizing on the divergence of C57BL/6 and DBAI2 on 
inhibition of hot-plate sensitivity. The trait was initially mapped using BXD recombinant 
inbred (RI) strains; only one significant QTL was observed, on Chr. 10 (Belknap et al., 
1995). A number of other putative QTL were found in a follow-up study using the same 
RI set and in a B6D2F2 intercross; these were investigated using a short-term se1ected 
breeding approach and congenic strains in which backcrossing was used to place small 
intervals of one strain onto the genetic background of the other (Bergeson et al., 2001). 
Four QTL were reliably confirmed, accounting for up to two-thirds of the genetic 
variance of the trait. The largest, on Chr. 10, comaps with the Il-opioid receptor gene 
(Oprml), which encodes the receptor for morphine and which has been implicated in pain 
variability (Uhl et al., 1999). This region has also been linked to voluntary morphine 
consumption (Berrettini et al., 1994), but not morphine antinociception on the writhing 
test (H. Hain and J.K. Belknap, unpublished data). A QTL on mid Chr. 9 appears to be 
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due to the serotonin I-B receptor gene Htrlb, based on pharmacological evidence (Hain 
et al., 1999), and a likely candidate for a female-specific QTL on proximal Chr. 1 is the K-
opioid receptor gene Oprkl, although more confirmatory evidence is needed. A second 
Chr. 9 QTL, also observed only in females, has not been identified to date. Details of an 
previously mapped pain- and analgesia-related QTLs are given in Table 1. 
Mapping quantitative trait loci has proven extremely useful in elucidating the 
nature of female-specific mechanisms of stress-induced and opioid analgesia. Analgesia 
produced by a short swim in cold water is mediated by NMDA receptors in male mice of 
most strains, but pharmacological blockade ofNMDA activity in females has no effect 
(Mogil et al., 1993; Mogil and Belknap, 1997). Similarly, NMDA activity is required for 
K-opioid analgesia in male deer mice but not females (Kavaliers and Choleris, 1997). 
Separate mapping projects affirmed that stress-induced analgesia (SIA) and U50,488 (a K-
opioid agonist) analgesia both mapped to distal Chr. 8, but the effect was only observed 
in females (Mogil et al., 1997b; Mogil et al., 2003). Although no genes in this region 
were obvious candidates, the melanocortin-l receptor gene Melr was investigated due to 
its expression in the P AG and the antinociceptive properties of its endogenous ligands, u-
melanocyte stimulating hormone (u-MSH) and adrenocorticotropic hormone (ACTH). 
Comparing mutant female mice with non-functional melanocortin-l receptors to their 
wild-type counterparts, we observed a "male" (i.e., NMDA-sensitive) pattern ofresponse 
to U50,488 injection in the mutants only (Mogil et al., 2003). Pharmacological 
antagonism of this receptor in wild-type females likewise resulted in a switch from the 
female to male system. 
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F.3. Simultaneous QTL mapping of multiple nociceptive and analgesic phenotypes 
Although we and others have demonstrated sorne success identifying a number of 
genes relevant for pain sensation and opioid analgesia, only a smaU number of 
nociceptive phenotypes have been explored. Strong genetic correlations between various 
assays of particular pain modalities, as weIl as between analgesics of multiple drug 
classes, suggest that overlapping sets of genes contribute to these traits. We have 
proposed (Mogil et al., 1999b; Wilson et al., 2003) that an efficient dissection of the 
genetics of pain should draw upon information gathered from these strain surveys, 
enabling the prediction of phenotypes that would display common genetic mediation. 
SpecificaUy, we predict that simultaneous mapping projects ofthree correlated analgesic 
drugs will implicate loci in common across aU three drugs. Such a finding would likely 
represent a gene (or genes) acting at a level of the descending modulatory pathway where 
analgesic mechanisms have converged. To test this hypothesis, we have used a 
B6129PF2 intercross population to map variability loci responsible for analgesic 
sensitivity to clonidine, morphine, and WIN55,212-2. 
In a separate line of experiments, we have used mice derived from an AxB6 cross 
to investigate two previously discovered QTLs mediating variability on the formalin test 
(Wilson et al., 2002). The biphasic formalin test may be considered as two distinct 
phenotypes, as the early and late phases appear to correspond to different nociceptive 
mechanisms. The first QTL, located on Chr. 9, was significant for the early phase only, 
but a QTL on distal Chr. 10 reflected early and late phase variance. We have used a 
number of genetic, molecular, and pharmacological techniques to determine the identity 
of genes regulating sensitivity to chemical/inflammatory pain. 
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CHAPTER 2: QTL MAPPING OF THERMAL NOCICEPTION AND ANALGESIA 
A. Experiment Summary 
Genetic correlation analysis of five analgesic drugs predicted that overlapping sets 
of genes may be responsible for sensitivity to analgesic drugs of multiple neurochemical 
classes (Wilson et al., 2003). We designed simultaneous QTL mapping projects to 
determine the genetic factors contributing to variability in clonidine, morphine, and 
cannabinoid analgesia using a common population of 896 B6129PF2 intercross mice. An 
mice were genotyped at 100 micro satellite markers spread throughout the mouse genome, 
and the software package Rlqtl was employed for interval mapping of an phenotypes. 
Baseline thermal pain mapped to two major loci on chromosomes 7 and Il, as weU as 
others. A locus exerting moderate effects on analgesia from aU three drugs was observed 
on distal Chr. 1. The peak of linkage for aU three drugs was within 5 cM of the 95 cM 
mark, suggesting a single gene is likely partially responsible for variability across drug 
types. This region of Chr. 1 has a number of potential candidate genes, of which many 
have been posited as quantitative trait genes for other neurobehavioral phenotypes. The 
gene Kcnj9, encoding a G protein-coupled inwardly rectifying potassium channel, is 
located at the peak of linkage and is differentially regulated between 129 and C57BL/6 
strains, making it a prime candidate for explaining variability in sensitivity to analgesic 
drugs. 
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B. Introduction 
Genetic diversity is a major component underlying individual differences in both 
nociception and analgesia. A growing literature has documented moderate heritability 
estimates for a number of clinical and experimental pain conditions in humans 
(Honkasalo et al., 1995; Larsson et al., 1995; Mac Gregor et al., 1997; Treloar et al., 1998; 
Hakim et al., 2002). There is also evidence that anàlgesia produced by opiate drugs is 
influenced by genetic factors (Liston et al., 1981); aUelic variants of several metabolic 
genes, including COMT (Zubieta et aL, 2003) and CYP2D6 (Sindrup et aL, 1990; Poulsen 
et al., 1996), have been associated with deficiencies in opioid activity. The use of 
isogenic and selectively bred mouse strains has overwhelmingly confirmed that genetic 
differences contribute significantly to variability in analgesic response from opiates 
(reviewed in Flores and Mogil, 2001) as weU as a number of distinct pain modalities 
(Mogil et al., 1999a; Lariviere et al., 2002). 
Non-opioid drugs are increasingly valued as adjuvant analgesics in conjunction 
with opioids, and there is considerable interest in developing them for stand-alone use to 
combat chronic pain. Studies comparing rodent strains have demonstrated a genetic 
influence on non-opioid analgesics, including the u2-adrenergic receptor agoni st clonidine 
(Marwaha, 1984; Tiurina et al., 1995) the nicotinic acetylcholine receptor agonist 
epibatidine (Flores et al., 1999), and cannabinoids (Onaivi et al., 1996), among others. 
Although the primary receptor for each of these drugs is unique, they are aU (except for 
the nicotinic receptor) G protein-coupled receptors (GPCRs), and they aU putatively 
inhibit pain by activating descending modulatory pathways in the spinal cord. However, 
the extent to which the genetic mediation of a particular drug class is distinct from others 
has been largely unexplored. 
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We recently examined this question by assaying a panel of inbred mouse strains 
for sensitivity to five analgesic drugs active against the tail-withdrawal and formalin tests 
(Wilson et al., 2003). These drugs included the K-opioid agonist U50,488, the 
cannabinoid WIN55,212-2, c1onidine, epibatidine, and (for comparison) the prototypical 
Il-opioid drug morphine. For each drug, the range ofhalf-maximal antinociceptive doses 
(AD50s) between strains was quite large, from a 2.5-fold difference between BALB/c and 
C58 strains in U50,488 sensitivity, to a 36.8-fold difference between A and AKR mice for 
the cannabinoid agoni st. Intriguingly, we observed similar response patterns across drug 
classes, such that mouse strains sensitive to one analgesic were likely to be sensitive to 
the others. Genetic correlation analysis (Crabbe et al., 1990; Mogil, 2000) suggested that 
overlapping sets of genes partially mediate analgesic magnitude regardless of the drug 
used, possibly by regulating neuronal excitability at CNS sites where analgesic 
mechanisms have converged. In addition, baseline pain response was shown to be 
negatively correlated with analgesic sensitivity, implying that the genes responsible for 
analgesia are also involved in determining nociceptive sensitivity. 
Although we can currently only speculate as to the nature of these "master genes" 
controlling pain and analgesia, quantitative trait locus (QTL) mapping has been used 
successfully to determine the identity of a number of genes involved in nociceptive 
modulation. The genetic determinants ofbaseline thermal sensitivity have been dissected 
using two commonly used pain tests. Mogil et al. (1997a) detected a locus on 
chromosome 4 that appearS to modulate hot-plate latencies in male but not female mice; 
this locus likely corresponds to the ~h-opioid receptor gene. Variation in the Calca gene 
on Chr. 7, which encodes the nociceptive neurotransmitter CGRP, was shown to be 
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responsible for the greater sensitivity of C57BL/6 over AKR mice (and very likely 
between aIl 12 strains tested) on the Hargreaves paw-withdrawal test (Mogil et al., 2005). 
Morphine antinociception against hot-plate pain has been thoroughly examined 
using QTL analysis in multiple populations derived from a C57BL/6 and DBA/2 cross 
(Bergeson et al., 2001). Five significant loci have been revealed, accounting for most of 
the genetic variance between the two strains. One of these, on Chr. 10, comaps with 
Oprml, the Il-opioid receptor gene. Although this result may seem intuitive, this locus 
was not linked with morphine inhibition of nociceptive behavior in the acetic acid 
writhing test (H. Hain and J.K. Belknap, unpublished results), indicating that the genetic 
mediation of analgesia may be dependent on the characteristics of the pain being 
inhibited. A second locus on mid-Chr. 9 is likely the serotonin-IB receptor gene Htrlb 
(Hain et al., 1999). Two other loci implicated in morphine analgesia are both markedly 
female-specific; the identities of the responsible genes are as yet unproven, although one 
on proximal Chr. 1 may be the K-opioidreceptor. Another female-specific locus has been 
found to mediate analgesia produced by both non-opioid stress mechanisms (Mogil et al., 
1997b) and the K-opioid drug U50,488 (Mogil et al., 2003). This locus, mapped to distal 
Chr. 8, was shown to be the melanocortin-l receptor gene, Mc1r (Mogil et al., 2003). 
Although genetic differences in the receptor to which a particular drug binds 
may pro duce variability between individuals (as has been shawn for morphine), it is 
highly unlikely that genes responsible for analgesia across drug classes encode membrane 
receptors. Rather, the "master genes" willlikely be those participating in mechanisms 
common to multiple analgesic systems, such as G protein-coupled second messenger 
systems, neuronal excitability, or neurotransmitter metabolism. Altematively, they may 
be those genes contributing to variable sensitivity to the pain modality itself. As a first 
step in localizing these genes, we performed simultaneous quantitative traitlocus 
mapping projects with three analgesic drugs active against the tail-withdrawal assay of 
thermal pain: morphine, clonidine, and the cannabinoid WIN55,212-2. 
C. Methods 
C.l. Subjects 
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Previous strain surveys revealed that 129P3 mice are relatively sensitive to aIl of 
the analgesics under consideration in this study, whereas C57BL/6 mi ce are among the 
most resistant to their antinociceptive effects (Wilson et al., 2003). Conversely, these two 
strains are resistant and sensitive, respectively, to thermal pain as assessed by the tail-
withdrawal test (Mogil et al., 1999a). Breeding pairs ofB6129PFlIJ animaIs (the 
reciprocal129PB6Fl cross is not commerciaIly available) were obtained from The 
Jackson Laboratory (Bar Harbor, ME) and bred on-site at Mc Gill University. Their F2 
hybrid offspring were weaned at 18-21 days and housed in groups of3-5 same-sex 
littermates in our humidity- and temperature-controIled vivarium. AlI mice were given 
food (Harlan Teklad 8604) and water ad libitum and maintained on a 14110-hr light/dark 
cycle. They were tested at no less than six weeks of age, in approximately equal numbers 
of males and females. Testing was performed near the middle of the light phase to 
minimize circadian effects (Kavaliers and Hirst, 1983). Immediately after testing, 
subjects were euthanized by cervical dislocation according to ethical guidelines, and their 
liver, spleen, and tail were harvested for genotyping. 
C.2. Phenotyping 
Morphine sulfate (National Institute for Drug Abuse, Rockville, MD) was 
dissolved in 0.9% saline and administered in a dose of 15 mg/kg. Clonidine 
hydrochloride and WIN55,212-2 (both from Tocris, Ellisville, MO) were also dissolved 
in saline, in doses of3 mg/kg and 10 mg/kg, respectively. Doses were chosen on the 
basis that they robustly distinguish 129P3/J mice from C57BL/6J mi ce (i.e. 129 mice 
show marked analgesia while B6 mi ce are relatively unaffected.) AlI drugs were 
administered intraperitoneally to naïve mice in an injection volume of 10 ml/kg. 
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AlI mi ce were phenotyped using the 49° tail-withdrawal assay; testing of aU drug 
groups occurred concurrently over the course of ~ 1 yr (summer to summer). Each mouse 
was secured gently inside a c1othlcardboard holder with its tail held outside. The tail was 
lowered into a hot water bath maintained at 49.0°C and the time for it to withdraw its tail 
was measured with a stopwatch to the nearest 0.1 s; 15 s was used as a cutoff latency in 
order to avoid damage to the tai!. Readings were taken at baseline (pre-injection) and at 
15,30, and 60 minutes post-injection of the drug. At each time point, two latencies were 
measured and then averaged to increase accuracy. For purposes of statistical analysis, 
phenotypic data at each time point were converted into percentage of the maximum 
possible effect using the formula: 
%MPE = (post-injection latency-baseline )/( cutoff-baseline) x 100 
The maximum %MPE for the three time points was used as a measure of analgesic 
magnitude for QTL analysis; as an alternative way of characterizing the effectiveness of 
analgesic compounds, we also computed the percent analgesia, or area under the time-
I~ 
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course curve (AUC). Baseline latencies were used as a measure of sensitivity to thermal 
nociception for use in interval mapping. 
C.3. DNA Isolation and Genotyping 
Genomic DNA from the mouse spleens was extracted using the DNeasy kit 
(Qiagen, Mississauga, ON) following the manufacturer's protocol, and PCR was 
performed using standard procedures. Primers were obtained from Invitrogen 
(Burlington, Ontario). Samples were genotyped either in our laboratory, by capillary 
electrophoresis using the CEQ 8000 Genetic Analysis System (Beckman-Coulter, 
Fullerton, CA), or off-site at the Genome Quebec Innovation Centre using the ABI Model 
3100 (Applied Biosystems, Foster City, CA), for 100 micro satellite markers (average 
intermarker distance: 15.6 cM) across the 19 autosomes and the X chromosome (Fig. 1). 
Markers were selected using the MGI database (www.informatics.jax.org) to differentiate 
between 129P3/J and C57BL/6J alleles. 
C.4. Statistical Analysis and QTL Mapping 
Phenotypic and genotypic data were assembled in Excel (Microsoft, Redmond, 
WA), and basic statistical analyses were performed in Systat 10 (SPSS, Chicago, IL). 
Frequency histograms of the phenotypes were generated using Prism 4 (GraphPad, San 
Diego, CA). Seven mice were excluded as statistical outliers on the basis oftheir 
baseline latency >3 s.d. from the mean. The analgesia score used in aIl subsequent 
analyses was percent analgesia, as the frequency distribution of this measure in the F2 
population exhibited more variability (and therefore more statistical power for mapping) 
than did maximum %MPE. Analgesia was analyzed within each drug group (clonidine 
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n=292, morphine n=302, WIN n=295), as well as collectively, regardless of drug (n=889). 
Baseline latencies of all mice (except outliers) were used to map thermal sensitivity 
(n=889). 
The Rlqtl programming environment (version 2.1.1; Broman et al., 2003) was 
used to perform full-genome scans as well as to evaluate multiple-QTL models for all 
phenotypes. Utilities within Rlqtl were used to calculate recombination frequencies and 
identify genotyping errors; the estimated genetic map compared favorably with 
established marker positions (data not shown). Interval mapping was generally 
performed using the EM algorithm as implemented in Rlqtl, except where noted. We 
assessed the significance level individually for each QTL search by permutation tests with 
1000 iterations; this analysis was occasionally done using Haley-Knott regression (Haley 
and Knott, 1992), when the computational demands were too great to be carried out with 
the EM algorithm. Except where noted, aIl results above a full-genome-corrected p < 
0.05 are reported as significant. "Suggestive" and "highly significant" results correspond 
to Type 1 error rates ofp < 0.63 and 0.001, respectively (Lander and Kruglyak, 1995). 
D. Results 
The mean ofthe baseline latencies in all F2 mice was 3.38 ± 0.03 s, intermediate 
between the means ofthe parental strains (l29P3 = 4.8 s, B6 = 2.2 s; Mogil et al., 
1999a). The trait distribution (see Fig. 2a) exhibited wide, non-normal variability around 
this mean (Shapiro-Wilk normality test W = 0.97, p<O.OOI, kurtosis = 0.3, skewness = 
0.7); the baseline scores were therefore normalized using a square root transformation for 
QTL mapping. The distributions of analgesia measurements appeared to be bimodal in 
all three drug groups (Fig. 2b-2d); a considerable number of mice exhibited 100% 
!~ 
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analgesia across time-points, whereas the remainder was distributed around a peak 
substantially lower. Such a bimodal distribution suggests that a single main effect gene 
(or unidentified environmental confound) separates mice into responsive and non-
responsive groups, with other smaller-effect loci determining variability around these 
peaks. At the doses used, morphine produced a greater mean level of analgesia (65.2%) 
than did clonidine (43.1 %) or WIN55,212-2 (42.6%) 
Male mice were significantly more sensitive to clonidine (t290 = 3.211,p < 0.001) 
than were females, and a trend toward differential responses between males and females 
was observed in thermal sensitivity (t888 = 1.638, p = 0.10) and analgesia produced by 
morphine (t300 = 1.691,p = 0.09), but not WIN55,212 (t293 = 0.665,p = 0.51). Baseline 
latencies correlated weakly with clonidine (r = 0.24,p < 0.001) and WIN55,212 (r = 0.12, 
p = 0.05) analgesia, but not with morphine (r = 0.04,p = 0.48) analgesia. These genetic 
correlations partially confirm our previous prediction that overlapping sets of genes are 
likely to be found contributing to both pain and analgesia variability in this mapping 
population (Wilson et al., 2003). 
As the phenotyping of the three groups was performed simultaneously over an 
extended period, we looked for trends across months in thermal sensitivity and analgesic 
magnitude for each group. Baseline latency appeared to decrease, as a main effect of 
month was noted (FlO,907 = 4.78,p < 0.001). An increase in morphine sensitivity was also 
observed over time (F6,295 = 10.55,p < 0.001), but no such trend was apparent for 
clonidine (F8,306 = 1.28,p = 0.25) or WIN55,212 (F4,294 = 1.19,p = 0.32). As the trends 
were not consistently observed in aIl groups, nor were they cyclical (i.e., seasonal), we 
hesitate to speculate as to the nature of any covariates systematically confounding these 
results. 
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D.1. Thermal QTL 
Interval mapping with a single-QTL model revealed two highly significant loci 
affecting baseline latencies on the tail-withdrawal test, one on Chr. 7 and one on Chr. Il 
(Fig. 3a). Additional suggestive loci were observed on four other chromosomes. A two-
dimensional scan was then performed, to detect any epistatic interactions between these 
QTL. No interactions were observed between the detected loci, but a strong interaction 
between a region of Chr. 4 and the X chromosome suggested the presence of a sex-
specifie QTL. Interval mapping with sex as a covariate confirmed a suggestive linkage to 
Chr. 4 in males only. A multiple QTL model may be constructed with the fitqtl function 
in Rlqtl; this method uses a drop-one-term analysis to compare the full model (all terms 
included) with the model obtained by dropping a given term. The best-fit model (Table 
2) accounts for 14.9% of the phenotypic variance in tail-withdrawal sensitivity (as Rlqtl 
uses the imputation method for modeling, Table 2 does not correspond exactly with Fig. 
3a-d, which were created using the EM method.) 
D.2. Analgesia QTL 
The analgesia scores of the F2 mice were bimodally distributed, with a spike at 
the upper limit, so the "two-part" model designed for such a pattern of responses was 
used for interval mapping with the EM algorithm (Broman, 2003). Although this model 
takes into account the added parameters of non-normal frequency distributions, it can be 
computationally intensive. Therefore, significance levels were estimated using 1000 
permutations of the phenotypes, as analyzed using Haley-Knott regression on a normal 
model; this method likely overestimates the significance estimates of our datasets. 
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In order to generate hypotheses regarding the presence and location of a "master 
analgesia gene," we first analyzed a composite analgesia phenotype inc1uding all mice, 
regardless ofwhich drug was administered. One significant locus was observed on distal 
Chr. l, and nine other peaks reached a level of suggestive significance (Fig. 4). We then 
performed interval mapping of the three drug datasets separately. The Chr. 1 locus was 
also significant in the c10nidine and WIN55,212 groups, but no linkages reached 
significance in the morphine group (Fig. 5). There was likely a great deal of data 
censoring in the morphine results, as the 15 mg/kg dose induced high levels of 
antinociception in the majority of animaIs. Therefore, we repeated the experiment in a 
new B6129PF2 population using a 10 mglkg dose, genotyping only three markers at the 
distal end of Chr. 1. Significant linkage (peak LOD = 2.8 at 93 cM, 95% threshold LOD 
= 1.95) to this region was observed in this population, mirroring the peaks seen in the 
c10nidine and WIN55,212 groups (Fig. 6). One other significant locus was observed on 
Chr. 7 in the WIN55,212 group, as weIl as numerous suggestive loci. The full QTL 
models for c10nidine and WIN55,212-2 analgesia, as determined by imputation mapping 
and the drop-a-term method, are given in Table 3. 
Additional analyses were conducted using sex and baseline latencies as covariates, 
in order to partition out the effects ofthese factors. However, the additional parameters 
resulted in a corresponding decrease in power, and no credible linkages were observed. 
.~. 
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E. Discussion 
Major genetic factors underlying variability in a number of nociceptive traits have 
been localized using quantitative trait locus mapping, and a few of the quantitative trait 
genes have already been identified. The present experiment extends our knowledge of the 
genetic determinants of thermal pain, with possible confirmation of previous findings. 
We have also explored the genetic mediation of multiple analgesic modalities, in 
particular the hypothesized existence of a set of genes mediating antinociception 
regardless of the pharmacological binding site. 
E.l. Thermal pain QTLs 
Performing simultaneous mapping projects from a common F2 intercross 
population allowed for maximal power in the combined dataset used to map base1ine 
thermal pain. Two loci were detected at high significance, despite having only moderate 
effects on the overall trait variance. The largest ofthese peaks, a locus on Chr. 7 (peak at 
33 cM, l-LOD drop-offC.r. 24-38 cM) accounting for 4.7 % of the phenotypic variance, 
localizes roughly near a known QTL for thermal pain. Using the Hargreaves paw-
withdrawal assay, we mapped a QTL at 50 cM (C.r. 34-62 cM) in a B6xAKR intercross 
(Mogil et al., 2005). Severallines of evidence implicated the gene Calca, which encodes 
the neurotransmitter CGRP, as the responsible gene (Mogil et al., 2005). However, 
located at 54 cM, Calca lies well outside the confidence interval of our present QTL on 
Chr. 7 and is an unlikely positional candidate. Few obvious pain-related candidate genes 
reside within our locus, although it does contain several genes with effects on neuronal 
activity, including subunits of GABA-A and cholinergic receptors and the nerve growth 
factor necdin. Interestingly, this region of mouse Chr. 7 is syntenic to a region of human 
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Chr. 15 that is deleted in Prader-Willi syndrome; Prader-Willi patients exhibit deficits in 
thermal sensation (Holm et al., 1993), and mice lacking the necdin gene Ndn (a nerve 
growth factor, located at 28 cM) have similarly diminished pain sensitivity (Kuwako et 
al., 2005). Although this QTL may help explain individual differences in normal and 
abnormal human populations, it does not explain the strain difference in nociceptive 
sensitivity between 129P3 and C57BL/6 mice, as the more sensitive strain (B6) carries 
the nociception-resistant allele of the locus. 
Conversely, the Chr. Il QTL at 46 cM (C.1. 30-55 cM) does mirror the direction 
of the strain difference, and allelic status at this locus accounts for 3.1 % of the phenotypic 
variance in the F2 population. Considering the large number of genes in this region that 
could be plausible candidates influencing thermal pain sensitivity, it is remarkable that it 
has not previously been linked to hot-plate (Mogil et al., 1997a), Hargreaves' test (Mogil 
et al., 2005), or oral capsaicin (Furuse et al., 2003) sensitivity. The primary thermal 
transducer protein is encoded by Trpv 110cated at 44.1 cM, and a number of ion transport 
channel proteins linked to pain (including the potassium channel Kcnj 12 at 34.2 cM, the 
sodium-potassium pump Afp1 b2 at 40 cM, and the amiloride-sensitive sodium channel 
Accn1, the nicotinic acetylcholine receptor Chrne, and the serotonin transporter Slc6a4 at 
42 cM) are also found within the confidence interval. Other genes in the region with a 
known role in pain modulation inc1ude a c1uster of arachadonic acid metabolism enzymes 
between 37 and 40 cM, and genes involved in wind-up and inflammation (guanylate 
cyc1ase Gucy2e at 37 cM and nitric oxide synthase Nos2 at 45.6 cM) and in opioid 
antinociception (B-arrestin 2 Arrb2 at 45 cM). 
Four suggestive loci on Chr. 3 (81 cM), Chr. 4 (56 cM), Chr. 6 (28 cM), and Chr. 
14 (3 cM) contribute only slightly (>2%) to the phenotypic variance. Of considerable 
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note, however, is that the chromosome 4 QTL, significant only in males, comaps with a 
similarly sex-specific QTL for thermal pain sensitivity on the hot-plate test (Mogil et aL, 
1997a). This QTL, located between 50-80 cM from the centromere, was discovered in 
the BXD set of recombinant inbred strains, and was subsequently confirmed in a 
C57BL/6 x DBA/2 intercross. Pharmacological evidenced amassed by Mogil et al. 
(1997a) concluded that the OprdJ gene (65 cM), which codes for the o-opioid receptor, 
may partially determine hot-plate sensitivity in a sex- and strain-dependent manner. 
Based on the parallellocalization and sex-specificity ofthese two loci, it is highly 
probable that we have replicated the hot-plate QTL using a different pain test in a novel 
cross, affirming our position that different assays of the same pain modality will share 
genetic mediation (Mogil et aL, 1999b; Mogil, 2000). 
E.2. Analgesia QTL 
Genetic correlation analysis (Wilson et aL, 2003) predicted that QTL mapping of 
analgesia produced by divergent compounds would implicate common sets of genes. We 
first looked for linkage in a combined dataset of almost 900 F2 mice, in which analgesic 
response to one of three drugs had been quantified for each mouse. Only one region, on 
distal Chr. 1, appeared to be significantly linked, despite the high power of the large 
datas et. Each subset of F2 animaIs was then examined to determine if the Chr. 1 QTL 
generalized to clonidine, morphine, and WIN55,212-2. We found significant linkage to a 
26 cM region (84-110 cM) for all three analgesic drugs. Though the peak of linkage 
differed slightly between drugs (100 cM for clonidine, 90 cM for morphine, and 96 cM 
for WIN55,212-2), we believe these differences are negligible, due to the imprecision of 
r--.. 
QTL mapping. Baseline thermal sensitivity did not significantly map to any region of 
this chromosome. 
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These results provide sorne support for our conjecture that variability in analgesic 
response is largely mediated by genes common to multiple analgesic modalities, rather 
than receptors distinct to individual drugs. The gene responsible for the Chr. l locus may 
be involved in GPCR second-messenger processes in neurons activated by drug binding, 
or it may regulate the excitability ofneurons downstream in the analgesic pathway. It is 
not likely that this gene exerts its influence on analgesia indirectly by affecting pain 
transmission mechanisms, as the QTL was not linked to tail-withdrawallatency itself. 
Distal Chr. 1 is a region rich in behavioral QTLs, many ofwhich could potentially 
share mediation with the analgesia phenotypes. A search of the Mouse Genome 
Informatics database (www.informatics.jax.org, March 16,2006) revealed 34 
neurobehavioral- and/or pain-related QTLs mapped to >75 cM; these inc1ude seven traits 
related to alcohol, six to morphine or other drugs, two to painful arthritis, five to 
emotionality/anxiety, and one to seizure susceptibility. Several ofthese QTLs have been 
finely mapped near the peak of linkage of our analgesia QTL. Ferraro et al (2004) 
mapped susceptibility to seizure (Szsl) to a 6.6 Mb region using the B6.D2-Mtv-7a/Ty 
congenic strain; they conc1uded that of four ion-transport genes in this region (Atpla2, 
Atpla4, Kcnj9, and KcnjlO), the potassium channel gene KcnjlO (93.5 cM) appeared 
most likely to underlie the phenotype, due to an amino acid change between B6 and D2 
mice. Yalcin et al. (2004) employed a quantitative complementation strategy using Rgs2 
null mutant mice to implicate this gene (78 cM) in regulating anxiety as measure by open-
field locomotion. Ethanol-induced locomotion was linked to a distinct but nearby region 
(82- 85 cM) using a multiple strain cross (Hitzemann et al., 2002); these researchers noted 
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that Kcnj9 (94.2 cM) was the only gene near this locus found to be differentially 
expressed by microarray analysis (Sandberg et al., 2000), making it a good candidate 
gene. These researchers (Hitzemann et al., 2004) similarly used a multiple cross mapping 
strategy, combined with novel gene expression and sequence analyses, to map basal 
locomotor activity to a 10Mb length (168-178 Mb). Again, Kcnj9 appeared a likely 
candidate, as it was the only gene for which gene expression patterns mirrored the 
behavioral data. 
Although none of the previously mentioned QTL studies included a 129 strain, 
they all used C57BL/6 to contrast with an oppositely responding strain, just as in the 
present study. It is worth noting, however, that the microarray experiment that 
establishedKoy'9 as the only differentially expressed gene on distal Chr. 1 was performed 
using B6 and a 129 substrain, 129SvEv (Sandberg et al., 2000). Future sections ofthis 
work will discuss haplotype correspondence between the strain used in this project, 
129P3, and strains used in other studies (e.g., other 129 substrains, A, BALB/c, DBA/2, 
LP, etc.). 
Many of the genes evaluated as candidate genes for other phenotypes are also 
possible quantitative trait genes for our analgesia phenotypes. Several, including Atpi a2, 
Atpia4, Kcnj9, and KcnjiO, encode cation channels involved in establishing membrane 
potentials. A number of G protein signaling pathway genes reside in this region, 
including several of the Rgs ("regulator of G protein signaling") family implicated in 
opioid analgesia (Sanchez-Blazquez et al., 2003), as well as the G protein-coupled 
potassium channel subunit, Kcnj9. Other genes in the QTL region with suspected links to 
pain include Psen2 (presenilin 2, 101.0 cM) which is down-regulated in response to 
inflammation (Saban et al., 2002), and Mpz (myelin protein zero, 92.4 cM), a variant of 
which causes neurosensory dysfunction and pain in the form of Charcot-Marie-Tooth 
disease (Gemignani et al., 2004). 
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Despite the se promising results, it does not appear that the gene underlying the 
Chr. 1 QTL (which we dubbed Manr 1, for "Multiple analgesic response 1") is a "master 
analgesia gene" responsible for the genetic correlations between multiple analgesics and 
baseline thermal pain. The allele associated with sensitivity to analgesia in the F2 mice 
derives from C57BL/6, the more resistant ofthe two parental strains. The allelic effect of 
the responsible gene explains at most 4.7% of the phenotypic variance (in the clonidine 
group), and as demonstrated by the morphine group, may be highly dose-dependent. The 
localization of the quantitative trait gene may be problematic, as the l-LOD drop-off 
confidence intervals are probably optimistic. Nevertheless, the existence of a gene that 
partially determines sensitivity to aIl three common analgesic drugs is a novel and 
remarkable finding. Identification of this gene holds promise for new drug development 
targets, as pharmacological manipulation of the relevant protein may be the key to 
increasing the analgesic sensitivity of opioid-resistant patients. 
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CHAPTER 3: FINE MAPPING OF Manrl 
A. Experiment Summary 
Quantitative trait locus mapping implicated a broad region of distal chromosome 1 
(80-110 cM) harboring a gene influencing antinociception produced by analgesic drugs 
acting at u2-adrenergic (clonidine), !l-opioid (morphine), and CB-1 cannabinoid 
(WIN55,212-2) receptors. Two strategies were used to reduce the confidence interval, in 
order to facilitate the identification of the gene responsible for variability in analgesic 
potency. We first employed in silico mapping to correlate the normalized analgesic 
response patterns of 8 inbred strains with an archivaI database representing the genetic 
architecture of the strains. This analysis confirmed the role of the Chr. 1 locus in 
analgesia produced by clonidine, morphine, WIN55,212-2, and the K-opioid agonist 
U50,488; additionally, it refined the probable location of the locus to the interva1170-180 
Mb. We also began the process of cloning the quantitative trait gene by position by 
exploiting the congenic region created concomitantly with knockout mouse construction. 
Fcgr3 null mice, which have 129-derived genetic material at the QTL region on a 
C57BL/6 background, exhibited attenuated analgesic response to clonidine and 
WIN55,212-2 (but not morphine) compared with wild-type mice. These results indicate 
that we have captured the relevant gene in the congenic interval, and have placed the gene 
within a 5 Mb region (170-175 Mb). 
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B. Introduction 
Traditional analgesics such as opioids have been used to effectively minimize pain 
and discomfort for centuries. However, the side effect profile of opio id drugs is often 
detrimental to successful pain management, as the doses needed to provide relief may be 
accompanied by intolerable complications such as nausea, constipation, sedation, and 
respiratory depression, as well as a liability to addiction. Wide interindividual variability 
has been frequently noted in the potency of morphine and similar drugs, in both clinical 
(Lasagna and Beecher, 1954; Levine et al., 1981; Maier et al., 2002) and experimental 
(Wolff et al., 1965; Chapman et al., 1990) contexts. Although much of the variability is 
produced by environmental (e.g. cultural, sociological, or psychological) factors, 
evidence is accumulating for a genetic component of analgesic variability (reviewed in 
Lotsch and Geisslinger, 2006). Polymorphisms of the OPRMI (Caraco et al., 2001; 
Klepstad et al., 2004) and COMI' (Rakvag et al., 2005) genes have been associated with 
magnitude of analgesia, and people with non-functional CYP2D6 alleles are unable to 
convert codeine into its active metabolite, morphine (Sindrup and Brosen, 1995). 
Quantitative trait locus mapping has linked genes with a number of analgesic phenotypes: 
Melr, which encodes the melanocortin-l receptor, is involved in determining stress-
induced and K-opioid analgesia (Mogil et al., 2003), and the serotonin receptor gene 
Htr 1 b has been implicated in morphine sensitivity (Hain et al., 1999). With recent 
advances in gene mapping and expression profiling producing a revolution in 
pharmacogenomics (Fagerlund and Braaten, 2001), it is likely that many other genes 
exerting smaller effects on analgesia will be uncovered. Characterizing the sources of 
variability in analgesic response is a promising avenue for optimizing pain control, in the 
form of personalized pharmacotherapy tailored to each individual' s genetic propensities. 
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A number of compounds acting at non-Il-opioid receptor sites have been identified 
as clinicaHy useful analgesics, either as adjuvants to complement lower doses of opioids, 
or as alternatives to such drugs. Many of these drugs bind to receptors belonging to the 
same super-family of G protein-coupled receptors as opioid receptors, including 
adrenergic, cannabinoid, cholinergic, and GABA-B receptors, and these receptors are 
located in many of the same CNS sites where opioids are thought to act. The extent to 
which the genetic factors underlying analgesia produced by disparate classes of drugs 
remains an unresolved question, however. We performed strain surveys offive such 
drugs, using mice of 12 different inbred lines, to determine whether analgesic sensitivity 
to one drug would predict responses to other drugs (Wilson et al., 2003). Moderate to 
high genetic correlations were observed between morphine (Il-opioid), U50,488 
(K-opioid), clonidine (u2-adrenergic), epibatidine (nicotinic cholinergic), and 
WIN55,212-2 (cannabinoid), suggesting that these drugs do in fact share genetic 
mediation. 
Quantitative trait locus (QTL) mapping was subsequently employed to localize the 
variability genes affecting analgesic magnitude across drug types, as described in the 
previous section of this work. In three simultaneous mapping projects, clonidine, 
morphine, and WIN55,212-2 were administered to an F2 population derived from a 
B6x129P3 intercross, and the resultant inhibition of thermal pain was quantified using the 
49° tail-withdrawal test. We used the interval mapping method to correlate phenotypic 
responses with genotypes at 100 microsateHite markers distributed across aH 19 
autosomes and the X chromosome. A locus on distal chromosome 1 (80-110 cM), 
dubbed Manr 1 for "multiple analgesic response 1," was linked to analgesic magnitude in 
aH three drug conditions, supporting our hypothesis that common genes will be found that 
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affect analgesia regardless of the triggering receptor type. This region contains a number 
of interesting potential candidate genes, but the size of the confidence interval precludes a 
systematic evaluation of the hundreds of known or predicted genes contained within it. 
We have used two separate strategies to confirm and improve the resolution of our 
mapping results. The first, known as in silico or haplotype mapping, was used to 
correlate the original strain survey data with a database of thousands of single nucleotide 
polymorphisms (SNPs), providing a much more refined placement of our variability gene. 
The second involved the creation of congenic mou se lines, in which the QTL region from 
one strain is placed onto the genetic background of a phenotypically divergent strain. 
This strategy isolates the QTL from interaction effects, and the congenic line can be 
further backcrossed to the background strain to narrow the confidence interval to a few 
Mb. 
C. Methods 
C.l. In Silico Mapping Methods 
The procedures used to house and phenotype mice included in the strain surveys 
have been described previously (Wilson et al., 2003). They are briefly described here. 
C.1.1. Subjects 
Mice ofboth sexes of the following 12 inbred strains-129P3, A, AKR, BALB/c, 
C3H1He, C57BL/6, C57BL/10, C58, CBA, DBAl2, RUIS and SM (all "J" substrains)-
were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were housed in a 
temperature-controlled (22±2°C) vivarium at the University of Illinois--Champaign-
Urbana on a 12:12 h light/dark cycle. Mice were weaned at 18-21 days of age, housed 
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with same-sex littermates in groups of2-5 and given ad lib access to food (Harlan Teklad 
8604) and tap water. Mice (n = 6-30/strainldrug/dose) were tested at not less than 6 
weeks of age, for a single drug and dose. An approximately equal number of male and 
female mice were tested in each condition. 
C.l.2. Drugs 
AlI drugs except for the cannabinoid were dissolved in physiological saline and 
administered in the folIowing doses: the selective u2-adrenergic receptor agonist, 
clonidine (Sigma, St. Louis, MO), 0.1-5 mg/kg; the nicotinic acetylcholine receptor 
agonist, (±)-epibatidine dihydrochloride (Sigma), 7.5-150 Ilg/kg; the Il-opioid receptor 
agonist, morphine sulfate (National Institute for Drug Abuse, Rockville, MD), 5-200 
mg/kg; and the selective K-opioid receptor agonist, (±)-trans-U50,488 methanesulfonate 
(Tocris Inc., Ballwin, MO), 10-150 mg/kg. The high affinity cannabinoid CB-l receptor 
agonist, R(+)-WIN 55,212-2 mesylate (Tocris), was dissolved in a 50% propylene 
glycol/saline solution and diluted to the desired concentration with saline; doses ranged 
from 0.5-480 mg/kg. The vehicle alone has no antinociceptive effects (data not shown). 
AlI drugs were administered intraperitonealIy (i.p.) in a volume of 10 ml/kg. Full dose 
response curves were generated by assaying maximum percent antinociception (see 
below), relative to baseline sensitivity, at a minimum ofthree doses. Successively higher 
and lower doses were tested in each strain until the folIowing criteria were fulfilled: a) 
data from at least 3 doses per strain were obtained; b) the lowest dose yielded maximum 
percent antinociception of:S35%; and, c) the highest dose yielded maximum percent 
antinociception of ;::::65%. 
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C1.3. Analgesia Phenotyping 
The 49°C tail-withdrawal/immersion (TW) test, originaUy described by 
Ben-Bassat (1959) and modified by Janssen (1963), was used to measure reflexive 
responses to thermal nociception. During testing, mice were gently restrained in a 
cardboard-bottomed cloth holder and the distal half of the tail was immersed in water 
maintained at 49±0.2°C by a thermal circulator. The latency to a reflexive withdrawal 
response was measured to the nearest 0.1 s by an experienced observer. For increased 
accuracy, two latency determinations separated by at least 10 s were made and averaged 
together at each time point. A 15 s cut-off was imposed to prevent any possible tissue 
damage and to decrease the possibility of repeated-measures effects. Nociceptive testing 
in aU strains occurred immediately prior to, and 15, 30 and 60 min post-injection for aIl 
drugs except for the shorter-acting epibatidine, which occurred immediately prior to and 
10, 20 and 30 min post-injection. 
Percent antinociception (i.e., percentage of the maximum possible effect) at each 
time point was calculated for individual mi ce as: [(post-drug latency - baseline 
latency)/( cut-off latency - baseline latency)] x 100. The maximal percent antinociception 
at any time point was used as the dependent measure of drug response. Dose-response 
curves--comprised of 3-4 doses of each drug within the linear portion of the dose-
response relationship for each strain--were used to calculate half-maximal antinociceptive 
doses (AD50s) (TaIlarida and Murray, 1981). The AD50 values across the 12 inbred 
strains were then transformed to Z-scores for purposes of comparison across drugs, and 
for in silico genetic analysis (Table 4). A composite analgesia Z-score was computed as 
the arithmetic mean of the five drug scores for each strain. 
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C.IA. In silico Genetic Mapping 
Although 12 strains ofmice were characterized in the strain survey (Wilson et al., 
2003), the genotyping database includes SNP data for only 6 ofthose strains (A, AKR, 
C57BL/6, BALB/c, C3HlHe, DBA/2), as weIl as the 129S1/SvlmJ strain, which is closely 
related to the 129P3/J we phenotyped; therefore, only these 7 strains were considered. 
The computational genetic analysis of the inbred strain data was performed as previously 
described (Grupeet al., 2001). In brief, allelic data from the inbred strains was analyzed 
and a gross haplotype map of the mou se genome was constructed by organizing SNP 
blocks into 10Mb segments. The haplotype-based analysis identifies segments in which 
the haplotypic strain grouping within the block correlates with the distribution of 
phenotypic data among the inbred strains analyzed. The degree of correlation for each 
segment is reported as the number of standard deviations from the mean correlation 
across the entire genome. The haplotype database on which this analysis is based is 
available at http://mouseSNP.roche.com. 
C2. KnockoutiCongenic Mapping Methods 
C.2.1. Subjects 
Breeder pairs ofthe B6.129P2_Fcgr3tmISjv/J (Fcgr3 KO) mutant strain were 
obtained from The Jackson Laboratory (Bar Harbor, ME). These mice have an 
engineered (via homologous recombination) deletion ofthe Fcgr3 (92.3 cM) locus; they 
were produced by introducing the deactivated gene into embryonic stem cells of the 
129P2 strain and injecting them into C57BL/6 blastocysts (see Hazenbos, 1996 for 
details). Homozygous Fcgr3KO and backcrossed B6xFcgr3KO progeny were maintained 
in our temperature- and humidity-controlled vivarium and given ad lib access to tap water 
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and mouse chow (Harlan Teklad 8604). The approximate extent of the 129 congenic 
interval was determined by genotyping micro satellite markers throughout Chr. 1 (Fig. 9). 
Markers at 73 cM (D IMitl 02) and 97 cM (Kmo) were determined to be 129-derived, 
whereas flanking markers at 67 cM (DIMit495) and 107 cM (D1Mit292) were from the 
background C57BL/6 strain. 
We obtained two subcongenic lines derived from the FcgrJ KO strain from the 
Wadsworth Institute (Troy, NY). These lines are the product ofbackcrossing the KO 
strain with C57BL/6, and selecting for progeny containing recombination events with the 
congenic interval. The first subcongenic line, Fcgr3-RF1, contains 129-derived DNA 
betweenRgll (152.5 Mb) and Cdcal (169.4 Mb), and the second line, Fcgr3-RF3, has 
donor genome between Mpz (171.0 Mb) and ~190 Mb (V. Bolivar, personal 
communication). 
C.2.2. Analgesia Phenotyping 
Clonidine hydrochloride (Tocris, Ellisville, MO), morphine sulfate (National 
Institute for Drug Abuse, Rockville, MD), and WIN55,212-2 (Tocris) were dissolved in 
saline and administered intraperitoneally in three concentrations per drug. All mi ce (n= 
6-17 /strain/drug/dose) were between 6-12 weeks of age and drug-naïve at testing. 
Both male and female mice were phenotyped using the 49° tail-withdrawal assay 
(Janssen et al., 1963). The tail of each mouse was lowered into a hot water bath 
maintained at 49.0°C, and the time for it to withdraw its tail was measured with a 
. stopwatch; 15 seconds was used as a cutoff latency in order to avoid damage to the tail. 
Readings were taken at baseline (pre-injection) and at 15,30, and 60 minutes post-
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injection of the drug. At each time point, two latencies were measured and then averaged 
to increase accuracy. We computed the percent analgesia (Le., area under the time-course 
curve) by the trapezoidal rule, as a measure of analgesic effect, and used this statistic to 
infer the AD50 (Le., the dose providing 50% analgesic relief), where possible (Tallarida 
and Murray, 1981). 
D. Results 
D.1. In silico Mapping 
The Digital Disease (Roche, Palo Alto, CA) algorithm was first used to correlate 
the analgesia Z-scores with an inbred strain genotype database (Grupe et al., 2001). This 
database arbitrarily breaks the genome into a low-resolution map of 10Mb segments, 
rather than empirically validated haplotypes, to enable rapid QTL mapping. For each 
trait, the Z-score distribution is compared to the genotypic status of the strains at each 10 
Mb block, and a correlation is calculated. The mean correlation across all blocks is 
computed, and the significance of a given correlation is reported as the number of 
standard deviations (sd) away from this mean. 
The first analysis was performed on the composite analgesia measure, comprised 
of the average value across all five analgesics for each strain, in order to detect 
complementary response patterns indicative of a "master analgesia gene." In this analysis 
(Fig. 7), 10% of the blocks exhibited correlation with the phenotype greater than 0.5 sd 
from the average correlation, and only 13 blocks were more than 1 sd above it. The 
large st correlation, at 9.5 sd from the mean, was located on Chr. 1 between 170 and 180 
Mb. Other prominent loci were found at proximal Chr. 5 (0-10 Mb), proximal Chr. 7 (20-
30 Mb), mid Chr. Il (80-90 Mb), and distal Chr. 19 (40-50 Mb). 
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The Chr. 1 locus was common to four of the five analgesics when analyzed 
separately (Fig. 8a-e). It was the strongest linkage in the c10nidine (8.4 sd), morphine 
(7.6 sd), and U50, 488 (7.4 sd) groups, and was the second strongest correlation in the 
WIN55,212-2 group (1.5 sd). It did not appear to be linked to epibatidine analgesia. The 
strong correlation in the 0-10 Mb block of Chr. 5 in the composite analgesia analysis was 
driven by large correlations to this segment in the epibatidine (13.1 sd) and WIN55,212-2 
(14.7 sd) groups. Other pro minent linkages were found for the c10nidine group (Fig. 8a) 
on Chr. 1 (130-140 Mb), Chr. Il (80-90 Mb), and Chr. 19 (40-50 Mb); for epibatidine 
(Fig. 8b) on Chr. 17 (30-40 Mb); for morphine (Fig. 8c) on Chr. 1 (130-140 Mb) and Chr. 
Il (80-90 Mb); and for U50,488 (Fig. 8d) on Chr. Il (80-90 Mb) and Chr. 19 (40-50 
Mb). 
D.2. Fcgr3 Knockout/Congenics 
The knockout/congenic strain, in which the "insensitive" l29-derived allele of the 
Manr 1 QTL has been introgressed onto the C57BL/6 background, was compared with 
wild-type mice that are fully B6 (i.e., "sensitive") in the QTL interval. The construction 
of dose-response curves for both strains revealed a significant interaction (p = 0.05) 
between strain and dose in c10nidine analgesia (Fig. 10a). Neither strain showed 
appreciable response at the lowest dose of 3 mg/kg, but higher doses produced attendant 
increases in analgesia in wild-type mice only (AD 5 Owt= 4.8 mg/kg, c.I. = 2.5...;9.4; 
AD50ko= not calculable). WIN55,212-2 (Fig. 10e) also produced analgesia of differing 
magnitude between strains (genotype main effectp<O.OOl); however, response to this 
drug did not exhibit dose dependeney in either strain (dose main effect p = 0.67). 
Analgesia from the cannabinoid was blunted in both groups, rendering AD50 estimations 
.~. 
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meaningless. In contrast, morphine (Fig. lOb) produced equivalent levels of 
antinociception in both strains at all doses tested (genotype main effect p = 0.09). The 
AD50 for the wild-type strain was 14.4 mg/kg (C.I.=12.1-17.1), and for the congenic, 
17.6 mg/kg (C.I.=15.0-20.5); the difference in potency was a non-significant factor of 0.8 
(C.I. =0.6-1.0). 
We investigated the mode ofinheritance of the QTL allele by crossing the Fcrg3 
congenic with wild-type B6, and measuring the sensitivity of the heterozygous progeny to 
20 mg/kg clonidine. In a Tukey post-hoc comparison with the two parental strains, the 
heterozygotes were significantly different from the B6 strain (p = 0.003) but not the 
congenic strain (p = 0.82), suggesting that the insensitive 129 alle1e is dominant 
(Fig. 11a). 
We then compared two subcongenic strains derived from the Fcgr3KO congenic 
strain, RFI and RF3, with wild-type and knockout-congenic mice (Fig. lIb). A main 
effect between genotypes was detected by ANOVA (F3,49=3.083,p = 0.016); Tukey post-
hoc tests revealed that only the Fcgr3KO mice were significantly different from C57BL/6 
(p = 0.010). 
E. Discussion 
Previous quantitative trait locus mapping efforts suggested that a gene influencing 
analgesic magnitude, regardless of the drug used to pro duce it, is located on distal Chr. 1. 
Two limitations ofthis finding were apparent, however, and needed to be addressed with 
further investigation. The localization of the QTL was imprecise, as the confidence 
interval containing the gene was conservative1y mapped to a 30 cM region (80-110 cM). 
Identifying the gene by position alone would require tremendous refinement of this 
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interval. The other limitation of the QTL was its specificity; the linkage, while strong for 
the drugs clonidine and the cannabinoid WIN55,212-2, was tenuous for morphine. It was 
also questionable whether the QTL represented a hypothetical "master analgesia gene" 
responsible for the differential sensitivities to five analgesics we observed in a survey of 
12 inbred strains. We therefore employed two complementary strategies to narrow our 
QTL confidence interval and extend our conclusions to the full panel of strains and 
analgesic drugs. 
We first correlated the phenotypic data from seven of the twelve strains in our 
original strain survey (Wilson et al., 2003) with a database of single nucleotide 
polymorphisms (SNPs). This analysis confirrned that analgesia sensitivity patterns across 
numerous strains could be predicted by their allelic status at an unidentified gene located 
between 170 and 180 Mb on Chr. 1. This interval (roughly 90-100 cM) corresponds to 
the center third of our QTL confidence region, significantly narrowing the region of 
interest and reducing the number of potential candidate genes by half (see Table 5 for a 
fulliist of the 112 genes in this interval). We also confirrned that the Manr 1 locus is 
relevant to analgesia produced by opio id (morphine and U50,488) and non-opioid 
(clonidine and WIN55,212-2) analgesics, although it was not linked to sensitivity to the 
nicotinic cholinergic agonist, epibatidine. 
In addition to the Manr 1 QTL, morphine and U50,488 analgesia have also been 
previously subjected to QTL analysis. An extensive investigation of morphine analgesic 
variability between DBA/2 and C57BL/6 mice revealed five major loci (Bergeson et al., 
2001). The QTL with the largest effect was located on proximal Chr. 10 and is likely 
Oprml, which encodes the )l-opioid receptor, the high-affinity binding site for morphine. 
Other loci were detected on proximal and medial Chr. 9 and proximal Chr. 1. Of the se 
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five experimentally verified QTLs, only two loci on Chr. 9 colocalize with regions 
identified by the in si/ico analysis. A region of distal Chr. 8 was linked to U50,488 
analgesia (as well as swim stress-induced analgesia) and was subsequently shown to be 
the melanocortin-1 receptor gene, Melr (Mogil et al., 2003). No corresponding linkage 
to this region was observed in the in silico analysis ofU50,488 analgesia. One probable 
reason for the apparent discrepancies between QTL and haplotype mapping is the sex-
specific nature of the Chr. 1, proximal Chr. 9, and Chr. 8 loci (Bergeson et al., 2001; 
Mogil et al., 2003), as the haplotype mapping did not account for sex differences. 
However, the inability of the in silico analysis to detect the Chr. 10 locus is not as readily 
explained. 
In principle, the in silico mapping technique holds several advantages over 
standard QTL mapping methods (Gmpe et al., 2001; Wang et al., 2005b), and it has the 
potential to minimize the expense and time needed to identify variability genes. The 
practical advantages of haplotype mapping arise from most of the work already having 
been done; once an inbred strain has been genetically characterized, there is no need to 
bear the cost of genotyping it again. Likewise, strain surveys are merely the beginning 
phase of phenotyping in linkage studies, whereas they are the endpoint for in silico 
mapping. Haplotype-based mapping methods derive their power from the entire breeding 
history of the common inbred strains (Wade et al., 2002), alleviating the need to generate 
novel recombination events in complicated crosses. The use of a dense SNP database 
affords resolution on the scale of a single gene. These advantages will become even more 
significant as more comprehensive haplotype maps featuring added inbred strains are 
developed, and future strain surveys should be designed to exploit these methods (Wang 
et al., 2005b). The Digital Disease algorithm presently employed boasts many of the se 
benefits, but because the genotypic data is grouped into arbitrary 10Mb segments, its 
power to exploit the underlying haplotype architecture is compromised. 
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In addition to the Digital Disease analysis, we also attempted to correlate our 
phenotypic data with a true haplotype map using the HapMapper (Roche, Palo Alto, CA) 
algorithm. Numerous genes within our QTL region exhibited linkage (at a liberal 
p < 0.02) with one or more analgesic measures (results are reported in Table 6). 
However, we do not believe that our study design is appropriate for taking advantage of 
the potential of dense haplotype mapping. Our CUITent efforts suffer from a lack of power 
related to the employment of only seven strains in our study. A power analysis conducted 
by Wang and Peltz (2005) suggested that even for twice the number of strains we used, a 
similar study would have only 80% power to detect a locus accounting for half the total 
phenotypic variance at a = 0.01. In fact, Darvasi (2001) has estimated that a minimum of 
40 strains may be needed to reliably map even the most amenable loci. A cursory 
analysis of the haplotype structure of the QTL region reveals a disconcerting situation: 
the most phenotypically divergent strain, C57BL/6, is also the most genotypically 
distinct, and spurious associations may be common for traits in which B6 is a clear 
extreme-responding strain. In fact, many of the linkages of haplotype blocks with the 
analgesia phenotypes result from aIl strains but-C57BL/6 bearing one haplotype, and B6 
bearing another. For this reason, we believe the more conservative course is to treat the 
in silico mapping exercise as a confirmation and gross refinement of our previously 
mapped Manr 1 locus. Any other conclusions that may be drawn from this analysis 
cannot be distinguished from chance results. 
In a separate line of experiments, we used a congenic strain strategy to place the 
"insensitive" QTL allele from the 129 strain onto a C57BL/6 background. Rather than 
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undertake the arduous process ofbackcrossing over multiple generations, we took 
advantage of the standard transgenic knockout construction protocol, in which a de facto 
129P2 congenic genotype is maintained around the deleted locus on a C57BL/6 
background (Bolivar et al., 2001). Although the 129P2 strain differs somewhat from the 
129P3 strain used to discover the Manr 1 QTL, the phenotype was largely preserved, 
indicating that the 129 strains share the "insensitive" allele. Positional cloning efforts 
involving 129P2 knockout-related congenic strains should prove as successful, and vastly 
more expedient, than ifwe had created a novel 129P3 congenic using marker-assisted 
selection. 
The effect of placing the "insensitive" 129 Manr 1 allele onto the otherwise 
resistant C57BL/6 background proved to be an almost complete attenuation of analgesic 
potency in clonidine- and cannabinoid-treated animaIs. Surprisingly, however, morphine 
analgesic potency was not significantly reduced in the congenic strain. The reason for 
this is unclear, but this result does not necessarily negate the convergent evidence of QTL 
and in silico linkage to this phenotype. One possible explanation for the disappearance of 
the QTL effect is genetic; other unidentified loci may interact epistatically with the Chr. 1 
locus, producing differential effects in contrasting genetic backgrounds (Frankel and 
Schork, 1996). The observance of synergistic and additive interactions between opioid, 
cannabinoid, and adrenergic mechanisms (Stone and Wilcox, 2004; Tham et al., 2005) 
suggests that such rnechanisrns are both cornrnon between, and independent of, each 
other. Morphine is known to act at numerous spinal and supraspinal sites (Yaksh et al., 
1988), and epistatic interactions modulating a subset of ~-opioid activity may mask other 
effects of morphine subject to the QTL. However, until the gene responsible for the QTL 
is determined, it is difficult to do more than conjecture as to the nature of such 
interactions. 
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The RFlIRF3 subcongenic results are also difficult to interpret, as neither 
subcongenic was shown to be significantly different from the B6 mice, and therefore to 
harbor the "insensitive" allele. This unfortunately prevents the use of the se strains in the 
creation of additional subcongenic lines to further isolate the QTL. Failure to replicate 
the QTL effect in either line may be due to the quantitative trait gene being located 
between the two non-overlapping subcongenic regions, or it may be due to epistatic 
factors from isolating the QTL. However, as the two subcongenic strains both appear 
intermediate between the B6 and Fcgr3 KO animaIs, the underlying architecture of the 
QTL may be more complicated than a single gene. Careful dissection of QTLs for 
epilepsy (Legare et al., 2000), lupus susceptibility (Morel et al., 2001), exploratory 
behavior (Yalcin et al., 2004; Zhang et al., 2005), and collagen-induced arthritis 
(Karlsson et al., 2005) has shown that a single major effect locus frequently separates into 
numerous small-effect loci. If Manr 1 is an exarnple of such a case, both the RF! (152-
170 Mb) and RF3 (170-190 Mb) intervals could contain one or more genes relevant to 
analgesia. 
As the knockout/congenic strain differs from the wild-type B6 animaIs, it is 
necessary to determine whether the deletion of the Fcgr3 gene is responsible for the 
phenotype, rather than the 129 segment flanking it. Bolivar et al. (2001) devised a simple 
breeding pro gram to isolate the effects of the gene knockout from its background; 
however, we would need numerous additional generations to see the protocol to 
completion, and the subcongenic results suggest that the QTL effect is not likely to be 
observable in such an experiment. The Fcgr3 gene is a particularly unlikely, but still 
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formally possible, candidate for the Manr ] locus. This gene encodes an Fc 
immunoglobulin G receptor, necessary for antigen-directed NK ceU and macrophage 
activity, and nuU mutants have impaired immune responses (Hazenbos et al., 1996). 
Although no studies have linked the protein with acute pain or analgesia, it is known to 
play a role in immune complex-induced arthritis (Nabbe et al., 2005; Skokowa et al., 
2005). It is one ofthe genes possibly linked to the composite analgesia phenotype in the 
HapMapper analysis (Table 6). 
Taken together, our efforts to narrow the Manr] confidence region have 
succeeded in placing the responsible gene (or genes) between 170 Mb and an 
undelineated crossover distal to the Kmo gene at 175.5 Mb. We have confirmed that the 
Manr] gene plays a role in analgesia produced by u2-adrenergic and cannabinoid 
mechanisms, and provided evidence that this gene is also likely involved in response to !l-
and K-opioid drugs; however, our results do not support linkage with epibatidine 
analgesia. Despite the significant refinement of the confidence interval, about 100 genes 
remain positional candidates. However, ofthese, only a few appear to be reasonable 
functional candidates controUing neuronal activity: the potassium channel subunits, Kenj9 
and Ken}] 0; two sodium-potassium pump subunits, Atp] a2 and Atp] a4; the G protein 
regulators, Rgs4 and Rgs7; and the myelin protein, Mpz. 
An evaluation of the relevant positional, functional, and expression evidence 
strongly predicts that Ken}9 is the most likely candidate gene to determine sensitivity to 
multiple analgesic modalities. At 94.2 cM, it lies within 6 cM of the peak linkage of aU 
three analgesics. The gene codes for the GIRK3 (Kir3.3) prote in, a member of a family 
ofinwardly-rectifying potassium channel subunits, ofwhich GIRK3 is the most 
abundantly and ubiquitously expressed in the brain. Members ofthis family (GIRKl-4) 
64 
form heterotetramers important for maintaining resting membrane potential in CNS and 
cardiac cells; these channels are activated following ligand binding of G protein-coupled 
receptors (GPCRs). Thermal pain sensitivity and at least sorne effects of morphine are 
mediated by GIRK3 (Marker et al., 2002; Torrecilla et al., 2002), and GIRK channels 
have been implicated in analgesic response from a full range of GPCR-binding drugs 
(Blednov et al., 2003; Mitrovic et al., 2003). The Kcnj9 gene is expressed in whole-brain 
tissue at a rate three times higher in 129SvEv than C57BL/6 mice (Sandberg et al., 2000). 
In parallel with our positional cloning endeavors, we have conducted experiments 
to determine whether Kcnj9 is in fact the gene underlying the Manrllocus. We evaluated 
the candidacy of Kcnj9 using quantitative gene expression assays and null mutant mice. 
These studies are described in the next section of this work. 
CHAPTER 4: EVALUATION OF Kcnj9 AS A CANDIDATE GENE UNDERL YING 
Manrl 
A. Experiment Summary 
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A quantitative trait locus common to several opio id and non-opio id analgesia 
phenotypes was discovered on distal Chr. 1, and subsequently fine mapped to a <10 cM 
interval. This region contained few obvious candidate genes known to play a role in the 
neurochemical mediation of pain/antinociception; among these, the most likely gene was 
Kcnj9, which encodes the inwardly-rectifying potassium channel subunit GIRK3. We 
evaluated the candidacy of this gene by quantifying the effects of variant alleles of this 
gene on expression levels, as well as by determining the effects of ablation of the gene on 
behavioral response to analgesic drugs. Mice of the C57BL/6 and 129P3 strains 
(containing the analgesia-sensitive and -resistant alleles, respectively, of the QTL) were 
used to determine Kcnj9 expression in three CNS areas known to be relevant to 
descending modulatory analgesia: periaqueductal gray (P AG), rostral ventral medulla 
(RVM), and spinal cord. DifferentiaI patterns of expression were observed between the 
two strains in the P AG, suggesting a possible mechanism for the observed strain 
difference. We then assayed mice with null mutations of the Kcnj9 genes for sensitivity 
to clonidine, morphine, and WIN55,212-2. The mutant mice displayed significantly 
attenuated analgesia from clonidine and morphine, relative to their wild-type 
counterparts. These lines of convergent evidence support the involvement of Kcnj9 in 
analgesia produced by multiple neurochemical analgesic classes. 
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B. Introduction 
Rapid advances in the tools and understanding of genetics have initiated a 
revolutionary shift in me di cine towards individualized treatment based on the specific 
genetic liabilities of the patient. The "pharrnacogenetic" approach has begun to be 
applied to the relief of post-operative and chronic pain. The pharmacogenetics of 
analgesia (reviewed in Flores and Mogil, 2001) holds promise for the significant minority 
of patients for which CUITent treatments are ineffective, but the number of genes currently 
known to influence analgesic variability in humans remains small. Up to 10% of 
Caucasians are non-responsive to codeine because of a mutation in the cytochrome P450 
enzyme CYP2D6, rendering them unable to metabolize the drug to morphine (Sindrup 
and Brosen, 1995). Analgesia from K-opioid agonists (such as pentazocine) is modulated 
by the melanocortin-l receptor (MeIR) in a sex-specific manner, as indicated by the 
greater analgesia produced by these drugs in red-headed women with non-functional 
MCIRs (Mogil et al., 2003). Variant alleles of the Il-opioid receptor (OPRMI) have been 
associated with increased analgesia requirement (Caraco et al., 2001; Klepstad et al., 
2004; Romberg et al., 2005), although it is unclear whether this is due to insensitivity to 
opiate drugs or to an increase in the underlying pain. 
Researchers have turned to murine genetics to help unravel the many genetic and 
environrnental determinants of analgesic response. Mouse models have proven 
invaluable in exploring the effects of genetic mutation on nociceptive phenotypes 
(reviewed in Mogil and Grisel, 1998; Mogil et al., 2000; Malmberg and Zeitz, 2004), and 
have also been instrumental in resolving the sources of natural individual variability in 
pain and analgesia. The use of such techniques as quantitative trait locus (QTL) and in 
silico mapping in studies of analgesia has been limited to investigations of the opioids 
67 
morphine (Bergeson et al., 2001; Liang et al., 2006a) and U50,488 (Mogil et al., 2003). 
In an effort to extend these findings to non-opioid drugs, and address the previous finding 
of genetic correlation between analgesics acting at different receptor sites (Wilson et al., 
2003), we performed mapping studies using five drugs: the fJ-opioid morphine, the K-
opioid U50,488, the u2-adrenergic clonidine, the cannabinoid WIN55,212-2, and the 
nicotinic cholinergic epibatidine. We observed strong evidence for the existence of a 
gene on distal chromosome 1 (near 95 cM) modulating analgesia produced by clonidine 
and WIN55,212-2, and likely the fJ- and K-opioid agonists as weIl. 
Efforts to clone this gene by position are underway using a congenic strategy, but 
a survey of possible candidates genes within the Manr 1 QTL confidence interval 
suggested a smaU number of interesting candidates worthy of foUow-up investigation. 
Our criteria for selecting appropriate candidates included position, CNS expression, and 
functional relevance to multimodal analgesia. It is unlikely that the gene underlying 
Manrl encodes a receptor, as the drugs aH have distinct binding sites. However, aU of the 
analgesics bind to members of the superfamily ofG protein-coupled receptors (GPCRs), 
suggesting that the quantitative trait gene (QTG) may play a role in neurochemical 
signaling mechanisms cornmon to aH ofthem. The analgesics aH modulate the PAG-
RVM-dorsal horn pathway, and the QTG may exert its influence anywhere in this 
descending inhibitory system. 
Although several genes with relevance to G protein signaling or l}euronal 
excitation are found within the QTL region, we believe that the Kcnj9 gene (which 
encodes the GIRK3 prote in) is the most likely candidate for the Manr 1 QTL. Located at 
94.2 cM, it is found very near the peak oflinkage for all ofthe analgesia phenotypes 
tested. It belongs to the GIRK family of inwardly-rectifying, G protein-coupled 
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potassium channel subunits vital to the regulation of membrane potential (Yamada et al., 
1998; Wickman et al., 2002), and its homolog is the GIRK subunit most prevalent in 
human (Schoots et al., 1999) and rodent (Kobayashi et al., 1995; Chen et al., 1997; 
Karschin and Karschin, 1997) brain. In the mouse, differential Kcnj9 expression in whole 
brain tissue between 129 and B6 strains has been established (Sandberg et al., 2000). 
GIRK channels are known to significantly influence analgesic potency for a wide range 
ofmodalities (Ikeda et al., 2002; Blednov et al., 2003; Mitrovic et al., 2003; Marker et al., 
2004), and GIRK3 in particular mediates the inhibitory effects of opioids (Marker et al., 
2002; Torrecilla et al., 2002). 
In order to evaluate the putative contribution of variants of GIRK3 to observed 
strain differences in analgesic phenotypes, we tested mi ce homozygous for the deletion of 
Kcnj9 for analgesia from clonidine, morphine, and WIN55,212-2. We have also 
conducted gene expression assays in C57BL/6 and 129P3 strains in areas relevant to 
nociceptive modulation: spinal cord, rostral ventral medulla, periaqueductal gray, and the 
anterior cingulate cortex. The purpose of these experiments is to establish whether Kcnj9 
gene knockout has an effect on the inhibition of acute thermal pain by mu~tiple 
analgesics, and determine where quantitative differences in GIRK3 expression may play a 
role in interindividual variability. 
C. Methods 
C.I. Gene expression quantification 
C.1.1. Tissue collection 
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Brain tissue from the periaqueductal gray (PAG) and rostral ventral medulla 
(RVM), and whole spinal cords were removed from 129P3 and C57BL/6 mi ce aged from 
at least six weeks. The harvested tissues were immediately placed in a preservation agent, 
RNAlater (Ambion, Austin, TX), and stored at 4°C until total RNA isolation. To obtain a 
sufficient quantity of tissue samples, approximately four mice from each strain were used 
for each tissue type. 
C.I.2. Total RNA isolation and cDNA transcription 
Total RNA from the six samples (PAG, RVM, and spinal cord from 129P3 and 
C57BL/6 mi ce) was isolated with Trizol (Invitrogen, Burlington, ON) and resuspended in 
30 ilL of DEPC treated water. The RNA solution was then treated with the DNAfree kit 
(Ambion, Austin, TX) to remove any trace DNA contaminants and purified with the 
RNeasy Mini kit for RNA c1eanup (Qiagen, Germantown, MD). Integrityand 
concentration of the total RNA samples were evaluated on the Bioanalyzer 2100 (Agilent, 
Palo Alto, CA). The reverse transcription (RT) reaction was performed according to the 
protocol ofthe TaqMan Reverse Transcription Reagents kit (Applied Biosystems, Foster 
City, CA). In addition to the unknown samples, seriaI dilutions ofknown concentrations 
of mouse brain total RNA (Ambion) acting as standards were reverse transcribed. 
Briefly, each RT reaction required l ilL ofthe total RNA to be added to 9 ilL ofRT 
master mix composed of 0.5 ilL of 50 IlM random hexamers and 0.25 ilL of 50U/IlL 
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Multiscribe RT enzyme. Reverse transcription was carried out on a Peltier Thermal 
Cycler (PTC-100; Bio-Rad, Hercules, CA) at the following cycles: 25°C for 10 min, 48°C 
for 30 min followed by 95°C for 5 min. The cDNA was stored at 4°C until the PCR 
reaction was made. 
C.1.3. PCR 
Iwo gene-specifie TaqMan probe and primer sets for Kcnj9 and Gapdh mouse 
genes were obtained from AB!. The target gene Kcnj9 was amplified in different wells of 
a 96-well reaction plate with the endogenous control gene, Gapdh, whose constitutive 
expression served to normalize quantification of Kcnj9 expression levels among unknown 
samples. Each 5 ilL cDNA sample of standards and unknowns was added to 20 ilL of 
Kcnj9 PCR master mix and 20 ilL of Gapdh PCR master mix. The Kcnj9 PCR master mix 
composition was: 12.5 ilL of2X TaqMan Universal PCR Mix with AmpErase UNG, 6.25 
ilL ofDEPC water, and 1.25 ilL of20X Kcnj9 gene specifie probe and primers mix. The 
Gapdh master mix composition was: 12.5 ilL of2X TaqMan Universal PCR Mix with 
AmpErase UNG, 6.00 ilL ofDEPC water, and 0.5 ilL of20X Gapdh gene specifie probe 
and primers. Standards were run in quadruplicate and unknowns in quintuplicate. 
Real-time PCR was carried out on an ABI 7000 system at the following cycles: 50°C for 
2 min, 95°C for 10 min followed by a round of 40 cycles of 95°C for 15 sec/60°C for 60 
sec. 
C.1.4. Data analysis 
After the PCR reaction was completed, a threshold was fixed across the linear 
region of aIl amplification curves. Determining the cycle numbers associated with this 
threshold revealed the Cr values for the known standards and unknown samples. Cr 
values of the unknown samples were then converted into expression values using the 
corresponding standard curve. The ratio of the average Kcnj9 amount over the average 
Gapdh amount provided the normalized Kcnj9 gene expression result. 
C.2. GIRK3 knockout animaIs 
C.2.1. Subjects 
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The use of animaIs for this study was approved by the University of Minnesota 
Institutional Animal Care and Use Committee (Protocol 0302A41421). Mice were 
housed in a temperature-controHed room on a 12 h lightldark cycle, with food and water 
available ad libitum. Efforts were made to minimize the pain and discomfort of the 
animaIs throughout the course ofthis study. The generation ofGIRK3 knockout mice 
was described previously (Torre cilla et al., 2002). The GIRK nuH mutations were 
backcrossed through at least 13 rounds against the C57BL/6 mouse strain prior to 
initiating behavioral testing. Genotypes were determined by PCR of crude DNA samples 
from tail biopsies (Wickman et al., 1998). Efforts were made to balance the wild-type 
and knockout groups for each drug condition with respect to gender and age. Drug naïve 
mice were used for aH tests. The experimenter was blind to subject genotype and drug 
condition during behavioral testing. 
C.2.2. Phenotyping 
2-(2,6-Dichloroaniline)-2-imidazoline (clonidine), morphine sulfate, and WIN 
55,212-2 were purchased from Sigma Chemicals (St. Louis, MO). AH drugs were 
dissolved in 0.9% saline in high concentration stocks, divided into single-use aliquots, 
and stored at -20°C. The highest doses of each drug administered were chosen on the 
basis of pilot studies, where the intent was to identify the drug dose that produced the 
maximum analgesic effect without causing significant toxicity or motor impairment. 
72 
Thermal nociception was assessed using the warm-water-immersion variant of the 
tail-flick assay on mice 6-7 weeks of age. Mice were acclimated to the testing 
environment for 2:1 h on the day oftesting. During tail-flick testing, mice were secured 
firmly with the full tail exposed using a soft clotho Tails were immersed in sequential 
fashion in water baths set at 49°C, 52.5°C, and 55°C, and were wiped dry between dips. 
After baseline latencies were determined for each animal, they were given an 
intraperitoneal (i.p.) injection of drug. Post-drug latencies were determined 15,30, and 
60 min after injection. Cutoffvalues were set at 20, 12, and 10 s, respectively, for the 
49°C, 52.5°C, and 55°C bath exposures to prevent tissue damage. Water bath 
temperatures were measured daily using a Traceable RTD platinum thermometer (Control 
Company, Friendswood, TX) and adjusted as necessary to ensure consistency throughout 
the study. AnimaIs with a baseline latency at 49°C less than 5 sor greater than 9 s were 
removed from the study. %MPE measures between wild-type and GIRK3 knockout mi ce 
at the same dose were analyzed at each temperature and time point by independent 
measures Student's t-test. %MPE measures between doses within genotype were 
analyzed by one-way ANOVA and post-hoc analysis was performed using Tukey's HSD 
test. Statistical analysis showed no difference between male and female mice, therefore, 
data from both genders were combined to increase the study power. As data from aU 
three temperatures produced similar results and the maximal drug effect was observed at 
the 30 min post-injection time point, only the subset of data obtained at 49°C and the 30 
min time point will be presented here. 
~ .. 
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D. Results 
D .1. Gene expression 
For each CNS region assayed, Kcnj9 gene expression in each strain was compared 
to the expression of the house-keeping gene Gapdh, and reported as a ratio of the two 
(Fig. 12). Expression of Kcnj9 was observed in an three tissues; no difference between 
strains was apparent in the RVM or spinal cord. Expression in the periaqueductal gray 
was divergent between the two strains, with 129P3 expressing almost three times more 
transcript than C57BL/6. 
D.2. GIRK3 phenotyping 
There was no significant difference in baseline latencies between wild-type 
(7.0±0.1 s) and GIRK3 knockout (6.7±0.1 s). However, there was a trend (p = 0.06) for 
the latencies of GIRK3 knockout mi ce to be shorter compared to wild-type mice. 
Clonidine produced strongly genotype-dependent analgesia (Fig. 13a; wildtype 
AD50 : 0.7 mg/kg, 95% C.I.: 0.4 -1.3 mg/kg; GIRK3KO AD50: 12.5 mg/kg, 95% C.I.: 
3.6 - 43.5 mg/kg). In contrast, morphine produced equivalent levels of analgesia in both 
strains at an doses tested (Fig. 13b; wildtype AD50: 5.0 mg/kg. 95% C.I.: 4.3 - 5.9 
mg/kg; GIRK3KO AD50 : 5.6 mg/kg, 95% C.I.: 4.3 -7.2 mglkg) (see also Marker et al., 
2002; Marker et al., 2004). WIN55,212-2 also produced genotype-dependent analgesia 
(Fig. 13e), with dose-dependency observed in wildtype mice (AD50 : 59.4 mg/kg, 95% 
C.I.: 22.0 -160.8 mglkg) but not GIRK3KO mice (AD50: not calculable). 
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E. Discussion 
Simultaneous linkage mapping projects implicated a region of distal Chr. 1 as the 
site of a gene responsible for analgesia produced by multiple opio id- and non-opioid 
drugs. We have successfully mapped this quantitative trait locus down to a short (~8 cM) 
interval through a combination of in silico haplotype mapping and congenic strain 
techniques; however, the ultimate goal of narrowing the confidence interval to a single 
gene remains distant. Many additional steps of breeding subcongenic animaIs still 
remain, and the final step to formally prove the involvement of a gene would require a 
technically difficult allele-transfer experiment in which the version of the gene from one 
strain is placed on the background of another strain (Rikke and Johnson, 1998; Nadeau 
and Frankel, 2000). An alternative to this extensive process is to compile evidence 
supporting the involvement of a likely "positional candidate gene" in the phenotype in 
question (Collins, 1997). Criteria which must be validated for a potential candidate gene 
inc1ude: genomic localization within the QTL confidence region; polymorphisms in or 
near the gene resulting in variant proteins or gene expression level differences; and 
relevant functionality of the gene, in appropriate organs or tissues; to affect the 
phenotype. An extensive search of aIl genes in our confidence region (Table 5) revealed 
one gene within the region as an especially promising candidate to account for the 
observed strain differences in analgesic sensitivity: Kcnj9. 
Located at 94.2 cM (172.2 Mb), Kcnj9 lies near the peak of linkage in all three 
analgesic mapping studies: c10nidine (100 cM), morphine (90 cM), and WIN55,212-2 (94 
cM). It also falls within the region (170-180 Mb) linked by in silico mapping with 
analgesia produced by c1onidine, morphine, U50,488, and WIN55,212-2, among seven 
different inbred strains. The intersection of these mapping efforts implicates the interval 
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90-96 cM (170-175 Mb), which contains about 100 known genes, including a cluster of 
~20 olfactory receptors; Kcnj9 is one of a small number of genes not excluded by any of 
our attempts to localize the analgesia QTL. 
In order to accept the gene as a strong candidate underlying the Manr 1 QTL, a 
convincing mechanism by which Kcnj9 modulates analgesia from multiple drug classes 
must be postulated; this explanation should preferably account for all of the observed 
characteristics of the QTL. The relevance of GIRK channels in modulating pain and 
pharmacological analgesia has been well established (reviewed in Ocana et al., 2004). 
The GIRK family of G protein-coupled inwardly rectifying potassium channels consists 
of four subunits (GIRK1-4) encoded by four distinct genes. These four subunits form 
functional heterotetramers in vivo, and the subunit composition seems to be an important 
factor in the tissue-specific properties ofthese channels (Kofuji et al., 1995). The 
purpose of potassium channels in neurons is to regulate membrane conductance by 
enabling the flow ofK+ ions down their electrochemical gradient (Shieh et al., 2000). 
GIRK channels are activated by interactions with G~y subunits subsequent to the binding 
of an appropriate ligand to any of a number of G protein-coupled receptors (Kofuji et al., 
1995; Sadja et al., 2003). These receptors include opioid, cannabinoid, adrenergic, and 
other receptor types involved in nociceptive modulation. The ultimate effect of GIRK 
activity is hyperpolarization of neurons, resulting in a decrease in neural excitability 
(Signorini et al., 1997). 
Null mutant mice for each of the subunits have been generated and tested for 
altered response to pain and analgesic drugs (Marker et al., 2002; Blednov et al., 2003; 
Mitrovic et al., 2003; Marker et al., 2004; Marker et al., 2005). Strong evidence 
especially supports the involvement of the GIRK2 subunit in analgesia from opioid and 
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non-opioid drugs alike (Ikeda et al., 2000; Blednov et al., 2003; Mitrovic et al., 2003). 
Mutant mice lacking GIRK2 expression have attenuated postsynaptic inhibitory responses 
to a number of G protein-coupled receptor agonists with analgesic properties (Lus cher et 
al., 1997), indicating that GIRK channels broadly contribute to analgesia. The role of the 
GIRK3 subunit in analgesia is less clear, however. Introduction ofGIRK3 cRNA into 
Xenopus oocytes does not result in measurable expression (Wischmeyer et al., 1997) or 
K + current (Schoots et al., 1999); co-injection of GIRK3 with GIRK1 cRNA into oocytes 
potentiates G protein-induced currents, but suppresses the CUITent of GIRK2 alone (Kofuji 
et al., 1995). Although the primary inhibitory channel in the mammalian brain is most 
likely to consist ofGIRK1/2 subunits (Koyrakh et al., 2005), channels composed of 2/3 
subunits have been isolated from native mouse brain (Jelacic et al., 2000), and have been 
shown to modulate the inhibitory effects of opioids in the locus coeruleus (ToITecilla et 
al., 2002). The function of the GIRK3 subunit in such channels is not yet known, but the 
availability of GIRK3 may be an important modulatory element, as GIRK2/3 channels are 
4.8 times less sensitive to Gpy compared to GIRK1-containing channels (Jelacic et al., 
2000). It has also been proposed (Ma et al., 2002) that a motif on the GIRK3 protein, 
unique among GIRK subunits, actually diverts channels containing the subunit for 
lysosomal degradation. 
Kcnj9 is an especially attractive candidate for purposes of explaining the 
contradictory results we have observed between sorne of our rnapping projects. The 
Manr 1 QTL effect was strong for adrenergic and cannabinoid analgesia, but weaker (and 
dose-dependent) for morphine. Although in silico mapping confirmed the linkage of the 
QTL to opioid analgesia (from ~ as weIl as K agonists), no effect was seen in either 
congenic or GIRK3 knockout strains. This disparity may be explained by the diverse 
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mechanisms by which morphine inhibits nociception. Postsynaptic opioid receptors are 
functionally coupled to GIRK channels (Lus cher et al., 1997), but a significant 
component of morphine analgesia arises from action at the presynaptic terminal 
(Cherubini and North, 1985), where its effects are mediated by G protein-linked calcium 
channels (Bourinet et al., 1996). Presynaptic inhibition, especially at higher doses of the 
drug, may mask genotype-specific deficits in postsynaptic antinociception. This 
hypothesis is bolstered by similar observations in GIRK2 knockout mice; these animaIs 
exhibited a drastic reduction in the analgesic potency of clonidine, but that of morphine 
was only slightly attenuated (Mitrovic et al., 2003). A related explanation may account 
for the failure of epibatidine analgesia to map to the Manr 1 locus in the haplotype 
analysis. Epibatidine's target receptor, the nicotinic acetylcholine receptor, is not a G 
protein-coupled receptor, and epibatidine analgesia would therefore not be strongly 
influenced by GIRK polymorphisms. It should be noted that the deletion of GIRK2 
produces a profound attenuation of nicotine analgesia; however, this effect is probably 
mediated by deficiencies in mono amine neurotransmission downstream fr~m the nicotinic 
terminal (Blednov et al., 2003). 
Herein we present evidence that Kcnj9 transcripts are present in differing levels in 
C57BL/6 and 129P3 strains in an analgesia-relevant CNS region. As previously reported 
(Marker et al., 2002; Marker et al., 2004), expression of Kcnj9 mRNA in the spinal cord 
was minimal, and appeared to be indistinguishable between strains. Expression in the 
rostral ventral medulla was marginally higher, but likewise equal between 129 and B6. A 
large strain difference was observed in the periaqueductal gray; expression in 129 mice 
was almost three times that of B6 mice. This finding replicates the difference between 
the two strains in six major brain regions assayed by microarray by Sandberg et al. 
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(2000). The overexpression of GIRK3 (as in 129P3 mice), or lack thereof (as in GIRK3 
KO mice), in analgesia-relevant areas of the brain may similarly disrupt the optimal 
balance of GIRK subunits. 
We have used transgenic mutant mice in which the Kcnj9 locus has been deleted 
to explore the role of the gene in modulating analgesia. These mice were created by 
introducing a null mutation into ES cells of the 129Sv/J strain via homologous 
recombination, producing a chimeric mouse by insertion of transgenic cells at the 
blastocyst stage, and then backcrossing this mouse with a C57BL/6 background for many 
generations to eliminate 129-derived genetic material (Torre cilla et al., 2002). Mice 
homozygous for the deletion exhibited a flattened dose-response relationship, compared 
with wild-type mice, for both clonidine and WIN55,212-2, indicating that these drugs 
were largely ineffective at producing any antinociceptive effect (Fig. 13a and 13c). 
Morphine analgesia was not significantly affected (Fig. 13b). One explanation for this 
phenotype is that the deletion of the Kcnj9 gene, and the subsequent loss of any functional 
GIRK3 protein, resulted in a deactivation of potassium channels necessary for adrenergic 
and cannabinoid (but not opioid) analgesia. However, the interpretation of knock-out 
studies is complicated by the "hitch-hiking donor gene" confound: instead of being 
caused by the non-functional gene, as is usually assumed, the phenotype may be produced 
by one of the 129-derived genes flanking the deleted locus (Mogil and Grisel, 1998). We 
have, in fact, exploited such "hitch-hiking genes" already, in the form of the 
Fcgr3KO-congenic mice used to isolate the gene. The pattern of analgesic response of 
the GIRK3KO mice mirrors that of the Fcgr3KO-congenic mice, such that it is 
impossible to determine whether it is a result of the deletion of either gene, or merely an 
unexpected side-effect of an unknown 129-derived allele near the knocked-out genes. 
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Confusion between mutation and strain effects can be resolved using a classical 
genetic method known as quantitative complementation (Rikke and Johnson, 1998; 
Yalcin et al., 2004). This method, also termed a "QTL-knockout interaction test" 
(Darvasi, 2005), uses crosses between null mutants and the high- and low-QTL strains to 
detect interactions between the mutated gene and the QTL. The test requires that the 
mutation be non-dominant (i.e., additive or recessive), however, to preserve the 
possibility of complementation with the QTL. Crossing GIRK3KO mice with B6 wild-
types, we found that clonidine analgesic magnitude in heterozygotes was 
indistinguishable from that ofhomozygous null mi ce (data not shown), indicating a 
dominant mode of inheritance. We can only conclude that the attenuated analgesia 
phenotype displayed by the GIRK3 mutants is corroborative evidence supporting the role 
of this gene in antinociception, rather than proof of its involvement. 
The precise polymorphism responsible for the difference in Kcnj9 expression (and 
possibly the analgesia strain difference) is not easily identifiable. The 129P3 strain is 
genetically not very well characterized; however, other 129 substrains such as 
129Sl/SvImJ and 129X1/SvJ, as well as the closely related LP/J strain (Beck et al., 
2000), are included in major SNP databases, and can serve as proxies for the 129P3 
strain. The sequence of C57BL/6J is in the public domain at www.ensembl.org, and the 
sequence of 129Sv/J has been made available as well (Wickman et al., 2002). The 
mouseSNP database (http://mousesnp.roche.comQ catalogues 50 polymorphisms between 
C57BL/6 and 129/SvImJ in the vicinity of Kcnj9, although this may not be an exhaustive 
list (Table 7). These polymorphisms, any of which may be potential quantitative trait 
polymorphisms (QTPs), include nucleotide switches (13 within exons, 4 in introns, and 
24 outside the gene itself, including the promoter region), and nucleotide deletions 
(including a set of three that putatively results in an extra aspartic acid residue in the 
GIRK3 product of 129 mice). It is likely that at least one ofthese extra-coding SNPs 
determines the level of expression of Kcnj9, as the gene shows cis-regulation as 
characterized by the Web-QTL method (Hitzemann et al., 2004). 
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A surprising degree of genetic correlation between numerous opioid and non-
opioid analgesic compounds, across a dozen inbred strains, led us to search for a genetic 
mechanism common to aIl of the drugs (Wilson et al., 2003). Linkage and in silico 
mapping isolated a short interval at the distal end of Chr. 1 that broadly predicted 
analgesic response to four of the drugs evaluated, and this locus was successfully 
transferred from the "analgesia-insensitive" to the "sensitive" strain using a congenic 
strategy. We then compiled molecular and behavioral evidence implicating Kcnj9 as the 
gene responsible for analgesic sensitivity. Although not the "master analgesia gene" we 
initially predicted, if Kcnj9 proves to play a role in human sensitivity to analgesics as 
weIl, this knowledge may ultimately prove beneficial to the millions of patients currently 
suffering from insufficient pain relief. The emerging field of pharmacogenetics holds 
promise for predicting a person's sensitivity to analgesic drugs, and may one day even 
offer the possibility ofincreasing drug efficacy through the manipulation ofGIRK-related 
mechanisms. 
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CHAPTER 5: HAPLOTYPE MAPPING OF Nociqi 
A. Experiment Summary 
Quantitative trait locus mapping revealed the influence of a gene on distal Chr. 9 
modulating the response of AB6F2 mice to the early phase of the formalin test, a common 
measure of chemical nociception. In question, however, remained the identity ofthis 
gene, and the extent to which this finding generalized to other mouse strains. By adding 
new strains to our previous strain survey data, we were able to carry out an in silico 
mapping analysis with enough power to implicate a set ofhaplotype blocks in the QTL 
region correlating with the variability observed across multiple strains. These haplotype 
blocks corresponded to a single gene, Afp i b3, a subunit of the ouabain-sensitive sodium-
potassium channel. We then showed that pharmacological blockade of this channel 
eliminated the strain difference between AlJ and C57BL/6 in both early and late phases of ' 
the formalin test. We also observed that formalin-sensitive C57BL/6 mice exhibit lower 
expression of Afpi b3 in the dorsal root ganglia than other, relatively resistant strains, 
suggesting a mechanism by which the gene may contribute to the behavioral strain 
difference. 
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B. Introduction 
Inflammation is the body's natural response to tissue damage from bums, injuries, 
and infection. The release of inflammatory mediators, including cytokines, 
catecholamines, nerve growth factors, prostaglandins, bradykinin, nitric oxide, and A TP 
(Dray, 1995), initiates defense mechanisms designed to prevent further injury and 
stimulate healing. Pain, in the form of hyperalgesia or aIlodynia, frequently accompanies 
these processes as an incentive to protect the damaged tissue. Although such pain may be 
seen as adaptive, inflammatory processes lead to central sensitization (Woolf and 
Costigan, 1999; Ji, 2004) often manifested as debilitating spontaneous pain (Djouhri et 
al., 2006), and inflammation underlies numerous pathological states such as arthritis, 
inflammatory bowel disease, fibromyalgia, and vulvodynia. 
Wide psychometric variability in thermal (Chen et al., 1989b; Sheps et al., 1999; 
Coghill et al., 2003; Hutchinson et al., 2004) and pressure (Sherman, 1943; Chapman and 
Jones, 1944; Brennum et al., 1989) pain has been convincingly demonstrated, and its 
determinants enumerated (Chen et al., 1989a; Davis et al., 1998; Fillingim et al., 1998; 
Myers et al., 2001; Fillingim et al., 2005), but less is known about variability in 
inflammatory pain in humans. Rodent models of inflammation have therefore been 
instrumental in establishing a genetic basis for interstrain variability in rats (Rosenthale, 
1970; Widy-Tyszkiewicz et al., 1995; Zhang et al., 2003), and we have demonstrated 
large strain differences in several models of inflammatory pain in mi ce as weIl. Strain 
surveys measuring response to a number of inflammatory agents, such as formalin, acetic 
acid, magnesium sulfate, bee venom, and the sea moss derivative carrageenan, have 
shown that strains may vary up to 17-fold in their exhibition of pain behaviors (Mogil et 
al., 1998; Mogil et al., 1999a; Lariviere et al., 2002). Such variability, while consistent 
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across chemical agents, does seem to depend on the particular stimulus evoking the pain, 
whether it be spontaneous or induced by thermal or tactile stimulation (Mogil et al., 
1999b). However, the genetic correlation of different inflammation modalities strongly 
suggests the role of genes causing variation between individuals (Mogil et al., 1999b). 
We recently used quantitative trait locus (QTL) mapping to search for genes 
responsible for variable response to the formalin test between the sensitive C57BL/6J and 
the resistant A/J strains (Wilson et al., 2002). In this assay (Dubuisson and Dennis, 
1977), an injection of 1-5% formalin (itself a dilute solution of formaldehyde) under the 
plantar surface of the hindpaw produces recognizable pain behaviors (Le., licking and 
shaking of the offended limb) in the mouse. Vigorous responses are observed for 5 to 10 
min (the early, or aeute, phase) before subsiding into a short quiescent interval; pain 
behaviors are renewed a few minutes thereafter (the late, or tonie, phase) and last for an 
hour or more. It is believed that the two phases may represent different nociceptive 
mechanisms (and therefore, divergent underlying genetic modulation). Overlapping 
regions on distal Chromosome 10 linked to both the early and late phases suggested that a 
single locus (Nociq2) near 60 cM contributed to variability in both phases. We also 
observed a locus on Chr. 9 (Nociql, peak 59.8 cM, C.I. 44-68) that accounted for 27.3% 
of the phenotypic variance of the early phase only. 
Mapping a QTL to a ~20 cM interval is only the first step in the identification of 
the quantitative trait gene (QTG) underlying the locus. Traditionally, an extensive 
process of cloning the QTG by position, accomplished 'via the generation of hundreds of 
recombinant individuals, has been the only recourse to narrow the confidence interval 
(Moisan, 2000). Recently, however, the completion of the mouse genome sequence and 
extensive cataloguing of genetic variation between inbred strains have vastly improved 
~ .. 
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our ability to relate observed phenotypes with essentially all of the basic units of 
inheritance. Haplotype mapping (Grupe et al., 2001) correlates in silico the behavior of a 
set of inbred strains with an archived database of single nuc1eotide polymorphism (SNP) 
variation within the set, such that one can implicate single genes as producing patterns of 
strain responses. We have subjected our formalin strain survey data to haplotype analysis 
in order to generate candidate genes with a high probability of producing variability 
across strains. 
C. Methods 
C.l. Subjects 
Eleven inbred strains, inc1uding 129P3, A, AKR, BALB/c, C3H1He, C57BL/6, 
C58, CBA, DBAl2, RUIS, and SM (all IJ substrains) were assessed in our initial strain 
survey; they were housed and maintained as previously described (Mogil et al., 1998). 
SNP data was only available for eight ofthese strains (after substituting the 129/SvlmJ 
strain for the c10sely related 129P3 strain), however, so an additional eight strains were 
phenotyped for the present study: A/HeJ, BI0.D2-H2/0SNJ, BALB/cByJ, MRL/MpJ, 
NZB/BlnJ, NZW/LaCJ, LG/J, and LP/J. These strains were obtained from The Jackson 
Laboratory (Bar Harbor, ME), and housed in our environmentally controlled vivarium 
with ad lib access to food (HarI an Teklad) and tap water. Behavioral candidate gene and 
expression studies were performed on AlJ and C57BL/6J mice reared on-site from 
breeders obtained from The Jackson Laboratory. Both males and females were tested in 
aU experiments. 
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C.2. Formalin testing 
Response to forrnalin treatment was assessed as described previously (Tjolsen et 
al., 1992; Mogil et al., 1998). Briefly, aH mice were injected in the plantar surface of the 
hindpaw with 5% formalin (37% w/w forrnaldehyde) in a volume of25 Ill, using a 30 
gauge needle. Mice were allowed to habituate singly for 1 hr in c1ear Plexiglas cylinders 
(12 cm diameter x 15 cm high) on a glass floor before injection. Following the 
habituation period, each mouse was removed and introduced into a c10th pouch, where it 
was restrained for injection. Mice were then returned to the Plexiglas cylinder and 
videotaped from below for 60 min. The recordings were later scored by trained observers 
blinded to strain or drug condition (as appropriate) using The Observer software package 
(Noldus, Leesburg, VA). Mice added to the strain survey for purposes ofhaplotype 
mapping were scored for early phase response (first ten minutes) only; the total amount of 
time spent attending to the injected hindpaw (licking or biting) over the duration was 
measured. For candidate gene studies, the early (0-10 min) and late (10-60 min) phases 
were both scored. Edema due to inflammation was assessed by weighing the injected and 
contralateral paws on a microbalance, and computing the percent difference in weight 
between them. 
C.3. Haplotype mapping 
Sixteen strains were evaluated for early phase response to forrnalin treatment, and 
the mean duration of response was converted to a Z-score for each strain. The phenotype 
scores were then subjected to computational genetic analysis as previously described 
(Grupe et al., 2001; Liao et al., 2004). This method uses a haplotype map of the mouse 
genome, constructed from blocks ofSNP alle1es of the inbred strains (Wang et al., 
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2005a). When this computational analysis was performed, the haplotype map had 5,694 
haplotype blocks generated from 215,155 SNPs characterized across 19 inbred strains 
covering 2,609 genes (see http://mouseSNP.roche.com).Linkedhaplotypeblocks,in 
which the strain grouping within the block correlates with the distribution of phenotypic 
data among the inbred strains, are identified in silico. A p-value is computed to evaluate 
the likelihood that genetic variation within each block could underlie the observed 
distribution of phenotypes among the inbred strains. The haplotype blocks are then 
ranked based upon the calculated p-value. The p-values for the numerical phenotype 
evaluated in this experiment were calculated as described using ANOVA (Liao et al., 
2004; Wang et al., 2005a; Wang et al., 2005b). As there are no widely recognized 
standards for significance of full-genome haplotype scans, this analysis is best considered 
to be exploratory, with follow-up experiments necessary to establish proof of a gene's 
involvement in the phenotype. 
CA. Candidate gene studies 
C.4.l Nociceptive behavioral testing 
Results of the haplotype mapping analysis strongly supported a role for the 
sodium-potassium ATPase channel in formalin early phase strain variability. We used 
ouabain (Sigma, St. Louis, MO), an antagonist ofthis channel, to evaluate behaviorally 
the effects ofblocking the channel on the strain difference. A/J (resistant) and C57BL/6J 
(sensitive) mice were given al mg/kg dose (in a volume of 0.1 ml/kg i.p.) of the drug, 5 
min prior to formalin injection. Formalin response in the early and late phases was 
quantified as above. 
~ .. 
f· 
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CA.2 Gene expression studies 
Dorsal root ganglia (DRGs) of the L4-L6level were removed from mice offive 
strains (A/J, C57BL/6, LG/J, MRL/MpJ, and NZWlLacJ), aged from at least six weeks. 
Tissues were removed from naïve as well as formalin-challenged mice, in separate 
experiments. The harvested tissues were immediately placed in a preservation agent, 
RNAlater (Ambion, Austin, TX), and stored at 4°C until total RNA isolation. To obtain a 
sufficient quantity of tissue samples, approximate1y 10-15 mice from each strain were 
used for each tissue type, and all samples of each type were pooled. 
The samples were homogenized with Trizol (Invitrogen, Burlington, ON) and 
resuspended in 30 ilL ofDEPC treated water. The RNA solution was then treated with 
the DNAfree kit (Ambion, Austin, TX) to remove any trace DNA contaminants and 
purified with the RNeasy Mini kit for RNA cleanup (Qiagen, Germantown, MD). 
Integrity and concentration of the total RNA samples were evaluated on the Bioanalyzer 
2100 (Agilent, Palo Alto, CA). The reverse transcription (RT) reaction was performed 
according to the protocol of the TaqMan Reverse Transcription Reagents kit (Applied 
Biosystems, Foster City, CA). In addition to the unknown samples, seriaI dilutions of 
known concentrations of mouse brain total RNA (Ambion) acting as standards were 
reverse transcribed. Brietly, each RT reaction required 1 ilL of the total RNA to be added 
to 9 ilL ofRT master mix composed of 0.5 ilL of 50 IlM random hexamers and 0.25 ilL 
of 5 OU/ilL Multiscribe RT enzyme. Reverse transcription was carried out on a Peltier 
Thermal Cycler (PTC-lOO, Bio-Rad, Hercules, CA) at the following cycles: 25°C for 10 
min, 48°C for 30 min followed by 95°C for 5 min. The cDNA was stored at 4°C until the 
PCR reaction was made. 
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Gene-specific TaqMan probe and primer sets for the target genes Atpi bi, AtpI b2, 
and AtpI b3, and the Gapdh control were obtained from AB!. The target gene was 
amplified in different wells of a 96-well reaction plate with the endogenous control gene, 
Gapdh, whose constitutive expression served to normalize quantification of target gene 
expression levels among unknown samples. Each 5 ilL cDNA sample of standards and 
unknowns was added to 20 ilL of target gene PCR master mix and 20 ilL of Gapdh PCR 
master mix. The target gene PCR master mix composition was: 12.5 ilL of2X TaqMan 
Univers al PCR Mix with AmpErase UNG, 6.25 ilL ofDEPC water, and 1.25 ilL of20X 
target gene specific probe and primers mix. The Gapdh master mix composition was: 
12.5 ilL of2X TaqMan Universal PCR Mix with AmpErase UNG, 6.00 ilL ofDEPC 
water, and 0.5 ilL of20X Gapdh gene specific probe and primers. Standards were run in 
quadruplicate and unknowns in quintuplicate. Real-time PCR was carried out on an ABI 
7000 system at the following cycles: 50°C for 2 min, 95°C for 10 min followed by a round 
of 40 cycles of 95°C for 15 sec/60°C for 60 sec. 
After the PCR reaction was completed, a threshold was fixed across the linear 
region of all amplification curves. Cr values for the unknown samples and known 
standards were determined as the cycle numbers associated with this threshold. Cr values 
of the unknown samples were then converted into expression values using the 
corresponding standard curve. The ratio of the average target gene amount over the 
average Gapdh amount provided the normalized target gene expression result. 
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D. Results 
D .1. Haplotype mapping 
Phenotyping additional strains beyond those inc1uded in our previous survey 
(Mogil et al., 1998) did not markedly affect the relative sensitivity rankings of the strains 
(Table 8). C57BL/6 remained the most sensitive strain, although three of the new strains 
were less sensitive than BALB/c and A/J, strains formerly identified as most resistant. 
The correlation between the phenotype distribution and each haplotype block was 
assigned a p-value, indicating the likelihood of the correlation being observed by chance. 
Twenty-six blocks exceeded the arbitrary significance threshold p<O.OI, corresponding to 
19 distinct genes on 14 chromosomes; four genes exceeded a threshold ofp<O.OOI. The 
ten haplotype blocks with the lowest p-value are shown in Table 9. The gene with the 
highest level of significance in the haplotype mapping analysis was Gstm3, located on 
medial Chr. 3 (p = 0.00035). Three genes with significance greater thanp<O.OI comap 
with the Nociqllocus on distal Chr. 9: Atplb3 (51 cM,p = 0.00039), Rbpl (52 cM, 
p=0.0038), and Rbp2 (57 cM,p = 0.007). 
The criteria for an identified gene to be considered a candidate gene underlying 
Nociql inc1uded position (between 44 and 68 cM on Chr. 9), expression in the CNS or 
relevant peripheral site, and nociception- or inflammation-related function. Only one 
gene in our haplotype analysis was observed to me et aIl of these requirements. The 
sodium-potassium channel subunit Atplb3 exhibited a high correlation with the 
phenotype across aIl 16 strains tested, and its role in the regulation of neuronal 
excitability suggests that it is responsible for the observed strain differences. We 
therefore contrasted the effects of an inhibitor of the sodium-potassium ATPase channel 
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between a sensitive (C57BL/6) and a resistant strain (AlJ) to determine if activity at this 
site modulates differential formalin response. 
D.2. Candidate gene studies 
The effect of the sodium-potassium ATPase inhibitor, ouabain, on both the early 
and late phase, as weIl as paw edema, was examined using ANOVA (Fig. 14). In the 
early phase (Fig. 14a), an interaction between strain (AlJ versus C57BL/6) and drug 
(ouabain or saline vehicle) was observed (F 1,42=4.604, P = 0.038). Post-hoc tests revealed 
that there was a significant difference in formalin response between the strains when 
administered saline (F 1,21=5.016, P = 0.036), but that this difference entirely disappeared 
after ouabain injection (F 1,21=0.173, P = 0.682). Similarly, an interaction between strain 
and drug effects in the late phase (Fl,42=13.622, p = 0.001, Fig. 14b) was due to the 
presence ofa strain difference in saline-treated (Fl,21=10.518, p = 0.004) but not ouabain-
treated (F 1,21=3.312, P = 0.083) animaIs. No significantmain effects or interactions were 
observed in paw edema (Fig. 14c). 
D.3. Expression of ATPase subunits 
We first compared baseline Afpi b3 expression in the DRG between NJ and 
C57BL/6 (Fig. 15a). AlJ mi ce had roughly twice the expression ofthis gene (5.8 versus 
2.7 arbitrary units). Expression oftwo other ~ subtypes, ~1 and ~2, however, was not 
divergent between the two strains (Fig. 15b). Atpib3 appeared to be upregulated in both 
strains following formalin injection (Fig. 15c), but remained higher in A mice. 
AdditionaIly, other formalin-resistant strains, including LG/J, MRL/MpJ, and NZW/LacJ, 
also expressed the gene at higher levels than B6. 
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E. Discussion 
The forma1in test, a common mouse mode1 of chemica1 and inflammatory pain, is 
considered one of the more clinically relevant experimental models of pain, pertinent to 
the study of chronic inflammatory diseases and conditions such as osteoarthritis and 
rheumatoid arthritis, inflammatory bowe1 disease, and vulvar vestibulitis. Mice of 
different strains exhibit wide variation in nocifensive behaviors (i.e., licking, biting) in 
response to sub-cutaneous formalin injection, indicating a major genetic component to 
this model (Mogil et al., 1998; Mogil et al., 1999a). The identification of genetic 
determinants responsible for individual variability in formalin response would increase 
understanding of the sequence of events involved in inflammation, and potentially 
provide novel therapeutic targets. We recently mapped a quantitative trait locus (Wilson 
et al., 2002) explaining over 27% ofthe phenotypic variance in the early phase of the 
formalin test to a region of Chr. 9 (peak LOD 5.2 at 60 cM, C.I. 44-68 cM). This result 
was limited in several ways: the QTL only appeared to influence early phase responding 
(i.e., chemosensation), not inflammation; the confidence interval was too large to pinpoint 
the responsible gene; and the locus was only known to mediate the strain difference 
between C57BL/6 and A/J. 
Haplotype-based mapping is a recently deve10ped technique (Gmpe et al., 2001; 
Liao et al., 2004) that may significantly improve resolution and specificity in conjunction 
with traditional QTL mapping approaches. By exploiting the natural genetic variation 
that has arisen in inbred strains over many years, it is possible to implicate single genes 
contributing to a complex trait (provided the number of strains queried is sufficiently 
large). Our analysis (Table 9) associated a small number of genes on Chr. 9 correlating 
highly with the observed pattern of formalin sensitivity across all 16 strains. Two re1ated 
92 
genes, Rbpi and Rpb2, were associated with moderate probability (p<0.01) and are 
located within the confidence interval of the QTL. However, these genes encode retinol-
binding proteins with no c1ear function in pain or inflammation; examination of the MGI 
and other gene expression databases conc1uded that these genes are largely active in the 
eye and small intestine, respectively. 
The other gene implicated by the haplotype analysis was Afpi b3 (highest 
correlationp<0.0004). The protein product ofthis gene is a ~ subunit of the Na+, 
K +-ATPase channel, which in conjunction with an a subunit, regulates ion transfer across 
neuronal cell membranes (Besirli et al., 1997). The a subunit is responsible for ATP 
hydrolysis and contains the binding site for the pharmacological antagonist ouabain 
(Jorgensen et al., 2003). The function of the ~ subunit is not well-characterized, but it is 
believed to be necessary for proper assembly of the channel on the membrane. The Na+, 
K +-ATPase channel has been implicated in two types of painful inflammation. A 
mutation in the Afpi a2 gene has been linked to a rare form of familial hemiplegic 
migraine (DeFusco et al., 2003). An inv~rse relationship between Na+ ion transfer by 
this channel and inflammation has been demonstrated in irritable bowel disease, although 
the dysregulated tissue is the colonic mucosa, rather than neurons (Allgayer et al., 1988). 
This channel is also believed to modulate opioid antinociception, although both 
synergistic (Zeng et al., 1999) and antagonistic (Masocha et al., 2003) interactions have 
been observed between morphine and ouabain. 
We used systemic injections of ouabain to look for evidence of strain-dependent 
activity of the Na+, K+-ATPase channel (Fig. 14). The large strain difference between 
AlJ and C57BL/6 in response to formalin injection was entirely eliminated by the 
co-administration of the ATPase blocker, ouabain, both in the early phase (Fig. 14a) as 
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well as the late phase (Fig. 14b). This would suggest that the efficiency of the channel in 
A mice is lower than that of B6 mice, and that inhibition of the channel equalizes ATPase 
activity. We cannot deduce from this alone the precise mechanism by which ATPase 
activity translates to behavioral response to inflammation, but the fact that edema was 
unchanged by ouabain in either strain (Fig. 14c) supports the assertion that the 
mechanism does not modulate basic inflammatory pro cesses, but rather the transmission 
of nociceptive impulses to the CNS. 
Interestingly, despite the lower activity of the allele carried by the A strain, 
expression of the AtpI b3 gene was higher than B6 (Fig. 15a). This relative increase was 
consistent across several of the formalin-resistant strains (Fig. I5c), suggesting that lower 
expression in B6 is responsible for its high sensitivity. Not enough is known about the 
different ~ subunits to explain this discrepancy, but it is possible that the ~3 subunit is less 
functional than other ~ subtypes competingfor dimerization with a subunits. No 
strain-specific expression differences were observed in either AtpI bi or AtpI b2 (Fig. 
15b); B6 mice may therefore have a greater proportion of these subunits than would A 
mice (although the absolute quantities ofmRNA ofthese two subtypes were considerably 
smaller than those of AtpI b3; data not shown). 
The present experiments validate the use of QTL and haplotype mapping to 
convincingly identify variability genes at very high resolution. Our analysis led us to a 
single plausible candidate, AtpI b3, a gene known to play a role in neuronal excitability 
and inflammation. Pharmacological manipulation of the Na+, K+-ATPase channel 
confirmed that this channel was responsible for the differential sensitivity between A/J 
and C57BL/6. Although we cannot presently postulate a mechanism to explain how 
variants of the gene manifest as behavioral differences, the level of expression of AtpI b3 
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appears to determine formalin sensitivity. The relevance ofthese findings to human 
inflammatory disease may prove to be substantial; the Na+, K+-ATPase channel has 
already been linked to migraine, and we believe it is likely that association studies of both 
acute inflammation and inflammatory disease states could implicate genetic variation in 
Atplb3 or any ofthe other genes involved in ATPase assembly. 
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CHAPTER 6: POSITIONAL CLONING OF Nociq2 
A. Experiment Summary 
Both the acute/chemical and the tonic/inflammatory phases of the formalin test 
exhibit wide variety between inbred mouse strains. Using quantitative trait locus 
mapping, we previously identified a region of distal Chr. 10 harboring a gene contributing 
to variability in both phases of the formalin test. As no obvious candidate genes were 
identified within the confidence interval, we have continued our search for this gene using 
a variety of recombinant mouse strains to clone the gene by its position. We surveyed 
panels of recombinant inbred and recombinant congenic strains derived from a cross 
between the A/J and C57BL/6 strains, which confirmed the presence ofthe QTL on distal 
Chr. 10. We also constructed congenic and subcongenic lines in order to further isolate 
the QTL to a <3 cM interval. The expression levels of the genes in this region were 
queried by microarray analysis, providing a short list of candidate genes with both 
positional and functional evidence supporting their involvement in formalin test 
variability. 
~ .. 
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B. Introduction 
Both experimental and clinical pain exhibit robust interindividual variability, and 
the role of genetic factors in this variability is increasingly appreciated (Mogil, 2004). 
Although the pace of human genetic association studies of pain is accelerating, much 
more is known about pain genetics (especially with regards to phenomics) in the mouse. 
Several quantitative trait loci (QTLs) have been identified for pain-related traits, and 
functional data provided in support of candidate genes (Mogil et al., 1997a; Hain et al., 
1999; Mogil et al., 2003; Mogil et al., 2005). However, much greater progress has been 
made with thermal pain (and analgesic responsivity against thermal pain) than more 
clinically relevant pain modalities. The most common CUITent preclinical assay of 
inflammatory pain is the formalin test (Tjolsen et al., 1992). In this assay, a dilute 
solution of formaldehyde is injected subcutaneously into the hindpaw, and a temporally 
biphasic pattern of recuperative behaviors (e.g., licking, biting, lifting) is observed. Of 
most clinical relevance is the tonic or "late" phase ofbehavior (Flate), which begins 
approximately 10-15 min after the formalin injection and lasts 30-60 min before 
subsiding. 
Mice show impressive strain-dependence in their licking/biting behavior in the late 
phase ofthe formalin test, with the Ail and 129P31l strains particularly resistant and a 
number of strains, including C57BL/6l (B6), sensitive (Mogil et al., 1999a). We have 
shown that these behavioral differences are not due to strain-dependent inflammation 
(Mogil et al., 1998), and that they correlate highly with immediate-early gene expression 
in the deep dorsal horn ofthe spinal cord (Bon et al., 2002). We recently identified two 
QTLs in an (Ail x B6)F2 intercross (named Nociql and Nociq2). Nociql's effects were 
specifie to the "early" phase of the formalin test (Fearly), but Nociq2 (peak LOD = 4.3; 1-
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LOD drop-off confidence interval: >58 cM on chromosome 10) explained 15% of the 
trait variance in Flate. Inheritance oftwo copies of the B6 alIele of the DJOMit35 marker 
(69 cM) resulted in an additional200 s oflicking in Flate compared to A/J homozygotes. 
Unfortunately, the only obvious candidate gene in the confidence interval containing this 
QTL was Ifng (interferon-y, 67 cM), and studies with Ifng knockouts and quantitative RT-
PCR convincingly excluded its candidacy. 
Thus, the purpose of the present study was to work towards the positional cloning of 
Nociq2, a QTL with potentialIy generalizable influence on inflammatory pain across 
multiple assays (Hain et al., unpublished data). To this end, we obtained or constructed 
recombinant inbred strains, recombinant congenic strains, and speed congenic Hnes to 
confirm the existence and refine the location of Nociq2. 
C. Methods 
C.l. Subjects 
Subjects of aIl experiments were naïve, adult (6-12 weeks old) mice ofboth sexes. 
Genotypes tested included A/J, C57BL/6J (B6), and several recombinant inbred (RI; from 
the AXBIBXA set), recombinant congenic (RC; AcB/BcA set), and congenic strains to be 
described below. Inbred and RI strains were purchased from The Jackson Laboratory 
(JAX; Bar Harbor, ME). RC strains were transferred to our vivarium from a breeding 
colony at the Montreal General Hospital. AlI congenic strains were bred in-house. Upon 
weaning (at 18-21 d) or immediately after arrivaI, mice were housed in standard shoebox 
cages of 2-4 with same-sex littermates in a temperature-controlIed (20± 1°C) environment 
(14 h:lO h light/dark cycle; lights on at 07:00 h), and with ad lib access to food (Harlan 
(~ 
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Teklad 8604) and tap water. Mice were habituated to the laboratory for at least one week 
before any behavioral testing commenced. 
C.2. Formalin Test 
Mice were habituated for 30 min in individual transparent Plexiglas cylinders (15 cm 
diameter; 22.5 cm high) placed atop a glass surface suspended over high-resolution video 
cameras. AU subjects were then given a subcutaneous injection of 5% formalin into the 
plantar right hindpaw (20 )lI volume), and videotaped digitaUy for 60 min foUowing the 
formalin injection. Videotape observations were later sampled for 5 sec at 1-min 
intervals, and the presence or absence of right hindpaw lickinglbiting in that 5-sec period 
was scored. The early/acute phase of the formalin test (Fear1y) was defined as 0-5 min 
post-injection, and the tonic/late phase (Flate) as 5-60 min post-injection. Data are 
presented as the percentage of samples in each phase in which licking/biting was 
detected. We and others have shown previously that this method of scoring is highly 
accurate compared to conventional assessment of total time spent lickinglbiting (Abbott 
et al., 1999; Chesler et al., 2003). 
Hindpaw edema was quantified in the following manner (Wilson et al., 2002). 
Immediately at the cessation of testing, mice were sacrificed by cervical dislocation and 
both hindpaws were severed at the ankle joint and weighed. Edema was expressed as the 
difference in the weight ofthe injected versus uninjected paw, as a percentage ofbody 
weight. 
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C.3. RI Strains 
The AXB/BXA set of RI strains includes 28 separate strains that have been reinbred 
to homozygosity from an F2 hybrid cross between AlJ and B6 strains (Nesbitt and 
Skamene, 1984). Each strain possesses approximately half of its genome derived from 
the two parental strains, but in different patterns. A consultation of the 8ll-marker 
micro satellite database of parental contributions in each strain (Prows and Homer, 2002) 
revealed nine strains with crossovers in the distal region ofChr. 10. Ofthese nine RI 
strains, eight were available from JAX for delivery: AXB-4, AXB-8, AXB-18, AXB-19, 
BXA-4, BXA-8, BXA-17 and BXA-26. These strains were tested on the formalin test 
along with A/J and B6 mi ce (n=5-7/strain) (see Fig. 16). 
C.4.RC Strains 
The AcB/BcA set ofRC strains includes 37 separate strains that have been reinbred to 
homozygosity from a (F 1 x Ail) x Ail and (F 1 x B6) x B6 double backcross (Fortin et al., 
2001). Strains of the AcB set possess approximately 13.25% oftheir genome from the 
B6 strain (on an A/J background); strains of the BcA set possess approximately 13.25% 
of their genome from the AlJ strain (on a B6 background). A consultation of the 
625-marker micro satellite database of parental contributions in each strain (Fortin et al., 
2001) revealed three strains with crossovers in the distal region ofChr. 10. Ofthese three 
RC strains, two were available: AcB64 and BcA72. These strains were tested on the 
formalin test along with AlJ and B6 mice and four AcB/BcA "control" RC strains 
(n=12-29/strain) (see Fig. 17). 
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C.5. Congenic Line Construction 
AcB64 and BcA72 have donor genome from B6 and AlJ, respectively, at regions 
other than distal mouse Chr. 10, including commonly recombinant genome on proximal 
Chr. 2 (0-15 cM) and mid-Chr. 15 (39-48 cM). Therefore, we used the AcB64 and 
BcA72 strains to construct speed congenics (A.AcB64NoCiQ2 and B6.BcA72NoCiQ2Iines, 
respectively). These were generated with marker-assisted selection ofbreeding males 
(Wong, 2002), in each backcross generation selecting for marker heterozygosity in the 
already recombinant Chr. 10 region (i.e., 65-70 cM for AcB64, DJOMit14-DJOMitJ03; 
49-70 cM for BcA72, DJOMit230-DJOMit297). AcB64 and BcA72 mice were 
backcrossed to AlJ and B6, respectively, for five generations, intercrossed, and separate 
wild-type and congenic lines then formed. We attempted to form four wild-type and four 
congenic lines in each case; in the BcA72 project three wild-type and one congenic strain 
were lost to poor fecundity. The purity of the congenic strains was confirmed by 
genotyping, and extant strains were tested on the formalin test (n=12-25/strain) (see Fig. 
18). 
C.6. Microarray Study 
Dorsal root ganglia (DRGs) of the L4-L6level were removed from mi ce of AlJ 
and C57BL/6 strains, aged from at least six. weeks. All mice were injected, as described 
previously, with either formalin or vehicle. The mice were sacrificed by cervical 
dislocation after 45 minutes, and tissue extraction immediately followed. The harvested 
ganglia were immediately placed in a preservation agent, RNAlater (Ambion, Austin, 
TX), and stored at 4°C until total RNA isolation. Three mice per strain per condition 
were used, with no pooling of samples; RNA for each chip was taken from a single 
individual. 
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The samples were homogenized with Trizol (Invitrogen, Burlington, ON) and 
resuspended in 13 ~L ofnuc1ease-free water. Integrity and concentration of the total 
RNA samples were evaluated on the Bioanalyzer 2100 (Agilent, Palo Alto, CA). Isolated 
RNA (40 ng/,.û samples, in a volume of 6 ~g) was then sent to the Genome Quebec 
Innovation Centre, for conversion to labeled cRNA using the small sample protocol 
established by Affymetrix. Briefly, oligo( dT) primers and reverse transcriptase were used 
to synthesize double-stranded cDNA using a two step PCR amplification process. The 
cDNA was then converted by in vitro transcription to biotin-Iabeled cRNA, which was 
fragmented into roughly 100 bp segments and then hybridized to probes on the chip. 
Staining with streptavidin phycoerythrin and signal detection were performed on a 
GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA). The chip used to assay gene 
expression levels was the Affymetrix MOE430v2 chip, w~ich contains probe sets for 
about 39,000 transcripts. 
We used a 2x2 c1ass comparison experimental design in order to detect expression 
differences between strains and as a result of formalin treatment. This design also 
enabled us to look for interactions between strain and treatment conditions. The raw 
signal intensity data from each condition was normalized using the Robust Multiple-array 
Average (RMA) method (to account for systematic differences in signal between chips), 
and averaged across the three replicates. Differences between conditions were assessed 
by ANOVA, and p-values were computed to test for strain, treatment, and interaction 
effects. Additionally, a transformed fold change was computed using the formula: 
fold change = log2([ condition 1 ]/[ condition2]) 
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where condition was defined as signal intensity for either B61 A, or fonnalin/control, 
depending on the analysis. A fold change is reported (Table 10) for all genes in which a 
significant effect was observed (a = 0.05), regardless of the magnitude of the change. As 
this was considered an exploratory analysis, no corrections were made for multiple testing 
in order to minimize Type II errors. 
D. Results 
D.l. RI Strains 
One-way ANOVAs revealed no significant effect of genotype on Fearly responding 
(FIO ,55 = 1.6,p = 0.14) or edema (FIO,55 = 1.8,p = 0.08). By contrast, the main effect of 
genotype on Flate licking behavior was highly significant (FIO,55 = Il.3, P < 0.001). 
Dunnett's (one-way) post-hoc test revealed the following RI strains as not significantly 
higher scoring than A/J: AXB-4, BXA-4. Dunnett's (one-way) case-comparison test 
revealed the following RI strains as not significantly lower scoring than B6: AXB-8, 
AXB-18, AXB-29, BXA-8, BXA-17, BXA-26. Results, surnmarized in Fig. 16, were 
consistent with the presence of a QTL for Flate sensitivity distal to DIOMit35 at 121.9 Mb 
on Chr. 10. 
D.2. RC Strains 
One-way ANOVAs revealed no significant effect of genotype on Fearly responding 
(FS,17l = 1.9,p = 0.06). By contrast, the main effect of genotype on Flate responding was 
highly significant (FS,171 = 6.6,p < 0.001), as was the main effect of genotype on edema 
(FS,171 = 5.8,p < 0.001). Note, however, that strain-dependent edema did not show any 
correlation with Flateresponding (r = -0.01). Dunnett's (one-way) post-hoc perfonned on . 
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data from AIl and AcB RC strains revealed AcB64 (but not AcB63) as showing 
significantly higher Flate licking behavior than Ail (p<0.001). Dunnett's (one-way) 
post-hoc performed on data from B6 and BcA RC strains revealed BcA 72 only as 
showing significantly lower Flate licking behavior than B6 (p<0.01). Results, summarized 
in Fig. 17, were consistent with the presence of a QTL for Flate sensitivity between 
DJOMit237 (at 119.6 Mb) and DJOMitJ03 (at 125.4 Mb). 
D.3. Congenic Lines 
We collapsed the various A.AcB64Nociq2 and B6.BcA72Nociq2 wild-type and congenic 
lines together for analysis. For A.AcB64NOCiQ2, a highly significant effect of genotype was 
observed for Fearly (F1,121 = 17.4,p < 0.001; due to the low Fearly licking oftwo wild-type 
lines, data not shown) and Flate (F1,121 = 14.9,p < 0.001), but not for edema (F1,121 = 0.4, 
p = 0.51). Congenic A.AcB64Nociq2lines displayed higher licking in Flate than their 
wild-type counterparts in every case (see Fig. 18a). For B6.BcA72Nociq2, the effect of 
genotype on Fear1y and edema was non-significant (F1,77 = 0.04,p = 0.84 and Fl,77 = 0.03, 
p = 0.86, respectively). However, a significant effect of genotype on Flate licking was 
observed (F l ,77 = 6.1,p < 0.05), with Dunnett's one-way post-hoc test showing the 
wild-type line having higher licking than any ofthe congenic lines (see Fig. 18b). 
D.4. Microarray Study 
As we were specifically looking for gene expression differences underlying the 
Nociq2 QTL, only probe sets derived from Chr. 10 genes will be discussed presently. 
The microarray analysis (Table 10) identified 54 genes and expressed sequences as 
differentially regulated (p<0.05) between A and B6, only 12 ofwhich were expressed 
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higher in B6 mice. An interaction between strain and treatment was observed for an 
additional four genes, two for which expression went up following formalin injection in A 
and down in B6, and two for which the opposite occurred. No genes on Chr. 10 were 
detected as being significantly regulated by formalin treatment alone. Of aIl of the genes 
identified on Chr. 10, only five are located in the QTL region (roughly corresponding to 
cytoband D3): Hmga2 (log-transformed B6 expression 1.1-fold higher than A,p<O.OOl), 
Rdh5 (1.4-fold higher in A,p = 0.002), Rnf41 (2.9-fold higher in B6,p<0.001) ,Baz2a 
(1.7-fold higher in A,p = 0.003), and an unidentified RIKEN cDNA clone (1.7-fold 
higher in A,p = 0.011). 
E. Discussion 
The genetic determinants of nociceptive variability are not yet understood, and 
although several quantitative trait loci have been implicated in individual differences in 
pain sensitivity (Mogil et al., 1997a; Furuse et al., 2003; Devor et al., 2005; Mogil et al., 
2005), only a couple of the underlying genes have been identified. These genes include 
the delta-opioid receptor gene Oprdl (Mogil et al., 1997a), which appears to be linked to 
latencies on the hot-plate test, and Calca, which predicts paw withdrawal from a radiant 
heat source (Mogil et al., 2005). Both of the pain tests mentioned assay sensitivity to an 
acute thermal stimulus, which poorly reflects the types of pain for which patients 
commonly seek analgesic relief. More clinically relevant pain tests include models of 
inflammation (e.g., formalin, acetic acid writhing), muscle pain (intramuscular injection 
of acidic saline) and nerve trauma (e.g., chronic constriction injury, partial-nerve injury). 
We have shown that the patterns of strain sensitivity to different pain tests are 
often highly correlated, such that "clusters" of genetically correlated tests may be 
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identified (Mogil et al., 1999b; Lariviere et al., 2002). The defining attribute ofmost of 
these clusters is the stimulus modality used to evoke the nociceptive response (i.e., 
thermal, chemical, or mechanical). For example, Spearman rank correlations between 
tests of chemical/inflammatory pain ranged from 0.41 (for formalin late phase with 
abdominal constriction induced by magnesium sulfate) to 0.79 (for formalin early phase 
with abdominal constriction induced by acetic acid) (Mogil et al., 1999b). Such high 
correlations suggest that a single set of genes is largely responsible for variability in all 
tests of chemosensation and inflammatory pain. Separate QTL mapping projects have 
supported this premise; linkage to distal Chr. 10 has been observed in both early and late 
phase formalin responses (Wilson et al., 2002), the acetic acid writhing test (Hain and 
Belknap, unpublished data), and arthritis (Dracheva et al., 1999; Yang et al., 1999). 
Based on these findings, we hypothesized that a single gene within the QTL region (>58 
cM) is broadly important to the modulation of inflammatory pain. 
Few genes in this interval are recognized as having a role in pain or inflammation, 
however, so we first endeavored to minimize the confidence region of the QTL. A major 
limitation of QTL mapping is the po or resolution it allows, due to the small number of 
crossovers in the F2 generation. In contrast, recombinant populations by definition offer 
substantially more recombination sites, greatly increasing the precision of QTL 
localization. We tested several recombinant inbred Hnes from the AXB/BXA set, which 
collectively dissected the QTL region into 1.5-3 Mb segments defined by five 
micro satellite markers. The QTL effect was observed most strongly in the region 
between 119.6 and 124.7 Mb. An additional analysis, using recombinant AcB/BcA 
congenic Hnes, supported the existence ofa QTL between 119.6 and 125.4 Mb. Finally, 
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pure congenic lines confirmed the bidirectional transfer of the QTL locus from AlJ and 
B6 backgrounds between 119.6 and 124.7 Mb, corresponding to 67.5-70 cM. 
Despite the tremendous refinement of the QTL interval, over 100 known genes 
may still be conservatively considered positional candidates (see Table Il for a fulllist). 
A small number may have a tenuous link to pain or inflammation, such as the 
neuropeptide tachykinin 2 (Tac2), the neuronal membrane structural protein tetraspanin 
31 (Tspan31), prostaglandin E synthase 3 (Ptges3), and cyclin-dependent kinase 2 
(Cdk2). However, none of the genes in the interval suggest themselves as obvious 
candidates mediating a broad spectrum of inflammatory conditions. 
As a complementary approach to our positionallocalization of the quantitative 
trait gene, we looked for expression differences in Chr. 10 genes that might be 
responsible for behavioral variability between A and B6. By identifying significantly 
strain-regulated genes within the QTL interval, we should be able to distinguish 
candidates with both linkage and functional evidence supporting a role in formalin 
response (Aitman et al., 1999; Eaves et al., 2002; Matthews et al., 2005). This strat~gy 
has previously been used to explore a number of neurobehavioral phenotypes, including 
ethanol use (Tabakoff et al., 2003), open field activity (Rodriguez de Ledesma et al., 
2005), and the pain-related phenotypes irritable bowel disease (de Buhr et al., 2006) and 
arthritis (Johannes son et al., 2005). Our analysis demonstrated that distal Chr. 10 harbors 
many genes with large expression differences between A and B6 strains (strain main 
effect p<0.05); interestingly, however, only a few genes were differentially regulated as a 
result of formalin treatment (strain x treatment interaction effect p<0.05), and none on 
Chr. 10 were found to be regulated in the same direction in both strains (treatment main 
effect p<0.05). It is probable that behavioral differences produced by the Nociq2 locus 
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are related to baseline gene expression patterns in the two strains, rather than a difference 
in how the strains react to formalin. 
If the QTL effect is in fact due to detectable transcript level differences, only 
regulated genes in the confidence region (67.5-70 cM) can be considered candidates 
underlying the QTL. A small number of potential candidates were identified by the 
microarray analysis, but little is known about their function, especially as relating to 
inflammation or nociceptive mechanisms. The chromosomal architectural transcription 
factor Hmga2 (70 cM) is known to be involved in tumorigenesis (Tallini and DaI Cin, 
1999). Mutations of the retinol dehydrogenase gene Rdh5 (72 cM) can have severe 
implications in the eye (Jang et al., 2001), but no activity is known in the DRG. Baz2a 
and Rnf41 (located in cytoband D3) both regulate the activity of other genes, but little is 
known regarding their specific functions. Baz2a belongs to a family ofbromodomain-
containing genes that interact with chromatin remodeling complexes (Jones et al., 2000). 
Rnf41 targets proteins, such as epidermal growth factors (Qiu and Goldberg, 2002), 
neuregulin receptors (Diamonti et al., 2002), and parkin (Zhong et al., 2005), for 
lysosomal degradation. 
The microarray results should be considered exploratory, as they are intended to 
generate hypothetical candidates for further testing. The specifie expression level 
differences we observed need to be replicated by qRT-PCR, an ongoing effort in our 
laboratory. A critical next step is to discover funetionallinks between genes with 
confirmed strain-speeific regulation and inflammatory mechanisms, by either interrupting 
the transcription/translation of the gene, or by pharmacological manipulations at the level 
of the proteins. Once a gene has been found that appears to regulate the behavioral 
response to formalin, it should be possible to find the SNP variation within this gene (or 
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in nearby regulatory regions) between the Ail and C57BL/6 strains responsible for the 
QTL effects. Altemately, another limitation ofthis study was its focus on gene 
expression in the primary nociceptors; extending the search for differentially regulated 
genes to other CNS structures involved in painprocessing may be useful if the QTG is 
not involved in peripheral nociception, but rather in higher-Ievel pain processing. It is 
probably imprudent at this point to speculate as to how these findings may translate to 
clinical advances in pain management, but continuing this work promises to uncover 
novel gene targets contributing to individual differences in inflammation. Such 
discoveries may have important implications in the treatment of arthritis, irritable bowel 
disease, and many other inflammatory disease states. 
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CHAPTER 7: GENERAL DISCUSSION 
The studies described in this work significantly advance our understanding of the 
genetic determinants of nociception and analgesia in a number of ways. Our most 
apparent conclusions are the novel candidate genes we have proposed to underlie 
individual differences in thermal pain, analgesic sensitivity, and formalin response. 
Additionally, our findings lend support to hypotheses we generated through the use of 
genetic correlation analysis, confirming the validity ofthis approach. Finally, the wide 
range of mapping methodologies we employed has allowed us to evaluate the utility of 
convergent strategies in QTL discovery. 
A. Discovery and evaluation of candidate genes for multiple pain phenotypes 
We explored the genetic basis of thermal nociception and its inhibition by opioid 
and non-opioid drugs in three simultaneous quàntitative trait locus mapping projects in a 
single B6129PF2 population. Combining baseline thermal sensitivity scores from aU 
three experiments allowed us remarkable power to detect small-effect QTLs at high 
significance levels. Loci on six chromosomes contributed to a multiple QTL model 
accounting for almost 15% of the phenotypic variability on the 49°C tail-withdrawal test. 
The two most prominent QTLs, on mid-Chr. 7 (peak 33 cM, C.I. 24-38 cM) and mid-Chr. 
Il (peak 46 cM, C.I. 30-55 cM), have not been previously linked to any pain phenotype. 
These regions contain a number ofwell-known pain modulatory genes, including those 
for necdin, the heat transducer, TRPV1, nitric oxide synthase, ~2-arrestin, and ion 
channels of GABAergic and cholinergic types, among others. The identity of the specific 
genes responsible for the QTLs, however, remains to be investigated. 
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The full power of our combined dataset also allowed us to map a QTL for 
sensitivity to multiple analgesic drugs to distal Chr. 1 (80-110 cM), which was 
subsequently confirmed in separate analyses for the u2-adrenergic clonidine, the 
cannabinoid WIN55,212-2, and the Jl-opioid morphine. We confirmed and refined the 
location of this QTL (dubbed Manr 1) to 90-100 cM (roughly 170-180 Mb) using 
haplotype-based and congenic strategies. Kcnj9, located at 94.2 cM, was identified as the 
candidate in this interval best suited to modulate analgesia from multiple drug classes. 
This gene encodes a subunit of the GIRK (G protein-coupled, inwardly rectifying 
potassium) channel, which is functionally coupled to post-synaptic neurotransmitter 
receptors of many types; ligand binding at these receptors results in an inhibitory 
hyperpolarization of the neuron. We demonstrated that mice with the Kcnj9 gene deleted 
exhibit substantially attenuated analgesia from clonidine and WIN55,212-2, and that 
Kcnj9 expression in the periaqueductal gray is strain-dependent. 
Haplotype mapping also pinpointed Afp1 b3 as the gene responsible for the Nociq 1 
QTL we previously mapped to Chr. 9 for early phase formalin response. This gene, 
involved in sodium and potassium exchange across neuronal cell membranes, is 
differentially regulated in the dorsal root ganglia of mi ce with different sensitivities to 
chemosensation.We were able to completely eliminate the strain difference in formalin 
response using a sodium/potassium channel inhibitor, ouabain. 
We used a traditional positional cloning strategy to locate another gene underlying 
formalin response on Chr. 10. We were able to minimize the confidence interval of the 
Nociq2 QTL, using recombinant inbred, recombinant congenic, and speed congenic Hnes, 
to about 5 Mb. Although this region contains no obvious candidate genes capable of 
modulating inflammatory pain response, we generated a short list of differentially 
~ .. 
regulated genes in this region using microarray technology. These genes, including 
Baz2a and Rnf41, among others, are currently being investigated for their potential 
involvement in formalin response. 
B. Validation of genetic correlation among pain phenotypes 
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The impetus for QTL mapping of multiple analgesic phenotypes was a series of 
strain surveys in which the analgesic potencies of five descending-modulatory drugs were 
found to be correlated (Wilson et al., 2003), such that a strain's sensitivity to morphine, 
for example, would predict its relative sensitivity to another drug. The correlation of two 
different complex traits implies that many of the same determining factors regulate both 
traits in a similar direction, and such a correlation observed between inbred strains 
suggests that the relevant factors are genetic (Crabbe et al., 1990). The results of our 
analgesia strain surveys led us to search for a gene (or genes) broadly involved in 
descending antinociception, regardless of the initiating receptor type. Our prediction 
proved correct, as four of the five drugs mapped in our in si/ica analysis were linked to 
the same interval on distal Chr. 1 we previously mapped using QTL methodology. 
Convergent evidence suggested that the protein producing the Chr.l effect was GIRK3, 
which interacts with the individual receptors for aU four drugs (clonidine, morphine, 
U50,488, and WIN55,212-2) via G protein signaling. The only drug not linked to Chr. 1 
was epibatidine, a nicotinic receptor agoni st which does not activate G protein 
mechanisms. It is apparent that other genes must also contribute to analgesia produced by 
multiple analgesic mechanisms, as the Manr 1 QTL does not itself explain the direction or 
magnitude of the strain differences we observed. However, we believe that a better 
understanding of GIRK channel mechanisms has great potential for increasing the 
effectiveness of clinical analgesics, especially for people genetically resistant to their 
therapeutic properties. Although the GIRK channel has been implicated in analgesia 
produced by multiple drug classes (Blednov et al., 2003; Mitrovic et al., 2003), the 
primary role of the GIRK3 subunit in variability between normal mouse strains would 
likely have gone unnoticed without the demonstration of linkage of the phenotype. 
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Another prediction of our genetic correlation experiments is that pain tests of the 
same stimulus modality (e.g., thermal, mechanical) partially share genetic mediation 
(Mogil et al., 1999b). Severalloci influencing the withdrawal threshold to an acute heat 
stimulus have been found using QTL mapping (Mogil et al., 1997a; Mogil et al., 2005), 
but no overlapping genomic regions have been identified between different pain tests. 
We mapped two additional prominent thermal pain loci to chromosomes 7 and Il, but 
interestingly, a smaller effect locus on Chr. 4 appeared very similar to one previously 
linked to hot-plate sensitivity (Mogil et al., 1997a). Both QTLs were between 45-80 cM, 
and both appeared to regulate thermal pain sensitivity in male mice only. 
Pharmacological evidence supported the candidacy of the ù-opioid receptor gene, OprdJ, 
underlying hot-plate sensitivity, and it is highly likely that this gene is similarly 
responsible for variability in tail-withdrawallatencies in male mice. 
C. Evaluation of complementary approaches in complex trait analysis 
Although researchers have prolifically identified QTL regions for hundreds of 
different structural, physiological, and behavioral traits, very few of the nucleotide 
polymorphisms underlying individual variability in these traits have been conclusively 
identified. It has therefore been a historically frequent criticism of the technique, that 
despite the great expenditures of time and resources involved in QTL mapping, it has 
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been too difficult to translate QTL findings into clinically useful knowledge (Nadeau and 
Frankel, 2000). Recently, however, a number ofmapping strategies have been developed 
that promise to vastly increase the efficiency of quantitative trait genetics. 
The traditional method of isolating a quantitative trait gene has been to clone it by 
its position, relying on ever-finer recombinant maps in complicated crosses. We 
successfully employed this technique to reduce the confidence interval of the Nociq2 
QTL to <3 cM. Unfortunately, this appears to be the reasonable extent of the resolution 
this technique currently allows, with the limited number of recombinant inbred and 
congenic strains commercially available. In the very near future, however, a powerful 
tool for the dissection of complex traits will become widely available. A panel of about 
1,000 recombinant inbred strains, known as the Collaborative Cross, will be derived from 
eight parental strains, such that maximal genetic diversity is achieved (Complex Trait 
Consortium, 2004). This resource will drastically increase the power and resolution of 
positional cloning efforts. 
An alternative to constructing panels of recombinant mice is to take advantage of 
the genetic diversity already present between inbred strains. Hundreds ofthousands of 
single nucleotide polymorphisms differentiate these strains, and vast numbers of these 
SNPs have been catalogued in electronic databases (Wang et al., 2005b). We correlated 
strain means from our analgesia and formalin strain surveys with patterns of SNP 
variation using in silico gene mapping algorithms, with varying levels of success. We 
only obtained data for seven genotyped strains in the analgesia project, and therefore had 
to be conservative in our estimation of the QTL location. However, we were able to 
confirm our prediction that a gene on distal Chr.l was influencing analgesic magnitude 
from multiple drugs with this analysis. In the formalin experiment, however, we were 
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able to correlate the SNP database with the me ans of sixteen strains, and the added power 
allowed us to implicate a single gene in early phase formalin response. Clearly, the in 
silico mapping strategy is an efficient and powerful method ofpain gene discovery, as we 
and others (Liang et al., 2006a; Liang et al., 2006b) have demonstrated, provided the 
number of strains assayed is sufficient. The number of strains needed for adequate 
statistical power remains controversial (Darvasi, 2001), but as more strains are genotyped, 
the utility of this technique is sure to increase. 
The use of knockout strains to confirm the presence of a QTL can be useful, but 
there are a number of caveats that must be applied in such an experiment. Even beyond 
the well-established confounds of epistatic interactions and compensation (Mogil and 
Grisel, 1998), knockout experiments are especially difficult to interpret in the context of 
candidate gene identification. Knockout strains serve as use fuI ready-made B6.129 
congenics, in the form of "hitch-hiking" donor genome surrounding the deleted locus near 
the QTL location (Bolivar et al., 2001). Comparing the knockout/congenic with the 
corresponding wild-type can confirm the transfer of the QTL alle1e from the donor to the 
background strain (assuming the deleted locus itself does not manifest a phenotype). This 
strategy can eliminate the many months needed to create a new congenic line and breed it 
to homozygosity. We employed such a strategy using FcgrJ knockout mice to isolate the 
Manrl QTL. However, the most common use ofknockouts is to confirm the active role 
of the deleted gene in a phenotype, by noting differences in mice that do not express 
normal copies of the gene. In most knockout experiments, there is a small chance that a 
donor gene is responsible for the effect, rather than the deletion. However, if it is already 
known that a QTL is in the area of the knocked-out gene, it can be practically impossible 
to eliminate the possibility of a hitch-hiking neighbor causing the effect. This situation 
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arose in our work with the GIRK3 knockout mice; a robust analgesia phenotype was 
observed in these mice, but we could not conclusively prove that it was the product of a 
lack of Kcnj9 expression. The use of knockouts to confirm a QTL candidate gene is not a 
reliable standard of proof; future candidate gene studies (in fact, aIl studies that use 
knockouts to explore the function of a gene) should be designed to minimize the chance 
of misinterpretation. 
FinaIly, we examined the global gene expression patterns of formalin-treated mi ce 
oftwo strains by microarray analysis, in order to identify genes within the Nociq2 interval 
whose regulation might generate the behavioral differences we observed. Although this 
strategy is becoming popular, only a few studies of pain-reiated phenotypes have made 
use ofit (e.g., Johannesson et al., 2005; de Buhr et al., 2006), and we know ofno example 
where a gene has been positively identified as responsible for a QTL by this method. 
However, for QTL studies in which no candidate genes in the confidence interval are 
obvious, obtaining expression profiles of aIl of the genes in the region may prove useful. 
Our own experiments demonstrated that only a handful of genes within our QTL are 
differentially regulated between strains, but more work needs to be done to confirm these 
expression changes and assess their functional consequences. We cannot presently 
evaluate the value of this strategy with the limited results we have so far obtained, 
although its potential may shortly be realized as more laboratories make use of it. 
D. Translating findings from mice to humans 
Our gene mapping experiments have already offered significant insights into the 
mediation of nociception and descending analgesic mechanisms, but the value of these 
results is best measured by their practical impact on the clinical relief of pain. In order to 
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translate our findings to human populations, it must be established that the variability 
genes we have identified in mice also contribute to individual differences in human pain 
perception. The most direct me ans to ascertain the effect of variation within a gene is by 
association of polymorphisms with the trait, using a case-control study design, for 
example. Our results suggest that a difference in sensitivity to c10nidine would be 
observed in humans with functionally different alleles of the KCNJ9 gene; likewise, 
variation in the ATP 1 B3 gene might play a role in differential response to inflammation or 
inflammatory diseases. Of course, the observance of linkage to a particular gene in the 
mouse does not necessarily imply that the phenotype will also be linked to that gene in 
humans, for a number of reasons. The exact polymorphisms between two inbred strains 
will not be the same amông human populations, and the structure and function of the gene 
itself may be quite dissimilar between species. However, by implicating the GIRK 
channel in analgesia variability in mice, we have identified an important pathway that 
probably modulates to sorne degree analgesic sensitivity in humans as weIl. Examining 
aIl of the genes in this pathway(GIRKl-4, G protein subunits, etc.) for association with 
analgesia phenotypes should distinguish genes important for human pain variability. 
The ultimate goal of such research would be to identify the genetic determinants 
of pain phenotypes, as risk factors for chronic pain diseases as weIl as novel targets for 
therapeutic treatments. A smaIlliterature of the pharmacogenomics of analgesia has 
begun to describe variation in response to opiates and cyc100xygenase inhibitors (Ikeda et 
al., 2005; Lee, 2006; Lotsch, 2006. However, much more understanding ofthe genetic 
mediation of analgesic drugs is needed before a truly individualized approach to medicine 
is achieved. Similarly, the genetic factors underlying human inflammatory pain 
conditions are too poorly characterized to adequately predict the ons et and development 
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of chronic disease. As we identify more of the genetic variants and mechanisms which 
lead to chronic pain diseases, we will better be able to treat the source of the pain, rather 
than merely aIleviate the symptoms. One day, the diagnosis of disease and the prognosis 
for various treatment possibilities may aIl be made on a single chip, uniquely tailored to 
the persona! characteristics of the patient. 
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Appendix A: Tables 
Table 1: Quantitative trait loci contributing to variability in pain- and analgesia phenotypes 
QTLname Chromo Location (cM)" Phenotype Populationb Candidate gene Reference 
Nociception 
Capsql 2 17 -47.5 Capsaicin intake KJRB6F2 (Furuse et al., 2003) 
Tpnrl 4 50 - 80 Hot-plate BXD/Ty RI, B6D2F2 Oprdl (Mogil et al., 1997a) 
Capsq2 6 3.5-24.5 Capsaicin intake KJRB6F2 (Furuse et al., 2003) 
Capsq3 6 44 - 57.5 Capsaicin intake KJRB6F2 (Furuse et al., 2003) 
Tpnr2 7 34-62 Hargreaves' test B6AKRF2, B6CF2, Calca (Mogil et al., 2005) 
A.B6-Tyr+jJ congenic 
Capsq4 8 21-43 Capsaicin intake KJRB6F2 (Furuse et al., 2003) 
Nociql 9 44-68 F ormalin (early) B6AF2, haplotype (Wilson et al., 2002) 
Nociq2 10 69-70 F ormalin (late) B6AF2, AcB/BcA RC, (Wilson et al., 2002) 
ISSC 
Nociq3 12 50 -54 Formalin (late) B6.MOLF congenic, ISSC Unpublished data 
Painl 15 41-46 Autotomy AXB/BXARI (Seltzer et al., 2001) 
Tpnr3 17 6.5 - 19 Hot-plàte, tail-withdrawal, B6.MOLF congenic Unpublished data 
Hargreaves' test 
Analgesia 
Morphl 1 0-20 Morphine BXD/Ty RI, B6D2F2 (Bergeson et al., 2001) 
Siafql 8 51 - 81 Stress-induced analgesia, BXD/Ty RI, B6D2F2 McJr (Mogil et al., 2003) 
U50,488 
Morph2 9 10 -30 Morphine BXD/Ty RI, B6D2F2 (Bergeson et al., 2001) 
Morph3 9 32-52 Morphine BXD/Ty RI, B6D2F2 Htrlb (Bergeson et al., 2001) 
Morph4 10 0-18 Morphine BXD/Ty RI, B6D2F2 Oprm (Bergeson et al., 2001) 
Ali of the QTLs shown above are significant based on permutation analysis, with LOD scores> 3 in every case. 
aConfidence interval (95%) based on a l-LOD drop off. In sorne cases, confidence intervals are based on known congenic donor regions. 
bMapping population abbreviations are by standard nomenclature or as stated in the text. Other abbreviations: haplotype: in.silico haplotype mapping using 
inbred strain means; ISSe: interval-specific subcongenic; RC: recombinant congenic strains. 
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Table 2. Multiple QTL model for tail-withdrawal sensitivity 
f'. 
Chr Pos LOD %Var F value p value 
3 81 3.0 1.3 6.7 0.001 ** 
4 56 2.9 1.3 3.3 0.011 * 
6 28 3.7 1.6 8.4 0.0003 *** 
7 28 10.4 4.7 24.2 6.2e-ll *** 
Il 40 6.8 3.0 15.7 2.1e-07 *** 
14 3 3.3 1.5 7.6 0.0005 *** 
sex 3.3 1.5 5.0 0.002 ** 
4*sex 2.4 1.1 5.4 0.005 ** 
Full Model 31.3 14.9 0*** 
Signif. codes: '***' p<O.OOl '**'p< 0.01 '*'p< 0.05 
Table 3. Multiple QTL models for clonidine and WIN55,212-2 analgesia 
Chr Pos LOD %Var F value p value 
~. Clonidine 
1 100 3.2 4.7 7.4 0.00072 *** 
19 15 1.9 2.8 4.4 0.013 ** 
Full Model 5.4 8.3 5.4ge-05*** 
WIN55,212 
1 100 3.7 4.4 8.2 0.00033 *** 
4 60 1.5 1.8 3.3 0.039 * 
7 40 4.0 4.8 8.9 0.00017 *** 
9 15 3.5 4.2 7.9 0.00044 *** 
10 20 1.8 2.1 3.9 0.021 * 
11 75 3.6 4.3 8.0 0.00041 *** 
19 52 3.2 3.8 7.1 0.00099*** 
Full Model 18.5 25.1 9.15e-12*** 
Signif. codes: '***' p<O.OOl '**' p<O.Ol '*' p<0.05 
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Table 4. Z-scores of ana1gesia sensitivity in 12 inbred strains 
-0.88 -1.05 -0.47 -0.74 -0.62 -0.75 
-0.88 1.69 -0.34 -0.37 2.78 0.57 
1.22 0.25 0.75 0.19 1.10 0.70 
1.53 -0.29 0.63 1.46 -0.06 0.65 
-0.76 -1.05 -0.16 -1.07 -0.56 -0.72 
-0.68 1.13 -0.85 0.60 -0.53 -0.07 
1.13 0.07 2.48 1.63 0.09 1.08 
-0.52 1.69 -0.52 1.15 -0.39 0.28 
-0.85 -0.77 -0.86 -0.98 -0.60 -0.81 
0.95 -0.61 -0.53 -0.90 -0.40 -0.30 
0.71 -0.24 0.80 -0.02 -0.20 0.21 
Strains not inc1uded in the haplotype analysis (see text) are in italics. 
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Table 5: Known genes in the Manr 1 QTL region 
112 genes between 90.0 and 100.0 cM 
cM Genome Coordinates Symbol, Name 
92.6 162739089-162775862 (-) FmoI, flavin containing monooxygenase 1 
92.6 162863114-162893805 (-) Fmo3, flavin containing monooxygenase 3 
90.0 169911824-170044739 (-) DdT2, discoidin domain receptor family, member 2 
90.0 py, polydactyly 
92.1 ge, greige 
92.1 sea, sepia 
170076181-170109124 (-) UapI, UDP-N-acetylglucosamine pyrophosphorylase 1 
170133434-170149571 (-) UhmkI, U2AF homology motif (UHM) kinase 1 
170211498-170220947 (+) Sh2dib, SH2 domain protien lB 
170252650-170555485 (-) Nosi ap, nitric oxide synthase 1 (neuronal) adaptor prote in 
170579571-170617530 (+) Olfml2b, olfactomedin-like 2B 
170641955-170802509 (-) Atf6, activating transcription factor 6 
170808930-170820205 (-) Dusp12, dual specificity phosphatase 12 
170852642-170863035 (-) Ferla, Fc receptor-like A 
92.3 170895468-170911110 (-) Fegr2b, Fc receptor, IgG, low affinity lIb 
92.29 170954178-170964934(+) Fegr3a, Fe fragment ofIgG, low affinity IlIa, receptor 
92.3 170986419-170994876 (-) Fegr3, Fc receptor, IgG, low affinity III 
171056007-171079446 (-) Sdhe, succinate dehydrogenase complex, subunit C, integral 
membrane prote in 
92.4 171079554-171089963 (+) Mpz, myelin protein zero 
171102106-171125875 (-) Pep41I, Purkinje cell prote in 4-1ike 1 
92.6 171142876-171147684 (+) Nrli3, nuclear receptor subfamily 1, group l, member 3 
/--, 92.6 171153929-171155210 (+) Apoa2, apolipoprotein A-II 
93.3 171158412-171163129 (-) FeerIg, Fe receptor, IgE, high affmity l, gamma polypeptide 
171163700-171175952 (-) Ndufs2, NADH dehodrogenase (ubiquinone) Fe-S prote in 2 
92.3 171179261-171189477 (+) Adamts4, a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 4 
92.6 171199228-171205735 (+) B4galt3, UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, 
polypeptide 3 
171205832-171210000 (-) Ppox, protoporphyrinogen oxidase 
92.6 171210798-171216801 (-) Usp2I, ubiquitin specific peptidase 21 
93.0 171217404-171223822 (-) UfcI, ubiquitin-fold modifier conjugating enzyme 1 
90.0 171260093-171270456(+) Dedd, death effector domain-containing 
92.6 171269418-171274446 (-) NitI, nitrilase 1 
92.6 171274539-171287010(+) Pfdn2, prefoldin 2 
171299238-171317438 (+) Pvr14, poliovirus receptor-related 4 
171317852-171339082(+) Arhgap30, Rho GTPase activating protein 30 
93.3 171340521-171347583 (+) UsfI, upstream transcription factor 1 
93.3 171366401-171393433 (+) FlIr, Fll receptor 
171432318-171433590(+) Rejbp2, RNA and export factor binding protein 2 
171446963-171464133 (-) Itlna, intelectin a 
171446963-171464124 (-) Itlnb, intelectin b 
93.0 171488165-171514158 (+) Cd244, CD244 natural killer cell receptor 2B4 
93.1 Lsd, lymphocyte stimulating determinant 
93.3 171517472-171536198 (-) Ly9, lymphocyte antigen 9 
171561243-171581877 (-) Slamj7, SLAM family member 7 
93.3 171610849-171634096 (+) Cd48, CD48 antigen 
93.3 171695971-171730016(+) Slamfl, signaling lymphocytic activation molecule family 
member 1 
~ 93.3 171769444-171817526(+) Cd84, CD84 antigen 
93.4 171931510-171957364 (-) Ltap, loop tail associated prote in 
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93.4 171981215-171986491 (0 NhlhI, nescient helix loop helix 1 
l'. 93.5 171994941-172011669 (-) Nestn, nicastrin 
93.5 172011723-172051248 (+) Co pa, coatomer protein complex subunit alpha 
93.6 172055682-172065417 (+) PexI9, peroxisome biogenesis factor 19 
93.7 172077062-172125309(+) Wdr42a, WD repeat domain 42A 
93.8 172081688-172129499 (-) PeaI5, phosphoprotein emiched in astrocytes 15 
94.0 172138821-172148753(0 CasqI, calsequestrin 1 
94.0 172152718-172186954 (-) AtpI a4, ATPase, Na+/K + transporting, alpha 4 polypeptide 
94.2 172203036-172234636 (-) AtpIa2, ATPase, Na+/K+ transporting, alpha 2 polypeptide 
94.2 172241327-172248757(+) Igsj8, immunoglobulin superfamily, member 8 
94.2 172249953-172258202 (-) Kenj9, potassium inwardly-rectifying channel, subfamily J, 
93.5 172270321-172303005(+) KenjIO, potassium inwardly-rectifying channel, subfamily J, 
member 10 
94.0 172305476-172309453 (+) Pigm, phosphatidylinositol glycan, class M 
172404288-172407495 (+) Slamj9, SLAM family member 9 
94.0 172411140-172427798 (+) Igsj9, immunoglobulin superfamily, member 9 
94.2 172428967-172436300 (+) Tagln2, transgelin 2 
94.2 172438295-172474790(+) Cedc19, coiled-coil domain containing 19 
172510678-172519408 (-) Slamj8, SLAM family member 8 
172559691-172561802 (-) Dusp23, dual specificity phosphatase 23 
94.2 172626986-172628882(+) Crp, C-reactive prote in, petaxin related 
94.2 172827594-172828675 (-) Apes, serum amyloid P-component 
94.2 173156636-173162566 (-) FcerIa, Fc receptor, IgE, high affinity l, alpha polypeptide 
94.0 173267298-173269025 (-) Dare, Duffy blood group, chemokine receptor 
94.2 Igsf41, immunoglobulin superfamily, member 4-like 
member 9 
173269606-173303047 (-) Igsf4b, immunoglobulin superfamily, member 4B 
95.0 Nba2, New Zealand Black autoimmunity 2 
~. 95.2 173816645-173845332 (-) Ifl204, interferon activated gene 204 
173828773-173845312 (-) Mnda, myeloid cell nuclear differentiation antigen 
95.2 lfl20I, interferon activated gene 201 
95.31 173852817-173874904 (-) lfl203, interferon activated gene 203 
95.3 173944409-173964166 (-) lfl205, interferon activated gene 205 
95.32 Ifl202a, interferon activated gene 202A 
95.4 174105279-174180475(+) SpnaI, spectrin alpha 1 
96.0 174435221-174813052 (+) Fmn2, formin 2 
174766770-174854521 (-) Grem2, gremlin 2 homo log, cysteine knot superfamily 
(Xenopus laevis) 
99.3 174991922-175425100 (-) Rgs7, regulator of G protein signaling 7 
175534094-175558298 (-) FhI, fumarate hydratase 1 
97.0 175619198-175621063 (-) Chml, choroideremia-like 
175564890-175594826(+) Kmo, kynurenine 3-monooxygenase (kynurenine 3-
hydroxy lase ) 
175595131-175625300 (-) Opn3, opsin (encephalopsin) 
97.0 175813508-175842003 (+) ExoI, exonuclease 1 
175896538-176207985 (-) Pld5, phospholipase D family, member 5 
176711103-176746835 (-) CepI70, centrosomal prote in 170 
176747374-176953730(+) Sdeeag8, serologically defmed colon cancer antigen 8 
176953382-177182067 (-) Akt3, thymoma viral proto-oncogen 3 
177380065-177388420(+) Zfp238, zinc finger protein 238 
177700836-177734174 (-) Adss, adenylosuccinate synthetase, non muscle 
178139987-178361220 (-) Hnrpu, heterogeneous nuclear ribonucleoprotein U 
178360780-178438722(+) Efeab2, EF-hand calcium binding domain 2 
97.58 Kif26b, kinesin family member 26B 
97.59 178910023-179472250 (-) Smyd3, SET and MYND domain containing 3 
97.6 179482302-179500464 (-) Tfb2m, transcription factor B2, mitochondrial 
98.0 
100.0 
98.6 
98.7 
98.5 
97.3 
98.7 
98.7 
95.0 
98.0 
99.5 
100.0 
180285326-180377370 (+) 
180523220-180555500(+) 
180679955-180707986(+) 
180943379-180971337 (-) 
181773478-181800807 (-) 
181862432-181978534 (-) 
182271238-182300553 (-) 
182387966-182421394(+) 
182933121-182936988(+) 
184225321-184230786 (-) 
MG! queried April 21, 2006. 
Sclr 1, stem cell frequency regulator 1 
Itpkb, inositoll,4,5-trisphosphate 3-kinase B 
Parpl, poly (ADP-ribose) polymerase family, member 1 
Acbd3, acyl-Coenzyme A binding domain containing 3 
Ephxl, epoxide hydrolase 1, microsomal 
Lbr, lamin B receptor 
Enah, enabled homo log (Drosophila) 
Fbxo28, F-box prote in 28 
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Trp53bp2, transformation related protein 53 binding protein 2 
Tlr5, toll-like receptor 5 
Hlxl, H2.0-like homeo box 1 (Drosophila) 
H25, histocompatibility 25 
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Table 6: Haplotype blocks correlated with analgesia phenotypes by HapMapper 
r~, 
location (Mb) gene p value phenotype 
171.14 FcgrJ 0.0036 composite 
171.31 Ndufs2 0.00049 epibatidine 
0.00052 composite 
171.78 Igsj8 0.015 c10nidine 
172.4 Kcnj9 0.000022 WIN55,212-2 
0.015 c10nidine 
172.44 KcnjlO 0.00016 c10nidine 
0.0067 morphine 
173.09 Apcs 0.0021 c10nidine 
173.35 Fcerla 0.00008 c10nidine 
0.0058 U50,488 
173.86 A1607873 0.000038 c10nidine 
174.03 Mnda 0.00028 WIN55,212-2 
0.015 c10nidine 
174.07 Iji203 0.00019 WIN55,212-2 
0.00039 c10nidine 
0.0028 morphine 
,~~'" 0.01 composite 
174.08 Iji202a 0.000056 WIN55,212-2 
0.0021 c10nidine 
178.27 Ebaf 0.000033 WIN55,212-2 
182.56 Capn2 0.000011 WIN55,212-2 
0.0005 c10nidine 
182.66 Capn8 0.00000011 WIN55,212-2 
0.00098 c10nidine 
0.0076 morphine 
0.014 composite 
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Table 7: Single nucleotide polymorphisms near the Kcnj9locus 
Number Position Gene Location 129 B6 
1 172.393288 Kcnj9 exon C G 
2 172.393295 Kcnj9 exon A G 
3 172.393821 Kcnj9 exon G A 
4 172.393833 Kcnj9 exon C T 
5 172.393855 Kcnj9 exon G -
6 172.393856 Kcnj9 exon A -
7 172.393857 Kcnj9 exon T 
-
8 172.394321 Kcnj9 exon A G 
9 172.394322 Kcnj9 exon A G 
10 172.394327 Kcnj9 exon A G 
Il 172.394438 Kcnj9 exon G C 
12 172.394439 Kcnj9 exon G C 
13 172.397251 Kcnj9 exon A C 
14 172.397489 Kcnj9 exon G C 
15 172.397597 Kcnj9 exon C T 
16 172.398050 Kcnj9 intron C G 
17 172.398054 Kcnj9 intron A G 
18 172.399095 Kcnj9 intron G A 
19 172.399427 Kcnj9 intron G A 
20 172.400477 Kcnj9 exon A G 
21 172.401108 Kcnj9,KcnjlO between T C 
22 172.401256 Kcnj9,Kcnj 10 between G A 
23 172.401258 Kcnj9,Kcnj 10 between T G 
24 172.401339 Kcnj9,Kcnjl0 between T C 
25 172.401363 Kcnj9,Kcnj 10 between C T 
26 172.401416 Kcnj9,KcnjlO between T C 
27 172.401434 Kcnj9,Kcnj 10 between T C 
28 172.401516 Kcnj9,Kcnj 10 between C A 
29 172.401686 Kcnj9,Kcnjl0 between T G 
30 172.401688 Kcnj9,KcnjlO between T G 
31 172.401691 Kcnj9,Kcnj 1 0 between G -
32 172.401749 Kcnj9,Kcnjl0 between G A 
33 172.401773 Kcnj9,Kcnj 10 between A G 
34 172.401783 Kcnj9,KcnjlO between A C 
35 172.401814 Kcnj9,Kcnj 10 between - T 
36 172.401815 Kcnj9,Kcnjl0 between - A 
37 172.401816 Kcnj9,KcnjlO between - A 
38 172.401817 Kcnj9,Kcnjl0 between - A 
39 172.401833 Kcnj9,Kcnj 10 between A G 
40 172.402236 Kcnj9,KcnjlO between G A 
41 172.402345 Kcnj9,KcnjlO between A G 
42 172.402399 Kcnj9,Kcnjl0 between G A 
43 172.402407 Kcnj9,Kcnj 10 between A 
-
44 172.402494 Kcnj9,Kcnjl0 between G A 
45 172.402495 Kcnj9,Kcnj 10 between T C 
46 172.411182 Kcnj9,KcnjlO between G T 
47 172.411616 Kcnj9,Kcnj 10 between T C 
48 172.411789 Kcnj9,KcnjlO between G T 
49 172.412339 Kcnj9,Kcnj 10 between C A 
50 . 172.412487 Kcnj9,Kcnj 10 between T G 
) ) ) 
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Table 8: Z-score-transformed formalin early phase responses of 16 strains 
Mouse Strain MRL NZW BIB BIC NJ LGJ AIH BIO LPJ C3H DBA 129 AKR SMJ NZB C57 
Mean -1.22 -1.15 -.57 -.42 -.39 -.37 -.36 -.14 -.07 -.03 .08 .17 .18 .24 .32 .38 
Response 
) ) ') 
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Table 9. Haplotype mapping of formalin response 
P value Genetic Chr. Position (Mb) # Symbol Description 
effect SNP 
0.00035 0.57 3 108.346 - 108.392 34 Gstm3 Glutathione S-methyl transferase, mu 3 
0.00039 0.64 9 96.1771 - 96.1775 9 Atp1b3 ATPase, Na+/K+ transporting, beta 3 
0.00073 0.6 3 108.344 - 108.346 17 Gstm3 Glutathione S-methyl transferase, mu 3 
0.00073 0.6 7 130.086 - 130.378 26 Cfsd Cathepsin D 
0.00099 0.65 8 123.353 - 123.677 19 Abcb10 ATP-binding cassette, sub-family B, member 10 
0.0011 0.64 9 96.184 - 96.187 10 Atp1b3 ATPase, Na+/K+ transporting, beta 3 
0.0013 0.48 9 96.179 - 96.184 9 Atp1b3 ATPase, Na+/K+ transporting, beta 3 
0.0027 0.52 9 96.1760 - 96.1766 4 Atp1b3 ATPase, Na+/K+ transporting, beta 3 
0.0029 0.58 17 42.388514-42.388517 4 Clic5 Riken cDNA clone 
0.0038 0.5 9 98.260 - 98.261 12 Crbp RNA-binding protein 1 
') 'î 
Table 10. Chromosome 10 genes identified by microarray as differentially expressed 
Unie:ene Cytobllnd Gene 1 A Control ATx B6 Control 
Genes with strong interaction effect (Regulation depends on both strain and treatment) 
Mm.200373 32.0 cM Sgpll 442 519 461 
Mm.45124 57.0 cM Kitl 302 341 296 
Mm.278577 Cl A230046K03Rik 1029 683 597 
Mm.268389 Cl MGC69704 351 222 240 
Genes with strong one-way treatment effect (Regulation depends primarily on treatment) 
none on Chr. 10 
Genes with strong one-way strain effect (Regulation depends primarily on strain) 
Mm.9213 12.0 cM Esrl 301 322 443 
Mm.6458 18.0 cM Timeless 2347 2057 1383 
Mm.22264 26.0 cM ApgSI 275 340 153 
Mm.4504 29.0 cM Gjal 3036 3395 2241 
Mm.4504 29.0 cM Gjal 4936 5550 3681 
Mm.240150 30.0 cM DlOUclal 850 818 532 
Mm.277498 35.0 cM Psap 900 1253 732 
Mm.235960 38.0 cM Ank3 1706 1148 2129 
Mm.2400 43.0 cM Gpx4 7592 9161 4552 
Mm.317188 43.0 cM Tde: 877 943 640 
Mm.9257 46.0 cM DlOWsuS2e 2432 2836 1830 
Mm.l32958 47.0 cM Timp3 6603 6919 2503 
Mm. 132958 47.0 cM Timp3 3887 4467 2173 
Mm.l32958 47.0 cM Timp3 1061 1301 608 
Mm.268521 48.0 cM Igf1 609 780 438 
Mm.l59684 49.0 cM Tmpo 252 401 193 
Mm.22670 66.0 cM Mdm2 357 367 256 
Mm.31379 67.5 cM Hmga2 622 643 308 
Mm.289371 72.0 cM RdhS 523 462 358 
Mm.248648 Al Stxll 258 257 344 
B6Tx 
296 
174 
735 
255 
579 
1417 
193 
1845 
3042 
444 
657 
2238 
4590 
553 
1513 
2571 
2412 
594 
371 
182 
224 
275 
231 
433 
) 
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1 Strain p Txp Interaction 0 
Max fold 
0.088 0.283 0.045 0.64 
0.015 0.073 0.021 0.77 
0.051 0.337 0.012 0.59 
0.211 0.069 0.029 0.66 
Fold B6/A 
0.020 0.319 0.515 0.72 
0.003 0.687 0.467 0.65 
0.033 0.348 0.836 0.83 
0.009 0.680 0.282 0.65 
0.023 0.744 0.340 0.64 
<0.001 0.207 0.467 0.77 
0.018 0.599 0.159 0.63 
0.011 0.211 0.124 0.61 
0.001 0.512 0.427 0.87 
0.001 0.652 0.235 0.61 
0.022 0.742 0.273 0.66 
<0.001 0.737 0.939 1.41 
<0.001 0.085 0.789 0.87 
<0.001 0.432 0.379 0.97 
0.003 0.777 0.134 0.78 
0.021 0.523 0.163 0.80 
0.023 0.720 0.518 0.59 
<0.001 0.629 0.427 1.12 
0.002 0.052 0.289 0.74 
0.002 0.281 0.290 0.59 
') ) ) 
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Unigene Cytoband Gene A Control A Tx B6 Control B6 Tx St ra in p Tx p Interaction p 
Genes with strong one-way strain effect (Regulation de pends primarily on strain) Fold B6/A 
-
Mm.227794 Al Shprh 725 839 488 501 0.003 0.436 0.592 0.66 
Mm.19304l Al Map3k7ip2 603 643 338 464 0.006 0.138 0.347 0.64 
Mm.10l115 Al E130306M17Rik 367 304 129 95 0.012 0.739 0.753 1.58 
Mm.27154 A1-B2 Vnnl 382 399 210 152 <0.001 0.317 0.191 1.11 
Mm.86670 A3 Tbpll 982 1193 701 731 0.001 0.179 0.339 0.60 
Mm.294783 A3 2610102K23Rik 844 849 1354 1318 0.003 0.885 0.879 0.66 
Mm.35251 BI Tubel 191 279 426 359 0.004 0.425 0.073 0.74 
Mm.36664 BI LOC270711 336 307 662 559 0.005 0.507 0.718 0.93 
Mm.64104 BI 2410016F19Rik 347 358 236 231 0.006 0.909 0.731 0.59 
Mm.243941 B3 ManIa 319 389 256 190 0.003 0.632 0.065 0.67 
Mm.234437 B4 1700056017Rik 1024 1194 786 686 <0.001 0.935 0.058 0.59 
Mm.29344 B4 Tde2 4916 6086 3617 3383 0.003 0.583 0.204 0.65 
Mm.19325 B5.3 1200003C15Rik 415 680 336 322 0.007 0.097 0.076 0.73 
Mm.27104 Cl 2700078HOlRik 209 240 458 576 <0.001 0.128 0.754 1.20 
Mm.256981 Cl 1700129L13Rik 466 543 129 185 <0.001 0.292 0.784 1.68 
Mm.278577 Cl A230046K03Rik 1060 1199 682 797 0.006 0.222 0.898 0.61 
Mm.236214 Cl Grin3b 1584 1684 957 1074 0.029 0.658 0.871 0.69 
Mm.289431 Cl Eef2 6894 6039 2896 3871 0.047 0.978 0.495 0.93 
Mm.27651 C2 BC030932 500 557 212 198 <0.001 0.767 0.234 1.37 
Mm.34980 C2 (hypothetical)mRNA 428 519 121 112 <0.001 0.676 0.376 2.02 
Mm.252843 C2 1700023M03Rik 419 352 897 902 <0.001 0.388 0.431 1.22 
Mm.27886 C2 2410011G03Rik 3890 3198 7648 6801 <0.001 0.123 0.659 1.03 
Mm.11982 C2 (hypothetical)mRN A 4110 4058 2068 2168 <0.001 0.898 0.818 0.95 
Mm.11982 C2 (hypothetical)mRN A 4508 3705 2689 2630 <0.001 0.197 0.260 0.63 
Mm.252843 C2 1700023M03Rik 344 241 145 140 0.001 0.167 0.256 1.03 
Mm.256845 C2 AI854408 566 649 395 392 0.005 0.619 0.577 0.63 
Mm.268400 C3 2810442122Rik 1997 2226 1463 1337 0.017 0.890 0.408 0.59 
Mm.2020 Dl Csrp2 625 588 1051 1011 <0.001 0.636 0.959 0.77 
Mm.37266 Dl 8430438D04Rik 1526 1416 898 948 0.005 0.841 0.725 0.67 
Mm.268025 Dl Lin7a 1608 1544 1078 1016 0.022 0.891 0.979 0.59 
Mm.22270 D2 Tm4sf3 4558 4763 7877 7821 <0.001 0.868 0.813 0.75 
Mm.294120 D3 Rnf41 153 130 1090 1069 <0.001 0.575 0.723 2.93 
Mm.252213 D3 Baz2a 1062 998 638 732 0.003 0.649 0.320 0.59 
Mm.296915 D3 5730551F12Rik 457 468 317 297 0.011 0.780 0.608 0.59 
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Table Il: Known genes in the Nociq2 QTL region 
104 genes between 67.5 and 70.0 eM 
eM Genome Coordinates Symbol, Name 
67.5 119939359-120054668(-) Hmga2, high mobility group AT -hook 2 
120365529-120482386(-) Msrb3, methionine sulfoxide reductase B3 
120506867-120563151(-) Lemd3, LEM domain containing 3 
120617453-120684092(+) Win, Wnt inhibitory factor 1 
121021345-121053500(+) Gns, glucosamine (N-acety1)-6-su1fatase 
121066610-121132513(-) Rassf3, Ras association (RalGDS/AF-6) domain family 3 
121202715-121243002(-) Tbkl, TANK-binding kinase 1 
121243640-121282408(-) Xpot, exportin, tRNA (nucIear export receptor for tRNAs) 
121441553-121611197(-) Srgapl, SLIT-ROBO Rho GTPase activating protein 1 
121736973-121755708(-) Tmem5, transmembrane prote in 5 
122099735-122104689(+) Avprla, arginine vasopressin receptor lA 
122369396-122633107(+) Ppmlh, prote in phosphatase 1H (PP2C domain containing) 
122685727-122767072(-) Mon2, MON2 homo log (yeast) 
122802307-122887864(-) Uspl5, ubiquitin specifie peptidase 15 
124920049-125022548(-) SIc16a7, solute carrier family 16 (monocarboxylic acid 
transporters), member 7 
125665573-125714974(+) Lrig3, leucine-rich repeat and immunoglobu1in-1ike domains 3 
126601327-126634252(-) Xree6bpl, XRCC6 binding prote in 1 
70 126728332-126732689(+) Ctdsp2, CTD (carboxy-termina1 domain, RNA po1ymerase II, 
polypeptide A) small phosphatase 2 
126733459-126753708(+) A vil, advillin 
126755052-126763534(-) Tsfm, Ts translation elongation factor, mitochondrial 
//-~' 126774652-126778181(+) Mettll, methyltransferase-like 1 
126780970-126785726(+) Cyp27bl, cytochrome P450, family 27, subfamily b, 
polypeptide 1 
126789291-126795433(-) Mareh9, membrane-associated ring finger (C3HC4) 9 
126796335-126800115(+) Cdk4, cyclin-dependent kinase 4 
126800000-126802984(-) Tspan31, tetraspanin 31 
126808152-126825249(+) Centgl, centaurin, gamma 1 
69.25 126897961-126905118(+) B4galntl, beta-l,4-N-acetyl-galactosaminyl transferase 1 
12692343 8-126929486(-) Dtx3, deltex 3 homo log (Drosophila) 
126932897-126947385(-) Pip5k2e, phosphatidylinositol-4-phosphate 5-kinase, type II, 
gamma 
70 126965002-126999708(-) Kif5a, kinesin family member 5A 
69.5 127003037-127018445(+) Detn2, dynactin 2 
69.5 Evi5-rsl, ecotropic viral integration site 5 related sequence 1 
70 127018594-127025409(-) Mbd6, methyl-CpG binding domain prote in 6 
127027446-127032926(+) Ddit3, DNA-damage inducible transcript 3 
127032866-127048316(-) Mars, methionine-tRNA synthetase 
127059481-127066603(+) Arhgap9, Rho GTPase activating protein 9 
69 127066527-127078227(-) Glil, GLI-Kruppel family member GLII 
69 127086040-12708841 0(-) Inhbe, inhibin beta E 
69 127092958-1271 07069(-) Inhbe, inhibin beta-C 
127136789-127236021(+) R3hdm2, R3H domain containing 2 
127238355-127245453(+) Stac3, SH3 and cysteine rich domain 3 
127253777-127259073(-) Shmt2, serine hydroxymethyl transferase 2 (mitochondrial) 
127262111-127271196(-) Nxph4, neurexophilin 4 
127274818-127357765(-) Lrpl, low density lipoprotein receptor-related protein 1 
70 127343745-127397114(+) Stat6, signal transducer and activator of transcription 6 
~ 70 127397630-127403389(-) Nab2, Ngfi-A binding protein 2 
70 127441967-127457649(+) Myola, myosin lA 
161 
127461189-127468478(+) Tac2, tachykinin 2 
127476249-127484066(+) Zbtb39, zinc fmger and BTB domain containing 39 
72 127486333-127488404(-) Admr, adrenomedullin receptor 
70 127496521-127505007(+) Rdhl, retino1 dehydrogenase 1 (aIl trans) 
127513116-127614028(+) Rdh16, retinol dehydrogenase 16 
127513116-127529408(+) Rdh9, retinol dehydrogenase 9 
70 127586639-127597887(+) Rdhs, retinol dehydrogenase similar 
127620739-127682049(-) Rdh7, retinol dehydrogenase 7 
127635246-127648472(+) Sdro, orphan short chain dehydrogenase/reductase 
127727647-127744219(-) Hsd17b9, hydroxysteroid (17-beta) dehydrogenase 9 
77 127751903-127766741(+) Priml, DNA primase, p49 subunit 
127772284-127785348(+) Naca, nascent polypeptide-associated complex alpha 
polypeptide 
127795693-127866122(+) Baz2a, bromodomain adjacent to zinc finger domain, 2A 
127795693-127813965(+) Ptges3, prostaglandin E synthase 3 (cytosolic) 
127820018-127827099(+) Atp5b, ATP synthase, H+ transporting mitochondrial FI 
complex, beta subunit 
127869927-127913299(-) Rbms2, RNA binding motif, single stranded interacting 
prote in 2 
127930839-127946754(+) Gls2, glutaminase 2 (liver, mitochondrial) 
127946726-127948614(-) Spryd4, SPRY domain containing 4 
74 127962658-127968631(+) Mip, major intrinsic protein of eye lens fiber 
18 127968912-127989763(+) Timeless, timeless homo log (Drosophila) 
76 127990951-127992721(+) Apon, apolipoprotein N 
73 128004817-128006971(+) Apof, apolipoprotein F 
70 128007396-128029669(+) Stat2, signal transducer and activator of transcription 2 
128032960-128034904(-) 1123a, interleukin 23, alpha subunit p19 
128040155-128058167(+) Usp52, ubiquitin specific peptidase 52 
/- 72 128059409-128064373(+) Tmem4, transmembrane protein 4 
128074652-128099299(+) Cs, citrate synthase 
128099917-128105817(-) CoqlOa,coenzyme QlO homo log A (yeast) 
128113944-128130826(+) Ankrd52, ankyrin repeat domain 52 
128132754-128138005(-) Slc39a5, solute carrier family 39 (metal ion transporter), 
member 5 
128138215-128146616(-) Obfc2b, oligonucleotide/oligosaccharide-binding fold 
containing 2B 
72 128148477-128178261(+) Rnf 41, ring finger protein 41 
128198102-128227202(+) Smarcc2, SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member2 
128227889-128230853(-) My16, myosin, light polypeptide 6, alkali, smooth muscle and 
non-muscle 
128231185-128235715(-) Myl6b, myosin, light polypeptide 6B 
128247347 -128262961 (-) Mbc2, membrane bound C2 domain containing prote in 
128279054-128284865(-) Zc3hlO, zinc finger CCCH type containing 10 
128285208-128286207(-) Rp141, ribosoma1 prote in L41 
128294857 -128303029( -) Pa2g4, proliferation-associated 2G4 
70 128304622-128327612(-) Erbb3, v-erb-b2 erythrob1astic leukemia viral oncogene 
homolog 3 (avian) 
128361627-128363574(-) Rps26, ribosomal protein S26 
128369506-128382917(-) Zfpnla4, zinc finger prote in, subfamily lA, 4 (Eos) 
128406985-128410952~) Suox, sulfite oxidase 
128414968-128433355~) Rab5b, RAB5B, member RAS oncogene family 
128435036-128442103(-) Cdk2, cyclin-dependent kinase 2 
70 128443349-128457215(+) Si, silver 
71 128457225-128481147~) Dgka, diacylglycero1 kinase, alpha 
128484980-128503654(+) 
70 128528146-128536967(+) 
128542767-128556537(+) 
128554993-128558685~) 
128621636-128628776(-) 
72 128647020-128649913(+) 
72 128650679-128656364(-) 
72 128657005-128660615(-) 
72 128670909-128695373(+) 
128695368-128698079(~ 
MGI queried August 16,2006. 
Wibg, within bgcn homo log (Drosophila) 
Mmpl9, matrix metallopeptidase 19 
162 
Dnajel4, Dnal (Hsp40) homolog, subfamily C, member 14 
Ormdl2, ORM1-like 2 (S. cerevisiae) 
Gdf1l, growth differentiation factor Il 
Cd63, Cd63 antigen 
RdhS, retinol dehydrogenase 5 
Bloelsl, biogenesis oflysosome-related organelles complex-
1, subunit 1 
Itga7, integrin alpha 7 
Mettl7b, methyltransferase like 7B 
Appendix B: Figure Captions 
Fig 1. Genetic map of the mouse genome showing marker distribution. 
Fig 2. Frequency histograms ofB6129PF2 for multiple phenotypes. (a) Baseline tail-
withdrawallatency. Analgesia produced by (b) clonidine (3 mg/kg), (c) morphine (15 
mg/kg), and (d) WIN55,212-2 (10 mg/kg) is quantified as percentage of the maximum 
possible effect (checkered) and as percent analgesia (diagonallines). 
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Fig 3. LOD score plots of thermal sensitivity. The Y-axis is the LOD score. Horizontal 
Hnes indicate level of significance: dashed Hne is significant (a = 0.05), dashed-and-
dotted line is highly significant (a = 0.001), anddotted line is suggestive (a = 0.63). Ca) 
Full genome scan ofbaseline tail-withdrawallatency. Chromosome number is given on 
the X-axis, with ticks above the axis representing micro satellite markers. The X-axis of 
interval mapping plots for individual chromosomes (b) 7, (c) Il, and (d) 4 gives the 
distance from the centromere in centiMorgans. The black horizontal bars represent 1-
LOD drop-off confidence intervals for each peak. The chromosome 4 graph shows 
interval mapping results in the presence (solid line) and absence (dashed line) of the 
covariate "sex." 
Fig 4. Full genome QTL scan of composite analgesia score. The Y-axis is the LOD 
score. Horizontallines indicate level of significance: dashed line is significant (a = 0.05), 
dashed-and-dotted line is highly significant (a = 0.001), and dotted line is suggestive (a = 
0.63). Chromosome number is given on the X-axis, with ticks above the axis 
representing microsateIlite markers. 
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Fig 5. Full genome QTL scans of analgesia phenotypes: (a) clonidine, (b) morphine, and 
(c) WIN55,212-2. The Y-axis is the LOD score. Horizontallines indicate level of 
significance: dashed line is significant (a = 0.05), and dotted line is suggestive (a = 0.63). 
Chromosome number is given on the X-axis, with ticks above the axis representing 
micro satellite markers. 
Fig 6. Linkage to distal chromosome 1 for multiple analgesia phenotypes. The 
phenotypes plotted are 3 mg/kg clonidine (dashed line), lO mg/kg morphine (dotted line), 
10 mg/kg WIN55,212-2 (dashed-and-dotted line), and baseline tail-withdrawallatency 
(solid line). The Y-axis is the LOD score. The X-axis gives the distance from the 
centromere in centiMorgans. The black horizontal bar represents the 1-LOD drop-off 
confidence interval for aIl analgesia peaks. Significance thresholds are not indicated, as 
they were determined by permutation analysis and are different for each phenotype. 
Fig 7. Full genome Digital Disease mapping output for composite analgesia Z-scores. 
Bars represent the 19 autosomes broken into 10 Mb haplotype segments (see text); the 
height of each bar indicates the strength of correlation between genotype and phenotype, 
in terms of the number of standard deviations away from the mean standard deviation for 
all correlations. The dashed line represents the top 10% of correlated haplotype 
segments. 
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Fig 8. Full genome Digital Disease mapping output for single-drug analgesia Z-scores: a) 
clonidine, b) epibatidine, c) morphine, d) U50,488, and e) WIN55,212-2. Bars represent 
the 19 autosomes broken into 10 Mb haplotype segments (see text); the height of each bar 
indicates the strength of correlation between genotype and phenotype, in terms of the 
number of standard deviations away from the mean standard deviation for aIl correlations. 
The dashed line represents the top 10% highest-correlated haplotype segments. 
Fig 9. Fcgr3 Knockout/congenic interval of Chromosome 1. Introgressed 129 DNA is 
shown in gray on a white C57BL/6 background. Microsatellite markers are labeled above 
the figure; other markers are shown below. 
Fig 10. Fcgr3 KO vs. C57BL/6 wild-type: three analgesic drugs. Percent analgesia 
scores for wild-type C57BL/6 (solid line) and Fcgr3 KO (dashed line) mice at multiple 
doses are shown for a) clonidine, b) morphine, and c) WIN55,212-2. 
Fig lIa. Comparison ofwild-type C57BL/6, knockoutlcongenic Fcgr3, and 
heterozygotic mice for analgesia produced by 20 mg/kg clonidine. Significance levels: 
** p < 0.01, *** p < 0.001. 
Fig lIb. Comparison of subcongenic strains derived from Fcgr3KO, and wild-type 
C57BL/6 and Fcgr3KO strains, on analgesia produced by 20 mg/kg clonidine. 
Significance levels: *** p < 0.001. 
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Fig 12. Expression of Kcnj9 in three central nervous system sites: periaqueductal gray 
(PAG), rostroventral medulla (RVM), and spinal cord (SC). 
Fig 13. GIRK3 KO vs. C57BL/6 wild-type: three analgesic drugs. Percent analgesia 
scores for wild-type C57BL/6 (sol id line) and GIRK3 KO (dashed line) mi ce at multiple 
doses are shown for a) clonidine, b) morphine, and c) WIN55,212-2. 
Fig 14. Effect of oabain treatment on formalin response. In a) and b), the Y-axis 
indicates the number of five second samples in which a nocifensive behavior towards the 
injured paw was observed in the early or late phase, respectively. Fig. c) shows the 
percent difference in paw weight between treated and untreated paws is shown. 
Significance levels: * p < 0.05. 
Fig 15. PCR of ATPase channel subunits. a) Basal expression of Afpi b3 relative to 
GAPDH in the dorsal root gang lia (DRG) of AlJ and C57BL/6. b) Relative basal 
expression ofthree ATPase subunit genes in the DRG, as expressed as a ratio of AlJ to 
C57BL/6 transcript levels. Ratios near 1.0 indicate no difference between the two strains. 
c) Expression of Afpi b3, relative to GAPDH, in the DRG 45 minutes post-formalin 
injection among five inbred strains. 
Fig 16. Recombinant inbred phenotype correlations-formalin. The top figure indicates 
the Mb position of micro satellite markers on Chr. la. The long bars in the lower figure 
represent the parental derivation for the queried section of Chr. 10 for each inbred and RI 
strain. White bars indicate AlJ-derived genome; black bars indicate B6-derived genome. 
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The phenotypic response is indicated by the mean number of positive samples (standard 
error in parentheses), and the phenotype is characterized as either A-like or B6-like (white 
or black squares) for purposes of correlation. The correlations shown below the long bars 
indicate the Pearson r between the given marker and the formalin strain means. 
Fig 17. Recombinant congenic phenotype correlations-formalin. The top figure 
indicates the Mb position of micro satellite markers on Chr. la. The long bars in the 
lower figure represent the parental derivation for the queried section ofChr. la for each 
inbred and RC strain. White bars indicate AlJ-derived genome; black bars indicate B6-
derived genome. The phenotypic response is indicated by the mean number of positive 
samples (standard error in parentheses). 
Fig 18. Congenic strain comparison-formalin. a) AcB64-derived congenic strains in 
which wild-type or congenic alleles have been maintained at the QTL locus. b) BcA72-
derived congenic strains in which wild-type or congenic alleles have been maintained at 
the QTL locus. The Y -axis expresses the formalin response of each strain as the 
percentage of five second samples in which nocifensive behavior toward the injured paw 
was observed. The strain me ans of each type were averaged for comparison; significance 
levels: * p < 0.05. 
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Appendix C: Figures 
Fig. 1. Genetic map of the mouse genome showing marker distribution 
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Fig.2a-2d. Frequency histograms ofB6129PF2 on multiple phenotypes 
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Fig.3a-3d. LOD score plots of thermal sensitivity 
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Fig. 4. Full genome QTL scan of composite analgesia score 
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Fig. 5. Full genome QTL sc ans of analgesia phenotypes 
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Fig. 6. Linkage to distal chromosome 1 in multiple analgesia phenotypes 
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Fig. 7. Full genome Digital Disease mapping output for composite analgesia Z-scores 
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Fig. 8a. Full genome Digital Disease mapping output for clonidine analgesia Z-scores 
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Fig. 8b. Full genome Digital Disease mapping output for epibatidine analgesia Z-scores 
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Fig. 8c. Full genome Digital Disease mapping output for morphine analgesia Z-scores 
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Fig.8d. Full genome Digital Disease mapping output for U50,488 analgesia Z-scores 
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Fig.8e. Full genome Digital Disease mapping output for WIN55,212-2 analgesia Z-
scores 
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Fig. 9. Fcgr3 Knockoutlcongenic interval 
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Fig. 10. Fcgr3 KO vs. C57BL/6 wild-type: three analgesic drugs 
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Fig. lIa. Dominance effects of the 129 vs. B6 allele in clonidine analgesic magnitude. 
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Fig. 12. Expression of Kcnj9 in three central nervous system sites 
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Fig. 13. GIRK3 KO vs. C57BL/6 wild-type: three analgesic drugs 
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Fig. 14. Effects of 1 mg/kg systemic ouabain on A vs. B6 strain differences 
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Fig. 15. qPCR ofNa,K ATPase channel subunits 
a. Basal expression of Atp1 b3 in the DRG oftwo mouse strains 
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Fig. 16. Recombinant inbred phenotype correlations 
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Fig. 17. Recombinant congenic strain phenotypes 
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Fig. 18. Congenic strain comparisons. 
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